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ABSTRACT
The ability of a compound to induce the rat hepatic microsomal 
drug metabolizing enzymes was investigated using a series of commonly 
prescribed barbiturates. The biological half-life of these barbiturates 
was also determined in the rat using a sensitive gas-liquid 
chromatographic method. It was found that inductive ability depends.■ 
on rate of metabolism of the compound and therefore on its 'chemical 
properties. .
Evidence is presented supporting the theory that ethanol is not a 
substrate of the enzyme system known to detoxify a diversity of 
compounds. The effect of chronic and acute ethanol administration on 
the mixed-function oxidase is investigated. The metabolic interaction 
of ethanol with barbiturates is studied both in vivo and in vitro.
Ethanol is shown to potentiate the inductive effect of the barbiturates. 
Possible mechanisms of interaction are discussed.
The interaction of barbiturates with imipramine is examined 
in vivo and imipramine is shown to inhibit the metabolism of pentobarbitone.
The importance of the allyl group in the chemical induction of 
porphyria is considered using a variety of allyl group containing 
compounds. Porphyrogenicity of a compound is compared with' its ability 
to induce drug metabolism. It is shown that compounds increasing the 
level of cytochrome P-450 in the microsomes do not necessarily induce 
6- aminolaevulinic acid synthetase and vice versa.
Finally the use of formic acid vapour in the carrier gas in gas 
liquid chromatography is critically, considered. Formic acid is shown 
to reduce adsorption of polar compounds on stationary phase of the 
column and thus improves the limit of quantitation. Evidence is 
presented for possible mechanisms.
"A desire to take medicine is perhaps 
the great feature which distinguishes 
man from other animals".
Osier, 1891.
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INTRODUCTION
INTRODUCTION
Brodie in 1964 stated that if there was no such process as drug 
metabolism, it would take the body about a hundred years to terminate 
the action of pentobarbital, which is lipid-soluble and thus cannot be 
readily excreted without being metabolized. The formation of more polar 
and water-soluble derivatives which results in reduction of the 
pharmacological action of a drug and its rapid excretion is known as drug 
detoxication.
Consequences of drug metabolism
Although most drug metabolites are biologically inactive there
are cases where drug metabolism leads to active compounds, e.g. imipramine 
is metabolized to desmethylimipramine, an active antidepressant
iproniazid an antidepressant, is dealkylated to isoniazid, an antitubercular 
agent. Intoxication can also take place as in the case of sulphonamides 
.where acetyl metabolites are highly water-insoluble and damage the kidney.
The metabolism of drugs takes place in two phases: phase I, metabolic 
transformation (biotransformation) and phase II, conjugation (Williams,1960). 
Both processes give rise to functional groups which transform the compound 
to a more polar less lipid-soluble molecule which is then readily excreted.
(Chapter 7). Metabolism can also alter pharmacological activity, e.g
c h 3c on h
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If a compound- already possesses a functional group it may undergo only 
conjugation e.g. benzoic, acid is only slightly oxidised to hydroxybenzoic 
acid and is mainly conjugated with glycine and glucuronic acid to form 
hippuric acid and benzoylglucuronide. Conjugates are mainly excreted 
in urine and bile.
Phase I reactions depending on their mode of action may be 
oxidations, reductions or hydrolyses. According to their nature and 
localization they may be divided into: (a) transformations catalyzed 
by the ’'microsomal drug metabolizing enzymes”, (b) transformations 
catalyzed by non-microsomal mammalian enzymes present in mitochondria, 
lysosomes or cytoplasm of tissue or by blood plasma enzymes and (c) 
transformations catalyzed by gut micro flora. The classification of 
metabolic transformations is summarised in Table 1.1.
Phase II reactions are syntheses involving addition of endogenous 
compounds to the functional groups formed as a result of phase I 
reactions. In many conjugations the transfer of endogenous substrate 
is mediated through coenzymes participating in the intermediary metabolism 
of nutrients, but different enzymes may be involved in catalysing the transfer
of drugs. The major routes of conjugation are given in Table 1.2.
Certain conjugation reach ions can also give rise to toxic products 
i.e. non- toxic fiuoroacetate condenses with oxaloacetate to form a 
fluorocitric acid, which blocks the tricarboxylic acid cycle by inhibiting 
aconitase (Peters, 1957). Glucuronide-forming enzymes can also detoxify 
normally occurring substrates, e.g. bilirubin conjugates with glucuronic 
acid giving rise to a glucuronide which is readily eliminated via the
bile (Schmid et al, 1957).
Chemical
Reaction
Microsomal drug
metabolizing
enzymes
Non-microsomal
mammalian
enzymes
Enzyme of the 
intestinal microflora
Oxidation
(oxygenation)
Aromatic 
hydroxylation
Acyclic'
hydroxylation
Alicyclic
Alcohol
oxidation (cytop) 
Aldehyde
oxidation (cytop) 
Alicyclic
hydroxylation
Epoxidation
N-oxidation
aromatisation
• , •' S-oxidation
Desulpharation
Dealkylation 
Deamination Deamination
(Mitoch.plasma)
Reduction Nitro
reduction
Reduction of 
sulphoxides and 
N-oxiaes
Reduction of N-oxide
Azoreduction
(cytoplasm) 
Reduction of Azoreduction
Dehalogenation disulphides Dehydroxylation
Hydrolysis Ester
hydrolysis
Hydrolysis of 
esters and amides 
(blood plasma)
Hydrolysis of esters
1
■ 1
Hydrolytic ring 
scission
Dehalogenation 
(cytoplasm .)
Hydrolytic ring scission
From Parke, D.V (1968)
Conjugate Major target group Deficient species
1. Glucuronic acid 
conjugation
~0H, -COOH, -nh2
>n h, -sh
j Cat, Gunn, rat
2. Sulphate
conj ugation
aromatic -OH, aromatic 
—NH2 some alcohols
Pig
3. Glycine
conjugation
aromatic -COOH, 
aromatic alkyl -COOH
Certain birds and 
reptiles
Ornithine
conjugation
aromatic. COOH Most
Glutamine
conjugation
aromatic CH2COOH
. ' -O
Most
4. Acetylation aromatic -NH2, hydrazides 
some aliphatic -NH2/
-SO2NH2
Dog
5..Mercapturic acid 
synthesis •
aromatic hydrocarbons, 
-Cl, -Br, -F, -N02
Guinea pig, Man'
6. Methylation aromatic -OH, NH2, >NH, 
—>N, -SH
From Mazel, P. (1972)
A. Phase I Reactions
Localization of enzymes
The phase I reactions of drug metabolism occur principally in the 
liver and to a lesser extent in the kidneys, lungs and gastro­
intestinal tract. These reactions are catalyzed by enzymes of the 
mitochondria (amine oxidase), the soluble fraction (alcohol 
dehydrogenase) but especially with the endoplasmic reticulum 
(microsomal mixed-function oxidases) .
The drug-metabolizing enzymes are not equally distributed in the 
microsomal fraction, the smooth surfaced microsomes containing 
more of these enzymes than the ’rough’ microsomes (Fonts, 1961;
Gram et al, 1967). It has been suggested that the enzymes are 
synthesized in the rough endoplasmic reticulum and when this is 
saturated with enzymes it loses its ribosomes and becomes smooth 
reticulum (Emster and Orrenius, 1965).
The first description of metabolism of a foreign compound by 
hepatic microsomes was described in 1949 (Mueller and Miller,
1949). This system was later found to metabolize many drugs and 
required NADPH as a reducing agent and also molecular oxygen 
(Brodie, et al, 1955). These requirements suggest that enzymes 
catalyse the consumption of one molecule of oxygen per molecule 
of substrate with one- oxygen atom appearing in the substrate and 
the other undergoing two-equivalent reduction. This system has been 
. termed a ’’mixed-function oxidase" (Mason, 1965) or a ’’monooxygenase" 
(Hayashi, 1964).
Solubilization of the enzyme has not been fully successful and'.available 
evidence suggests that enzymes are associated with the• lipoprotein • 
membrane of the endoplasmic reticulum. Liver cytochrome P-450,
the carbon monoxide-bincling pigment, was obtained in a solubilised 
form which could w-hydroxylate fatty acids, hydroxy3.ate and demethylate 
drugs, and which also exhibited characteristic electron paramagnetic 
resonance spectra and difference spectra with carbon monoxide and 
various substrates (Coon and Lu, 1969; Lu, et a3_, 1970). This 
system was resolved in three fractions, namely, cytochrome P-450,
NADPH-cytochrome P-450 reductase, and a heat stable component, 
all of which are required for fatty acid hydroxylation to occur at 
maximal rate. Similar systems were obtained from bovine adreno­
cortical mitochondria (Isaka and Hall, 1971), and chick embryo 
liver microsomes (Mitani, et al, 1971).
Mechanism of microsomal .'oxygenation
Drug oxidation occurs when ITactive oxygen" is transferred to the 
drug (Gillette, 1963) . Active oxygen is foimed through reaction 
of molecular oxygen with a component of microsomes reduced by 
NADPH. The overall reactions are as follows:
NADPH + .A + H+  --- — — > AH, + NADP+
A^2 + ^2 --------- *---> "active oxygen"
active oxygen .+ drug -— :------> oxidised drug + A + H^O
NADPH + 02 + d r u g ------- 1— > oxidised drug +; NADP * + ^ O h
Where A' is a microsomal component later identified with cytochrome 
P-450 in reduced form. NADPH™cytochrome c reductase is involved in 
the oxidation of NADPH, and NADPH-cytochrome P-450 reductase 
functions in the reduction of oxidised cytochrome P-450.
Stoichiometry of 1:1:1 in oxygen utilization, NADPH disappearance 
and formaldehyde-formation from aminopyrine demethylation has
results to the contrary (Estabrook and Cohen, 1969). With the 
discover)'' of the involvement of cytochrome P-450 in drug metabolism 
the following pathway.was proposed.
NADP ^
NADPH
v
rch2c h2o h
where F is a flavoprotein (cytochrome c reductase in liver and 
adrenodoxin reductase in the adrenals), and NHI is a non-haem 
iron protein (in the adrenals adrenodoxin). No direct evidence 
has been presented to show that electron transfer in liver 
microsomes is the same as in the system found in adrenal cortex.
But spectral and oxidation-reduction properties of the P-450 
complex prepared from beef liver microsomes are very similar 
to those obtained from beef adrenal cortex (Maclennan et al, 1967).
Substitution of NADI-I for NADPH does not support mixed function 
oxidation reactions but when. NADI-I is added together with NADPH 
there is an additive effect resulting in increased drug metabolism 
(Estabrook and Cohen, 1969). This synergistic response suggests
8.
that NADH in the presence of NADPH may serve as an electron 
donor for mixed function oxidation... When the amount of NADPH 
is kept constant, increasing amounts of NADH increase metabolism 
until a stoichiometry of 1:1 is achieved. When this situation 
is reached additional NADH has no marked influence on drug 
metabolism. These findings led to the following scheme 
(Estabrook and Cohen, 1969).
P-45i?
f \2
P-450 -
S
*  P-450-0,
ILO
NADPH
P 1
S
f *
P-450-02"
/
SOH
NADH
v
cyt b£
P^-450- 2^
Here NADPH serves as an electron donor through a respiratory 
chain direct to cytochrome P-450 with an associated branched 
pathway to cytochrome b^, the only other cytochrome, other than 
cytochrome P-450 found in the microsomes. In this way cytochrome 
b,- may serve as a second electron donor to cytochrome P-450 
and thus account for the ’’missing electron”. The complete electron 
transport and role of cytochrome b^ are repeated schematically 
in the following pathway.
9.
Mg
S
-NADPH
CO
2 +P-450
hvCO
P-4503+ AH2°
NADHCyt. b5 4
P-450
\/„
O2
41
SOH .
P-450
\/2-
0^
In this pathway S is the substrate fp^ and fp^ are the flavo- 
proteins cytochrome reductase and NADPH-cytochrome c reductase.
The side pathway of lipid peroxidation is labelled LP to LPO. |
I
Major pathways are given in solid lines. The factor "X" is an ■ 5
unknown intermediate having the same function as the iron sulphur f
i
protein adrenodoxin, required for the reduction in adrenal cortex ;
mitochondria (Omura, et al, 1966). J
’ ’
Mechanism of microsomal reductions j
Microsomes are also capable of cleaving azo dyes reductively and ;
1
to reduce nitro-compounds producing in both cases primary amines j
(Fouts et al, 1957). Azo dyes are reduced by two mechanisms
involving: (a) a carbon monoxide- and solubilization-sensitive -
pathway requiring cytochrome P-450 and (b) a carbon monoxide 
insensitive pathway involving NADPH-cytochrome c reductase which 
is not destroyed by solubilization (Gillette, 1966). A third
10,
pathway insensitive to carbon monoxide but sensitive to 
.solubilization was observed in microsomes from animals that 
received 3-methylcholanthrene (Hernandez, et al, 1967).
Both.NADH and NADPH can act as electron donors in the reduction of 
nitro-compounds. Reduction is mediated through the formation of 
nitroso- and hydroxyl amine derivatives to give rise to the 
.primary amines. Nitro-reduction is only active under anaerobic 
conditions and is mediated through cytochrome P-450 (Gillette 
et al, 1968). Sensitivity to oxygen may be in part due to auto­
oxidation of the hydroxyl amine derivative. The above workers 
proposed the following electron transport system which would 
explain both oxidative and reductive function of the microsomal 
drug metabolizing system.
Reduced
NADPH"*8**
NADP <
Reduced
Y FI
Reduced A
product
Nitro
productavins ' x
ZO
Components of 'microsomal drug metabolizing system 
(a) Cytochrome. P-450
Localization and general properties: Cytochrome P-450 was first
described by Klingeriberg, 1958 and Garfinkel, 1958, and it was 
subsequently studied by Gmura. and Sato (1962, 1964). It is a 
haemop rote in found in a variety of vertebrates, including several 
mammals, in bacteria'(Katagiri et al, 1968) and in yeast (Ishidate 
et al. 1969) although it is not identical in every tissue or species. 
It is mainly found in hepatic microsomes but also has been reported 
in the microsomes and mitochondria of adrenal cortex where it 
functions in the hydroxylation of steroids although not in the 
oxidation of most drugs (Estabrook, et al, 1963). To a lesser 
extent it is found in the kidney and intestinal mucosa and has 
also been reported in the mitochondria of the corpus luteum 
(Yohro and Hoiie, 1967).
Carbon monoxide forms a complex with reduced cytochrome P-450 
giving a maximum absorption at 450 nm, and inhibits drug 
metabolism (Orrenius and Emster, 1964). This is reversed by 
monochromatic, 450 nm light (Cooper et al, 1965). Certain 
substances such as deoxycholate, steapsin and snake venom which 
inhibit microsomal drug metabolism (Gillette, et al, 1957.;
Posner, et al, 1961) also convert cytochrome P-450 to its inactive 
form P-420 (Gmura and Sato, 1964). Furthermore, detergents used 
to solubilise microsomes lower the rate of drug metabolism 
proportionally to the conversion of cytochrome P-450 to its P-420 
form (Gillette, 1966). Agents that increase or decrease drug 
metabolism frequently cause parallel changes to cytochrome P-450 
concentration (Orrenius and Ernster, 1964).
Conversion of cytochrome P-450 to cytochrome P-420: Cytochrome 
P-450 is converted to cytochrome P-420,by a variety of agents, e.g. 
snake venom containing phospholipase A (Omura and Sato, 1964), 
detergents such as lysolecithin, guanidine, neutral salts, aniline, 
iodine (Imai and Sato, 1967), metal reagents such as bathophenan- 
throline, trypsin, ureas, -SH binding agents such as p-chloro- 
mercuribenzoate, alcohols (Mason, et. ad, 1965), and a variety of 
amides and phenols (Ichikawa, et al, 1968).
These-agents are believed to disrupt the association between 
haemoprotein and microsomal lipid (Imai and Sato, 1967).
o
Depending on the agent this may be the result of direct action on 
the lipid or due to an effect on the protein associated with the 
lipid. This conversion of cytochrome P-450 is the result of 
disturbance of the hydrophobic environment around the haem, either 
by primary action of the-agent or by secondary effects caused by 
conformational changes in the haemoprotein (Omura and Sato, 1964). 
Cytochrome P-420 formed from treatment of microsomes with 
sodium cholate.-or p-chloromercuribenzoate can be converted back to 
cytochrome P-450 by polyols and reduced glutathione (Ichikawa 
and Yamano, 1967).
Binding of drugs to cytochrome P-450: Drugs and foreign compounds
interact with cytochrome P-450 to produce two kinds of spectral 
changes (Imai and Sato, 1966; Remmer, et al, 1966). Type I spectra 
are characterized by a peak at 385-390 nm and a trough at 418-427 nm 
while type II have a peak at 425-435 nm and a trough at 390-405 ran.
A modified type II spectrum, also known as an inverse type I spectrum 
lias been described with a trough near 390 nm and a peak at 420 nm 
(Schenkrnan, et al, 1967; Diehl, et al, 1970; Wilson and Orrenius, 
1972).
Type I spectral, change represents the interaction of a substrate 
with mixed function oxidase to form a coup lex (Schenkrnan, et al,
1967). Formation of this complex parallels enzyme activity 
(Schenkrnan et al, 1967a). Phenobarbital increases both drug 
metabolism and. type I spectral change. The type I spectral 
change has/been shown to be a characteristic of the protohaem 
itself and to be caused by an increase in the elctronegativity of I
one ligand of the haem'(Schenkrnan and Sato, 1968). It is the 
result of the shift of absorption maximum of the oxidised form 
of cytochrome P-450 from 419 to 415 nm and appearance of a 
shoulder at 394 nm. . . i
i
The type II spectral change is similar to the reaction between j
a basic amine and a ferrihaemoprotein and was shown to be a ;
1
ferrihaemochrome spectral change (Schenkrnan et al, 1967). The ]
compounds causing such a change react with both ferricytochrome 
P-450 (absorption maximum 419 nm) and the substrate bound 
haemoprotein (394 nm peak) as determined in absolute spectrum 
(Remmer, et al, 1969) and in difference, spectrum (Schehkman,
1970). Peak position depends on basic amine added. Aniline 
like ethyl isocyanide can displace carbon monoxide from reduced 
haemoprotein indicating interaction at the haem iron and can 
interact with reduced cytochrome P-450 to form a spectral change 
containing two Soret peaks (Imai and Sato, 1968).
Modified type'll spectra were shown to be reverse of type I spectral 
change in both absolute and difference spectra, and it was suggested 
that this was due to displacement from the enzyme of some pre-existing 
compound bound in vivo (Schenkrnan, et al, 1969). This type of spectrum 
involves interaction between compounds and a non-haem part of the 
mixed-function .oxidase. The reverse type I spectra appear not to
14. . '
be related to substrate metabolism (Jansson et al,, 1972).
It is possible that modified type II compounds may act at the 
same or different site from type 1 compounds. The-most probable 
explanation is that they interact with type I and another site 
(Schenkrnan, et al, 1972).
Since cytochrome P-450 has not yet been obtained in purified form, 
little is known about the chemical bonds of the haem moiety or 
of the coordination bonds of the fifth and sixth ligands of the 
haem iron. The following hypotheses were put forward about 
spectral interactions (Schenkrnan et al, 1967): (a) two molecular
species of cytochrome P-450 exist giving rise to type I and type II 
binding spectra; (b) type I and type II compounds affect different 
ligands of the haem with the enzyme protein thereby modifying the 
haem “-protein ligand interaction and causing a spectral shift. 
Electron paramagentic resonance spectroscopy supports the suggestion 
that, substrate interaction modified ligand interaction with the 
haem iron of cytochrome P-450 (Cammer et al, 1966); (c) type I
and type II spectral changes result from an alteration of the 
oxidation state of cytochrome P-450. In the same year Imai and 
Sato (1967) put forward the following hypotheses: (a) the 
substrate substitutes a ligand for the haem iron of a cytochrome 
P-450, thereby modifying the molecular extinction coefficient 
.of the haemoprotein} (b) the substrate modifies ligand state 
of the haemoprotein by interacting with the porphyrin ring;
(c) the substrate combines with a specific site located on the 
protein moiety of cytochrome P-450 causing a conformational change 
in the haemoprotein molecule to alter the ligand state; (d) substrate 
interacts indirectly with cytochrome P-450 through phospholipid 
surrounding the haemoprotein thus altering the hydrophobic 
environment of the haem group resulting in .the modification of the
ligand state.
Cytochrome P-450 is oxygenated in its reduced form and with'the 
exception of metyrapone (Hildenbrandt et al, 1969) drugs do not 
bind to microsomes reduced with dithionite. The reduction of 
cytochrome P-450 is considered to be the rate-limiting step in 
microsomal drug metabolism (Davies et al, 1969; Gillette and 
Gram, 1969). It is now believed that during drug metabolism 
the substrate forms a complex with the oxidised form of cytochrome 
P-450. -This complex is then reduced either directly through an 
unknown carrier or directly by NADPH-cytochrome c reductase. The 
reduced cytochrome P-450-substrate complex rapidly combines with 
molecular oxygen-to form an-^-cytochrofte- P-450 substrate complex 
which quickly decomposes to form the oxidised substrate and the 
oxidised-form of the cytochrome. The rate limiting step is the 
reduction of the complex of the substrate and the oxidised 
cytochrome.
Under anaerobic conditions the cytochrome catalyses reduction of 
azo- and nitro-compounds but the rate limiting step may be either 
the reduction of the cytochrome or the transfer of electron from 
the cytochrome to the azo- and nitro-substrates (Gillette and 
Gram, 1969).
Forms of cytochrome P-450: Studies on the induction of microsomal
drug metabolising enzymes by phenobarbitone and polycyclic hydro­
carbons suggested the- formation of a modified cytochrome P-450 
■known as ’’cytochrome P^-450M (Sladek. and Mannering, 1966; 1969). 
.This new haemoprotein has been, shown to have a slightly different 
maximum absorption from that of the normally-occurring cytochrome
■P-450, namely at 448 nm, (Alvarez et al? 1967) and appears to be 
incapable o£ binding with type I compounds (Shoeman etal, 1969). 
Electron paramagnetic studies have shown that cytochrome P-450 
is a high spin form of the cytochrome having five unpaired 
electrons (Hildenhrandt et al, 1968; Jefcoate and Gaylor, 1969) 
compared with the low spin iron having one unpaired electron in 
normal cytochrome P-450 (Hashimoto et. aL, 1962; Ichikawa and 
Yama.no , 1970)« Cytochrome P-420 derived from the cytochromes 
P-450 and P^-450 are different in that P-420 binds both type I and 
type II drugs but P^-420-binds only type IIcompounds. On the 
basis of their haem contents the molar absorbancies of P.,-420 ^ X
and P-420 differ (Mannering, 1972). . '
Cytochrome P-450 and cytochrome P^-450 may be similar, but separate 
entities each' of which can exist in two interconvertible forms 
(Mannering, 1972). Schenkman and his associates (1969) suggest 
that the changes in the haemoprotein after the administration of 
polycyclic hydrocarbons result from the -irreversible addition of 
the hydrocarbon to the type I binding of native cytochrome P-450. 
They concluded that cytochrome P-450 exists in only two forms : 
the native enzyme and the enzyme substrate complex.
3Using H-6-aminolaevulinic acid it was shorn that loss of 
incorporated radioactivity into haemoprotein in the CO-binding 
particles decreased in two phases: a rapid phase with a half-life 
of 7-8 hours and a slow phase with a half-life of 46-48 hours 
(Levin and Kuntzman, 1969; Meyer and Marver, 1971). Phenobarbital 
administration does not alter the rate of the two phases but
increases the fast phase to 11-12 hours (Levin and Kuntzman,
1969). On the other hand, 3-methylcholanthrene administration 
does not change the biological half-life of the two phases but 
changed the proportion of fast/slow phase from 3.8:1 to 1:1 
(Levin and Kuntzman, 1969a). These findings suggest that either 
two haemoproteins exist, both of which are. sensitive to phenobarbital 
administration, while 3-methylcholanthrene only affects one, or 
one haemoprotein is formed and is catalytically converted to a 
second type. Phenobarbital and 3-methylcholanthrene could 
differentially affect this conversion. It is also possible that 
, a single haemoprotein exists in two forms with different half- 
lives.
The increase in protohaem content by phenobarbital is the result 
of an increase in the amount of both the rapidly- and slowly- 
decaying components. .
Reductases
NADPH-cytochrome c reductase: The properties of this enzyme have
been reviewed (Kamin et al, 1965). It is believed that NADPH- 
cytochrome c reductase reduces cytochrome P-450 directly or 
indirectly though a non-haem iron protein or some otherunident if ied. 
carrier.
NADPH-cytochrome P-450 reductase: NADPH-cytochrome P-450
reductase is rate limiting in the overall reaction involving ' 
microsomal ding metabolism (Gillette and Gram, 1969). Type I binding 
compounds stimulate NADPH-cytochrome P-450 reductase whereas type II 
binding compounds either inhibit or have no effect (Gigon, et a_l,1968 
Gillette and Gram, 1969). This is not yet understood. NADPH- 
cytochrome-P-450 reductase is assumed to reflect the activity of
NADPH-cytochrome c reductase or of some other flavoprotein as it 
functions as part of the microsomal multienzyme.
B. Phase II Reactions
Although conjugation takes place mainly in the liver, it has also 
been shown to occur in kidney, gastrointestinal mucosa and skin (Dutton 
and’Stevenson, 1959; Stevenson and Dutton, 1960, 1962). Metabolic 
products formed by phase I reaction are conjugated with glucuronic
. , acid, sulphate, glutathione or undergo methylation or acetylation.
By far the most common procedure is glucuronide formation because 
of the general availability of glucose in the biological system 
(Dutton, 1966). Uridine-diphosphate glucuronic acid (UDPGA) is 
formed from UDP-glucose and it activates glucuronic acid.
Glucose-l-phosphate + UTP UDP-glucose + pyrophosphate
UDP-glucose + 2NAD+ + H90 —  ciehydrogenas^  UDP-glucuronic acid
2 + 2NADH + 2H
UDP-glucuronic acid + RXH f^hnsferase  ^^ "g^-ucuron -^c acid + UDP 
0
rvhere X is 0, &,  NH, or S.
' Factors affecting drug metabolism
The metabolism of drugs is affected by genetic, physiological, 
pharmacodynamic and environmental factors. These have recently 
been reviewed (Parke, 1968) and will be discussed only briefly with 
a few cited examples.
(a) genetic factors ■
Species differences: These differences can be both quantitative
and qualitative .and can effect.both conjugation and biotransformation .
reactions. Aniline is hydroxylated in the para-position in the
rabbit but in the ortho-position in the rat (Parke, 1968).
Activity of biphenyl-4-hydroxylase varies in different species 
being higher in the mouse and lower in the cat (Creaven et al, 
.1965). Many excellent reviews have appeared in this field (Parke, 
1968; Smith, 1968; Hucker, 1970). Species variation has also 
been observed during enzyme induction (Conney, 1967).
Strain differences: It is now known that the .activities of the
drug-metabolizing enzymes differ among certain strains of the same 
species. Strain differences also influence enzyme induction (Gram 
et al, 1965). Differences in hexobarbital oxidase and hexobarbital 
sleeping time were observed in different strains of rats (Mitoma 
et al, 1967).
Difference in the individual response to drugs is.also known. Hie 
anti-tuberculosis drug isoniazid, is deactivated by acetylation and 
the rate of acetylation has been shown to vary among -individuals 
(Peters et al, 1965). These individual variations are genetically 
controlled (Evans et al,.1960).
O3) Physiological factors
Age: Foetal and newborn animals have a limited ability to
metabolize and thus detoxify drugs (Fouts and Adamson, 1959;
Jondorf et al, 1959) . This is due to absence of microsomal enzymes 
in the foetus which, however, increase rapidly after birth (Kato 
et al, 1964). Older rats generally have slower rates of drug 
metabolism (Kato and Takanaka, 1968).
Nutritional status: Activity of the drug-metabolizing enzymes is
dependent on the nutritional status of the animal. Rats on calcium 
or protein deficient diets 'exhibit decreased activities of drug- 
metabolizing enzymes (Dingell et al, 1966). On the.-contrary,' rats 
maintained, for 15 days oh a diet deficient in choline, casein.
methionine and cysteine showed increased activities, in aniline 
hydroxylase and nitro-reductase (Rubin et al, 1968).
Disease: Patients suffering from liver disease are more sensitive
to drugs probably as the result of impaired drug metabolism (Muting 
1963; Kato et al, 1968). Hepatic microsomes from rabbits with 
obstructive jaundice show impaired metabolism of acetanilide and other 
drugs (McLuen and Fouts, 1961). Animals suffering from disease or 
tumour-bearing are more susceptible to phenobarbitone induction 
(Chiesara et al , 1967).
Sex differences: Male rats metabolize drugs faster than females
(Kato et al, 1962; Kuntzman et al, 1966; Davies et al, 1968).
Tliis difference is attributed to sex hormones as it appears only, 
at puberty, and is abolished by castration and may be induced in 
female rats by administration of androgens. It has been observed 
only in rats and probably does not occur in humans.
Pregnancy:‘ Tissue levels of progesterone and pregnanediol are 
increased during pregnancy. These steroids are inhibitors of 
glucuronyl transferases in vitro (Hsia , et al 1963; Creaven 
and Parke, 1965). Some* hepatic microsomal drug metabolizing enzymes 
are also inhibited by certain progestational steroids used as oral 
contraceptives such as progesterone and norethynodrel (Juchau 
and Fouts, 1966).
Hormones: Administration of ACTH, adrenaline or thyroxine inhibit
microsomal metabolism only in male rats and only in those drugs 
which show sex-dependence (Kato and Gillette, 1965). Alloxan- 
induced diabetes reduces drug metabolism in vitro and these effects 
are reversed by insulin (Dixon et al, 1963).
■(c) pharmacodynamic factors .
Pharmacodynamic factors such as protein-binding and urinary pH 
may affect the excretion of drugs. These factors are discussed
in more detail in later chapters (Chapter 5).
(d) environmental factors
Many drugs, pesticides and toxic chemicals can. stimulate or 
inhibit the activities of the drug-metabolizing enzymes.
Inhibition of drug metabolism: Inhibition of drug metabolism
generally leads to prolonged pharmacological activity of drugs. 
Inhibition of steroid metabolism also occurs, resulting in the 
potentiation of their action (Kupfer and Peets, 1967;Levin 
et al, 1968). Inhibitors include drugs such as iproniazid, 
imipramine, glutethimide, but other chemicals such as SKF 525A 
(3-diethy1aminoethy1 diphenylpropylacetate hydrochloride), DPEA 
(2,4-dichloro-6-phenylphenoxyethylamine) have proved more potent.
The most widely studied inhibitor is SKF 525A (Cook and Toner, 
1954; Axelrod et al, 1954). It is believed that it acts by compet 
with other drugs for the active site of the microsomal enzymes 
(Anders and Mannering, 1966). After its preliminary inhibitory 
effect SKF 525A subsequently acts as a stimulator. Similarly, 
stimulators of the microsomal enzymes also have a preliminary 
inhibitory phase. Thus both inhibitors and stimulators of drug 
metabolism have two uhases of action.X.
Inhibition of hepatic microsomal drug metabolism can also be 
brought about by chemicals such as piperonyl sulplioxi.de and 
piperonyl butoxide which are consequently used.as insecticide 
synergists. They reduce the metabolic deactivation of pesticides 
and potentiate their insecticidal activity (Metcalf et al, 1966).
Carbon monoxide inhibits microsomal enzymes non-competitively by 
poisoning cytochrome P-450 (Kato, 1966). A detailed review of
this field has recently.been published (Anders, 1971).
Enzyme induction: More than two hundred drugs, insecticides,
carcinogens and other chemicals are known to stimulate the 
activity of drug-metabolizing enzymes in liver microsomes. The 
characteristic pharmacological actions of these compounds on the 
organism are extremely diverse and there is no apparent relationship 
between either their actions or structure and their ability to 
induce the enzymes.
Inducers fail into two categories (a) drugs and insecticides.
These induce the metabolism of a wide variety of drugs, a major 
representative of this group being phenobarbitone; (b) large 
polycyclic hydrocarbons. These have inductive effects towards • 
only a small number of substrates, the major representatives being
3-methylcholanthrene and 3,4-benzpyrene.
When rats were given doses of the inducers maximal for their 
characteristic enzyme inductions, the liver microsomes were 
even more active in metabolizing drugs when both 3,4-benzpyrene 
and phenobarbital were given than when either were given separately 
(Gillette; 1963a). However, the activity was about the same when 
the inducers used were 3,4-benzpyrene and 3-methylcholanthrene, 
together or separately. These studies suggest that phenobarbitone 
and 3,4-benzpyrene induce microsomal enzymes in different ways.
The two types of inducers differ also in the course.and intensity 
of induction.
Mechanism of induction: The term ’’enzyme induction” is specifically 
used to describe the process which increases the rate of synthesis 
of an enzyme relative to its normal rate of synthesis in the 
individual organism.
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Enzyme induction by both 3-methylcholanthrene and phenobarbital is 
independent of the hormones of testis or ovaries, or of adrenals, 
pituitary or thyroid glands (Gillette, 1963a;Shimazu, 1965;
Conney v : k: . 1967).
Liver homogenate 100,000g supernatants from animals treated with 
phenobarbitone or '3-methylcholanthrene do not alter the activity 
of the microsomal drug-metabolizing enzymes of control preparations 
This indicates that induction is not due to increasing levels of 
an endogenous activator or cofactor or by decreasing the level 
of an inhibitor (Conney et al, 1960; Kato et_ a1, 1962a). Neither 
inducing agent influences the Michaelis constant but both increase 
the maximum velocities suggesting that the affinity of enzyme for 
the substrate is not altered (Netter and Seidel, 1964).
Inhibitors of protein synthesis or DNA-dependent RNA formation 
prevent drug-induced increases in microsomal enzyme activity. The 
induction of drug-metabolizing enzyme activity by 3-methylcholan­
threne or phenobarbital is blocked by ethionine (Conney-et al, 1956 
Fujimoto and Plaa, 1961), puromycin (Conney and Gilman, 1963; 
Gelboin and Blackburn, 1964), or actinomycin D (Gelboin and 
Blackburn, 1964; Orrenius et al, 1965). • The ability of 
actinomycin D to block the induction of drug-metabolizing enzymes 
by 3-methylcholanthrene or phenobarbital suggests that these enzyme 
inducers may accelerate the DNA-directed synthesis of RNA which 
functions as a template for the synthesis of the drug-metabolizing 
enzymes.
Studies suggested that phenobarbital increased the total liver 
microsomal protein in rats by increasing the rate of synthesis
• " ' ‘ . ' . \  
and by decreasing the breakdown of microsomal protein. Thfe 
molecular basis for liver microsomal enzyme induction is still 
not clear. Phenobarbitone and 3-methylcholanthrene induction of 
microsomal protein in vivo is parallel&lby increased incorporation 
of amino acids into microsomal protein in vitro (Gelboin and 
Sokoloff, 1961). Treatment of rats with phenobarbital stimulates 
the incorporation of C -leucine into microsomes in vivo but has 
no effect on the incorporation of this aminoacid in other 
subcellular fractions (Kato et al, 1965).
Treatment of animals with phenobarbital causes a marked proliferation 
of smooth endoplasmic reticulum with little or no effect on rough 
endoplasmic reticulum (Fouts and Rogers, 1965; Remmer and Merker,
1965). In contrast, treatment of animals with 3-methylcholanthrene 
or 3,4-benzpyrene had little or no effect on the proliferation of 
smooth membranes of endoplasmic reticulum (Fouts and Rogers, 1965). 
Phenobarbitone increases the rate of incorporation of inorganic phosphate 
into phospholipid of both smooth and rough fractions of the micro-
somes suggesting that enhanced phospholipid synthesis was an early 
step in the phenobarbital-induced proliferation of smooth-surfaced 
■ endoplasm (Orreniusm 1965; Orrenius and Ericsson, 1966). These 
results were not confirmed by other workers (Holtzman and Gillette,
1966), who showed that phenobarbital increased hepatic microsomal 
phospholipid by inhibiting phospholipid catabolism.
Bxtrahepatic enzyme induction: Administration of polycyclic
aromatic hydrocarbons induced 3,4-benzpyrene hydroxylase in kidney 
and small intestine, placenta, skin, ovaries, increased drug 
metabolism and also caused the appearance of activity which was 
previously too low to be detected (Wattenberg and Leong, 1962;
Welch et al, 1969). Phenobarbital, and several other stimulants
of hepatic drug-metabolism, were among the compounds'-that had 
little or no effect on benzpyrene hydroxylase activity in the 
gastrointestinal tract or placenta of rat. It has also no effect 
on pentobarbital oxidase in lung, nitro-reductase in kidney or 
aminopyrine N-demethylase in kidney, heart, spleen muscle or 
lung.
Glucuronide synthesis is stimulated when 3,4-benzpyrene is added 
to the skin of rodents (Dutton and Stevenson, 1962). Injection 
of 3-methylcholanthrene induced the formation of aminoazo-dye 
N-demethylation activity in lung and kidney (Gilman and 
Conney, 1963) and menadione reductase in the lung (Huggins and • 
Fukunishi, 1964).
Consequences of drug interaction: Since the duration of the
phaimacological action of a drug is largely controlled by the rate 
of metabolism any changes in the metabolic organization will also 
influence the duration and intensity of drug action. Enzyme 
induction can increase or decrease phaimacological activity 
depending on whether metabolic transfoimation leads to activation 
or deactivation of the parent drug.
A drug can induce its own metabolism so that on prolonged 
administration its pharmacological action is diminished and a 
higher dosage is required to maintain therapeutic levels. This 
phenomenon is known as "tolerance" and this effect led workers to 
study barbiturates as enzyme inducers (Remmer, 1962). Prolonged 
administration of one drug can also lead to tolerance towards 
another drug if they are both substrates of the same enzyme 
system and this is termed "cross .tolerance".
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Several examples are known in which enzyme induction blocks 
.chemical carcinogenesis. The formation of cancers at a variety 
of sites > resulting from the administration of 2-acetyl-aminofluorene 
and 4-dimethylaminostilbene is inhibited by the administration of 
polycyclic hydrocarbons that stimulate the activity of carcinogen- 
metabolizing enzymes in liver microsomes (Miller, et al, 1958).
Since polypharmacy is now a common feature in hospitals and in 
general practice extra care is required to eliminate adverse 
effects due to enzyme interaction. ••
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Proposed- thesis
For a drug to have an effect on the hepatic drug metabolizing 
enzymes it must remain in the body for a sufficient period of 
time. It has been suggested by many workers that the extent of 
stimulation or .inhibition of microsomal drug-metabolism by a 
particular compound is related to the rate of its elimination.
The present project provides evidence to support this suggestion.
A series of commonly used barbiturates has been studied and their 
biological half-lives and enzyme-induction potential are I 
determined in male rats; a possible mechanism is discussed.
Since many drugs are substrates of the same enzyme system • 
their simultaneous administration will affect the rates of 
metabolism and elimination, and thus alter their pharmacological 
activity. The interaction of barbiturates with imipramine and 
ethanol has been investigated after acute and chronic ethanol 
administration. Possible mechanisms of interaction are proposed.
Barbiturates, especially those containing one or more allyl 
group, have also been implicated in porphyria. The importance of 
the allyl group is evaluated and the relation between drug 
metabolism, enzyme induction and porphyrogenicity is considered.
Chapter Two 
MATERIALS AND METHODS
MATERIALS and methods •
A. MATERIALS 
• Substrates
Biphenyl m.p. 70°C, aniline hydrochloride, p-nitrobenzoic acid, 
glycine, sodium citrate and 99*9% (‘ /v) alcohol were obtained from 
B.D.H. Ethylmorphine m.p.' 123°C and hexobarbital were obtained from 
May and Baker. Cytochrome c (73%)' was obtained from Sigma and-glucose- 
’ 6-phosphate (77%) from Boehringer. Zoxazolamine m.p. 184°c, was obtained 
from K.& K. laboratories. All the above were «used without further 
purification.
Standards
Potassium dihydrogen phosphate, formaldehyde, p-aminophenol, 
p-aminobenzoic acid m.p. 181°C and 2-hydroxybiphenyl m.p. 51°C and 
4-hydroxybiphenyl m.p. 162°C were purchased from B.D.H. Bovine serum 
albumin was obtained from Koch-Light laboratories and S-aminolaevulinic 
acid hydrochloride from Sigma. All standards were.used as obtained.
Cofactors
Nicotinamide-adenine dinucleotide phosphate (NADP) and the reduced 
form (NADPH) were obtained from Boehringer. Nicotinamide adenine 
dinucleotide (NAD) and adenosine triphosphate (ATP) were also purchased 
from Boehringer. Nicotinamide-adenine dinucleotide reduced (NADH) was 
purchased from Koch-Light and flavin mononucleotide (FMN) from Sigma.
Enzymes
Alcohol dehydrogenase (60% appr. 200 U/mg) was purchased from 
Boehringer.
Solvents
All solvents were of the Analar grade and were obtained from
B.D.H.
Animals
The entire project was carried out in rats. In all experiments rats 
were used from a randomly bred colony of Wistar-albino rats (Porton strain). 
Breeding nucleus was obtained from Laboratory Animals Centre, Carshalton, 
Surrey. Animals were kept in polypropylene cages covered with stainless 
steel tops made by North Kent Plastic Cages Ltd. The breeding took place 
on woodshavings sterilised with ethylene oxide. Prior to experimental work 
animals were transferred to sterolite bedding (U.P. Usher Ltd). Rats were 
fed Spiller’s No. 1 diet (small animal diet autoclaved)’ and water ad libitum 
and were kept in a room with no other species . Temperature was kept at 
37°C, humidity was maintained at 50% and lighting was on a twelve-hour 
system.
B-. METHODS
General considerations
The study of in vitro systems is considered to provide information 
about the in vivo situation when the latter cannot be investigated directly. 
The conditions under 'which in vitro studies are carried out do not 
necessarily correspond to the in vivo situation. They are arbitrary 
conditions chosen to provide sufficient activity measurable by the 
available techniques. Optimum conditions are usually preferred although 
there is no indication that the living organism carries out 'the reactions 
at maximum velocity. Optimum conditions vary considerably among laboratories 
and results obtained by in vitro methods do not often parallel the in vivo 
observations, e.g. ethanol is metabolized in vitro by a microsomal system 
involving catalase and alcohol dehydrogenase but this system was found to 
be unimportant in vivo (Wallgren and Barry, 1970). The in vitro activity 
of microsomal enzymes is also affected by non-physiological factors such 
as method of enzyme preparation, level of cofactors etc. Minor changes 
in methodology may markedly affect the in vitro microsomal activity.
Pretreatment of animals may alter optimum conditions so that 
extraporation to the in vivo situation becomes even more difficult. Pre- 
treatment of animals with 3,4-benzpyrene alters the pH optimum of the 
conversion of aniline to p-aminophenol (Rickert and Fouts, 1970) so that 
the true action of 3,4-benzpyrene on aniline metabolism-cannot be clearly 
established.
Preparation of liver subfractions
Animals were sacrificed by cervical dislocation. Hie livers
were rapidly removed and washed in ice-cold, homogenizing medium to remove
blood. The livers were blotted gently on filter paper and adhering fat
and fibrous tissues were removed and liver sample was then weighed. Liver
was minced with scissors and homogenized in a glass homogenizer (size C)
using a loose fitting Teflon pestle (Potter and Elvehjem, 1936). For each
homogenization'two slow-.up and down strokes were used. The homogenizing
vessel was kept in an ice-bath during homogenization to avoid enzyme
destruction due to overheating. The homogenate was then adjusted so
that 1 ml e 250 mg of liver, placed in 50 ml polycarbonate centrifuge
tubes and centrifuged in an M.S.E. ’High-speed 18* centrifuge at
10000 x g (11000 r.p.m.) for 20 minutes to remove debris, nuclei, av
mitochondria and lysosomes. The centrifuge was maintained at 4°C. The 
supernatant was carefully removed and was designated "microsomal super­
natant" and comprised microsomes and soluble fraction. An aliquot is 
further centrifuged in an M.S.E. ’Superspeed 50’ in a 10 x 10 or 8 x 25..ml 
angle head rotor at 105000 x gav (40000 r.p.m.) for one hour at a 
temperature of 4°C. Supernatant is carefully removed and comprised the 
"soluble fraction". Microsomal pellet was washed with homogenising 
medium to remove any traces of supernatant fraction and was resuspended 
in original volume of • homogenizing medium using one slow up and down 
stroke using a size B homogenizing vessel. This fraction consitituted 
"microsomar suspension".
To obtain "mitochondrial fraction" the whole homogenate was 
centrifuged in an M.S.E. bench centrifuge for 10 minutes (speed number 4) 
to remove debris and nuclei. The supernatant was. subsequently centrifuged
in an M.S.E. ’High-speed 18’ centrifuge at 5000 r.p.m. for 20 minutes. 
Supernatant was decanted and the mitochondrial pellet was resuspended 
in the original volume of the-’’microsomal suspension”.
then washed fractions were required, the pellets were resuspended 
in the original volume of homogenizing medium and recentrifuged.
All preparations were carried out as quickly as possible and all 
manipulations were done at 4°C to avoid any loss of enzyme activity.
In vitro studies w
The following standard conditions were observed so that a direct 
comparison between experiments is always applicable.
All animals were kept in cages with similar bedding (Ferguson,
1966) and each cage contained the same number of animals to avoid 
differences in activity due to crowding (Vesell, 1968). No insecticides 
were used in the animal house to prevent stimulation of drug metabolism 
(Kinoshita, et al, 1966).
Animals were killed at 9.00 a.m. ± 1 hour to avoid differences in 
activity due to diurnal variations. Circadian changes in the activities 
of drug metabolizing enzymes have been reported (Davis, 1962; Vesell,
1968; Radzialowslki and Bousquet, 1968).
Microsomal preparations were prepared in isotonic 1.15%'KClas 
sucrose preparations are appreciably less active (Roth and Bukovsky,
1961). The 10000 x g supernatant was used for investigation of microsomal 
drug metabolism since activity is greater and linear for a longer period
when compared to microsomes (105000 x g pellet) and an NADPH generating 
system (Mazel, 1972). Mien isolated microsomes are used, rate of 
metabolism may not be proportional to the protein concentration (Alvares 
et al , 1969). Mien reduction of cytochrome c by NADPH was estimated 
isolated microsomes are used as they are less turbid.
All incubations were carried out in test tubes in duplicate in a 
Mickle shaking water bath kept at 37°G. Hie rate of shaking was kept 
constant at 60 cycles/minute (Fouts and Waters, 1961). Cofactors were 
always prepared immediately before use. All enzymic assays were performed 
under conditions where substrate and cofactor levels were not limiting 
and product formation was linear with' time during the incubation period.
To all incubation mixtures Mg was added, as previous reports 
showed that magnesium ions stimulate rat liver microsomal metabolism of 
many drug substrates in both control and induced animals (Peters and
H—b
Fouts, 1969) . The activation by Mg may be the result of alteration 
of the microsomal membrane structure allowing a more rapid interaction 
of enzyme and substrate thus enhancing the rate of electron flow from 
electron drug to substrate or it may effect on cytochrome P-450 reductase 
(Peters and Fouts, 1970), although other workers reported no effect on 
reduction of cytochrome P-450 (Gigon et al, 1969).
When overnight storage was required, microsomes were stored in the 
form of a pellet at 4°C. Previous work showed that there is a considerable 
loss of activity when microsomes were kept.in suspension on lyophylized 
(Leadbeater and Davies, 1964; Levin et al, 1969).
The following classes of enzymes were studied:
(a) Drug metabolizing enzymes
Biphenyl hydroxylation: Liver microsomal preparations metabolize 
biphenyl, a type I substrate to the 2- and 4-hydroxybiphenyl 
(Mitoma et al, 1956; Creaven et al, 1965).
Hydroxylation at the 4- position is the predominant pathway 
and about 7 weeks after birth the levels of 2-hydroxybiphenyl 
are negligible (Basu et al, 1970).
Both hydroxybiphenyls can be determined in the same 
preparation because the 2-isomer shows excited state ionization, 
whereas the 4-isomer does not (Bridges et al, 1965).
Biphenyl
2-Hydroxybipheny1
'V-OH
4-Hydroxybiphenyl
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The incubation system consisted of:
Tris buffer, pH = 8.1 (25 ymoles) . .. .. .. 0.5 nil
Biphenyl in 4% Tween-80 (3 ymoles).. .. .. 0.25ml
MgC^ (10 ymoles) .. .. .. .. ,. .. 0.2 ml '
Homogenising medium (1.15% KC1) .. . . . .  0.3 ml
NADP+ (1.5 ymoles) .. .. .. .. .. .. 0.25ml
Microsomal supernatant (25%) .. . . . . . .  0.5 ml .
Total volume 2 .0 ml
Incubation was carried out for 20 minutes and reaction was 
terminated by addition of 2M-KC1 (0.5 ml) T Biphenyls were extracted 
with n-heptane (10 ml) mechanically for 5 minutes. Heptane aliquots 
(2.0 ml) were further extracted similarly with 0.1 M NaOH (10 ml). 
Phases were separated by centrifugation and 2.0 ml aliquots of the 
aqueous layer were placed in a cuvette and pH was adjusted to 
5.5 with the addition of 0.5 N succinic acid (0.5 ml). The 
fluorescence was then measured in a Baird-atomic spectrofluorimeter 
at two wavelengths • 338 nm and 415 nm, with excitation at 275 nm 
■and 295 nm respectively.
Blanks were prepared by addition of substrate after incubation. 
Similarly standards containing either 2-hydroxybiphenyl (6 yg) or 
4-hydroxybiphenyl (30 yg) in 5% ethanol were carried through the 
same procedure. Fluorescence response was linear with concentration 
at the range used (0-8 yg for 2-hydroxybiphenyl and 0-30 yg for
4-hydroxybiphenyl).
Aniline hydroxylation: Aniline, a type.II substrate is metabolized 
by rat liver microsomes to p-aminophenol. '
NH,
N/
Aniline p-Aminopheno 1
The method of estimation of aniline hydroxylation is 
essentially that of Guarino et al (1969) . The incubation mixture 
contained:
Tris-lICl buffer, pH 7.6 (150 yMoles) .. 
Aniline hydrochloride pH 7.6 (20 yMoles) 
MgCl2 (10 yMoles) .. .. .. . . . .
NADP (2 yMoles)
Glucose-6'-phosphate (20 yMoles)
Microsomal supernatant (25%)
Total volume
0.5 ml 
0.5 ml 
0.1 ml
0.2 ml
0.5 ml 
1.8 ml
Incubation was carried out for 15 minutes - longer incubations 
have been shown to result in p-aminophenol disappearance (Mazel, 1972) 
and stopped by addition of solid NAC1 (approx 1 g). Peroxide free 
ether containing 1.5% (V/v) isoariTyl alcohol was added (12 ml) and 
p-aminophenol was extracted in a rotary shaker .for 20 minutes. Ether 
aliquots (10 ml) were subsequently added to 4.0 ml of alkali phenol 
(0.5 M tripotassium orthophosphate containing 1% (W/v) phenol) and
extracted for another 5 ' minutes. Hie blue phenol-indophenol 
complex was measured at 620 run, 30 minutes after addition of 
in a-Cecil .’2 7.2 spectrophotometer.
Suitable blanks and standards (0.1 ymoles in 0.1 M HC1) 
were carried out through the same procedure
Reduction of p-nitrobenzoic acid: Microsomal nitroreductase
activity can be determined by measuring the quantity of p-amino- 
benzoic formed from the reduction of p-aiitrobenzoic acid to 
p-aminobenzoic acid, probably through the formation on nitroso- 
and hydroxylamine intermediates.
Anaerobic
NADPH ->
COOH
-Nitrobenzoic acid
JHOH
OOH
NH,
COOH
p-Aminobenzoic acid
The p-aminobenzoic acid formed is diazotised and then coupled 
to N-1-nap thy lenediamine (NED) to yield a coloured complex (Bratton 
and Marshall, 1939). The p-aminobenzoic acid is diazotized by 
addition of sodium nitrite.
Excess sodium nitrite is removed with ammonium sulphamate,
nh4oso2n h2.
Then
H'
hoso2n h2
sulphamic acid
BONO + E0SO2NH2 - — > H20 + I\T2 + H2S04
The diazonium salt is coupled with' NED
NHCH CH HH v
+
N+2C1
COOH NHCH2CH2NH
Incubation was carried out using a modification of the method 
of Fouts and Brodie (1957). Optimum level of NADPH was determined 
for rat liver microsomal supernatant (Fig. 2.1). The incubation 
mixture consisted of:
p-Nitrobenzoic acid (20 pMoles) in 
Trizma buffer pH 7.6 (100 pMoles)
MgCl2 (25 tMoles)
NADP (3.3 pMoles) .. .. ..
FMN (0.125 pMoles) ..
Glucose-6-phosphate (25 pMoles)..
Microsomal supernatant (25%)
Total volume
2.0 ml
0.5 ml 
0.5 ml 
0.5 ml 
0.5 ml 
0.5 ml 
4.5 ml
Tubes were kept in an ice bath while N2 was flushed through 
2(1-2 lb/in ) for 10 minutes to maintain anaerobic conditions.
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Fig.. 2.1
Optimum level of NADPf for the reduction of p-nitrobenzoic acid by rat liver
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Incubation was carried out under for 30 minutes and reaction 
was terminated by addition of 12.51 trichloroacetic acid (0.5 ml). 
After centrifugation an aliquot of supernatant (2.0 ml) was used
after addition of 0.11 NaNO^ (0.5 ml). This was followed by 
0.5 % ammonium sulphamate (0.5 ml) and finally 0.II NED (0.5 ml) 
was added. The volume was made up to 10 ml with* distilled /water 
and the mauve colour was determined 30 minutes later at 545 nm in 
a Pye-Unicam SP-600 automatic spectrophotometer.
Suitable blanks and standards (0.25 yMoles) were carried 
out through the same procedure. The product, p-aminobenzoic acid, 
was found to obey Beer’s law at the range used (0-0. 5 yMol.es).
N-Demethylation of ethylmorphine: The N-demethylation of ethyl-
morphine is followed by measuring the formaldehyde formed from 
the. methyl group.
for diazotization. Tubes were allowed to stand for 3 minutes-
CPI OH
OCH2CH3
OH
HCHO
Ethylmorphine Unstable intermediate
Formaldehyde is.trapped by semicarbazide according to the 
equation:
H - C + NHoNHC0NH« — > C=NNHC0NHo- + 1L0\ Z Z ■ / 1 1
H H
Trapped formaldehyde is then heated with the Nash reagent to 
form a yellow complex (Nash? 1953).
NH.COOCHECHO + CELCOCH^COCH
• 3,4 diacetyl 1,4 dihydrolutidin
The incubation mixture was essentially that of Holtzman et al (1968).
Tris-buffer, pH 7.6 (150 yMoles) .. . . . .  0.5 ml
MgCl2 (10 yMoles) .. .. .. .. .. .. 0.1 ml
, Ethylmorphine (15 yMoles) .. .. .. .. 0..25ml
Semicarbazide hydrochloride .. .. . . . .  0.2 ml
2% at pH 7.0
Glucose-6-phosphate (15. yMoles) .. .. .. 0.5 ml
NADP (1.25 yMoles) .. .. .. ..........  0.5 ml
Microsomal supernatant (25%) .. .. .. .. 0.5 ml
Tota] volume 2.55ml
After 10 minutes incubations the reaction is terminated by 
addition of 15% ZnSO^ (1.0 ml) followed by a mixture (2:1) of
are centrifuged to remove protein* Aliquots of supernatant (2.0 ml) 
are added to 2.0 ml of freshly prepared Nash reagent (4 M-ammonium 
acetate containing 4 ml of acetylacetone/litre). The mixture is 
incubated for 40 minutes in a shaking bath at 37°C. The yellow 
colour was then measured at 412 nm in a Cecil 272 spectrophotometer.
Suitable blanks and standards (0.3 pMoles) were also carried 
through the same procedure.
NADPH-cytochrome c reductase: Cytochrome c is of mitochondrial
origin and has been found to be involved in the electron transport 
chain in animals, plants,yeasts and molds. It is synthesised 
in the microsomes and transported to mitochondria (Kadenbach, 1967). 
NADPH-cytochrome c reductase (NADPH-cytochrome c oxidoreductase,
E.C. 1.6.2.3) was first observed by Borecker (1950) and was found 
to be localized in the microsomes (Phillips and Langdon, 1962). 
Prosthetic group was found to be FAD (Williams and Kamin, 1962) 
and was shown to be present in the amount of two moles per mole 
of enzyme (Masters 1962). The enzyme is also believed to
function as a component of the mixed function- oxidase (Gillette,
1966). Recent evidence suggests that this enzyme may serve as a
cytochrome P-450 reductase in the mixed function oxidase system 
(Hayashi, 1969; Schenkman and Cinti, 1970). The enzyme can reduce 
both one and two electron acceptors.
NADPH + H+ + 2 cyt. c3+--- > NADP* -i- 2 cyt.2++ 2H+
NADPH + H4 + dye ---> reduced dye + NADP4
Fig; 2.2
Spectra of oxidised and reduced cytochrome c
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The enzyme activity was measured by using a slightly 
modified 'version of the method by Williams, and 'Kamin (1962). Use 
is made of the difference in abosrption between oxidized and 
reduced cytochrome c at 550 nm (Fig. 2.2).
In two cuvettes the following were added:
- Test Reference
Potassium phosphate buffer
0.05 M, pH 7.6 containing .. .. 
10"3M KCN •
1.7 ml 1.8 ml
Cytochrome c (0.1 yMole) 1.0 ml 1.0 ml
Microsomal suspension (25%) .. 0.2 ml 0.2 ml
NADPH (3 yMoles) .. .. .. 0.1 ml -
Total volume 3.0 ml 3.0 ml
After drawing a base line the reaction is commenced by 
addition of NADPH and after mixing the reaction is followed at 
550 run in a Pye-Unicam SP-1800 recording spectrophotometer and 
followed for 1-2 minutes (Fig. 2.3). The initial velocity is taken 
as. tire measure of cytochrome c reduction.
(b) Cytochrome content of microsomes _
Cytochrome P-450: Cytochrome P-450, the terminal mixed function
oxidase, is measured by making use of its ligand binding properties. 
Carbon monoxide combines onto the reduced form of cytochrome P-450 
to. form a single peak at 450 nm when, compared to untreated micro­
somes. The method used in this study was described by Sladek and 
Mannering (1966).
Fig. 2.4
Absorption spectrum of cytochrome-P-450 using carbon monoxide as ligand
‘Microsomal suspension (25%) is diluted threefold with 
' 0.1 M phosphate buffer pH 7.4 and then added into two 1 cm glass 
cuvettes. A few granules of sodium dithionite are added in both 
■cuvettes, and CO is bubbled through one of the cuvettes (for 
approx. 30 sec). A difference spectrum is obtained between 390 
and 500 nm in a Pye Unicam SP 1800 dual beam recording spectro­
photometer (Fig. 2.4). Cytochrome P.450 is expressed as the difference 
in optical density between 450 and 490 nm.
Cytochrome. b : Cytochrome b^ is measured as the difference spectrum 
of NADH reduced microsomes against oxidised microsomes. The.method - * 
used is by Schehkman et al (1967). 0
Microsomal suspension (251) is diluted threefold with 0.1 M 
phosphate buffer pH 7.4 and then added into two 1 'ail glass cuvettes.
In one cuvette 0.1 ml NADH (1 mg/ml) is added and a difference 
spectrum is obtained between 390 and 450 run in a Pye' Unicam SP 1800 
dual beam recording spectrophotometer (Fig. 2.5). Cytochrome b^ 
is-taken .on the difference in optical density between 410 and 426 nm 
(i.e. trough and peak).
(c) Binding of drugs to hepatic microsomes
Many compounds bind to hepatic microsomes to produce characteristic 
spectral changes' (Chapter 1) . These changes are considered to represent 
interactions of drugs with cytochrome P-450 (Imai and Sato, 1967). The 
magnitude of the spectral change is proportional to the content of 
cytochrome P-450 available for binding and the dissociation constant,
(analogous to I<k) represents affinity of the substrate' for binding site.
Washed microsomes (2530 are diluted threefold with Tris-buffer 
0.1 M pH 7.6 and then added (3 ml) into two 1 cm glass cuvettes. 
Substrate (12 yMoles) is added into one cell with a Hamilton syringe 
and spectrum, obtained between 350 and 500 nm in a Perkin Elmer 356 
dual beam recording spectrophotometer. A base line is obtained 
before addition of substrate.
(d) Microsomal enzymes not involved 'in drug metabolism
Glucose-6-phosphatase: Glucose-6-phosphatase (E.G. 3.1.3.9)
is a microsomal enzyme (Grant, 1959) present in the rough'endo­
plasmic reticulum and catalyzing the reaction:
Jvfo
D-Glucose-6-phosphate +■ JI^ O -- •> D-glucose + H^PO^
It is an enzyme of the'glycolytic pathway found also in 
kidney and intestine but not in muscle.'
Estimation was carried out basically as described by 
De Duve et al (1955). The incubation mixture comprised
3,3-Dimethyl glutamate buffer .. .. .. .. 0.3 ml
pH 6.4 (60 yMoles)
Ethvlenediamine tetraacetic acid .. .. .. 0.1 ml
(EDTA) (1 yMoIe)
Glucose-6-phosphate (5 yMoles)..................0.1 ml
Microsomal suspension (25%) further ‘ ..• .. 0.5 ml
diluted (1:25) with 1.151 KC1 ______
Total volume 1.0 ml
Incubation was carried out for 15 ininutes and reaction was 
terminated by addition of ice-cold 6% TCA (1.5 ml). Precipitated 
protein was removed by centrifugation and an aliquot (2.0 ml) of 
supernatant .was used for phosphorus estimation. Phosphomolybdate 
complex was formed by addition of 5% PGA containing 0.6! ammonium 
molybdate (0.5 ml) and was then reduced by addition of 0.2 V  freshly 
prepared ascorbic acid (0.5 ml). The resulting blue colour is 
estimated 30 minutes later at 720 nm in a Pye Unicam SP-600 automatic 
spectrophotometer.
Suitable tissue and reagent blanks were also carried through 
the same procedure. Phosphorus standards (0.1-1.0 yg atom of 
phosphorus) were prepared from KH^PO^..
(e) Mitochondrial enzymes .
6- Amino 1 aevulinic acid synthetase: 6-Aminolaevulinic acid synthetase 
(S-ALA synthetase) is considered to be the rate limiting step in- 
porphyrin biosynthesis in the mitochondria (Granick and Urata, 1963;
■ Wilt^ 1965; Wainwright and IVa.inwr igh t, 1966). It catalyses the 
condensation of glycine and succinyl CoA to form 6 - aminol ae vul ini c 
acid in the presence of pyridoxal phosphate.
coo“ ‘ coo" coo“
+NH^
CO
CKA ! . pyridoxal CIV  2 CK*2 I pytiuuAai 2
C H 2 phosphate % 2
CH . |  > CH
I COO 1 1 2
0=C-gCoA
Succinyl CoA Glycine
c=o c=o
H-C-NH3+.' CH2
COO NH3
Cx-amino“3 -heto 6 -aminolaevulinic
adipic acid acid
50 ,
Enzyme activity was studied in the whole homogenate according 
to the method of De Matteis (personal-communication) .The 6-amino- 
laevulinic acid formed is condensed with acetylacetone to form a pyrrole 
and then reacted with Ehrlich’s reagent (Mauzerail and Granicky 1956) 
in acidic conditions.
+ .
+ H - +
' H
CH
0=0
CH
Dimethylamlnoberizaldehyde
(DMAB)
CH
L I
w
3
The pink salt formed can react with another molecule of the 
pyrole to form a colourless compound.
H3C CH3
Under, acidic conditions and excess DMAB the rate of first 
reaction is very fast • compared to the second.
The incubation mixture consisted of:
Sodium-potassium buffer ,. .. .. .. .. 0.1 ml
• pH 7.4 (50 yMoles)
Sucrose (0.25 M) . ... .. .. .. .. .. 0.4 ml
Glycine (200 yMoles)
EDTA (20yMoles) ., .. 0.5 ml
Trisma-HGl buffer, pH 7.4 (100 yMoles)
Citrate (100 yMoles) .. .. .. .. •. 0.1 ml
ATP (2 yMoles) ..- . . . .  .. . . . .  0.1 ml
Liver homogenate (101) ... .. .. .. .. 1.5 ml
Total volume 2.7 ml
After 30 minutes incubation, reaction was stopped by addition
of 50V TCA (0.25 ml) and protein was centrifuged off. Supernatant
aliquots (2 .0 ml) were added to a mixture (1:2 V/v) of M-NaOH and
M-sodium acetate buffer pH 4.6 (1.2 ml) followed by addition of
acetyl ace tone (40 yl). The stoppered tubes were then heated in a
boiling bath for 10 minutes to form the pyrrole. After the mixture
had cooled, freshly prepared 66.0 nMN-e thy lmaleimede was added
(0.15 ml) to neutralize any free thiol groups interfering with the
Ehrling reaction (Rimington et al, 1956). Thirty minutes later 10 M-
NaOH is added (approx. 70 yl) to adjust pH to 8.0. Tie solution is
then extracted with equilibrated ether (3.0 ml) in a 20 ml separating
funnel. Tiis extraction removes pyrrole formed from amino ace tone
(Gibson et al, 1958; Granick, 1966). The water phase (3.0 ini) is
/
added to acetic acid (0.2 ml) to bring pPI to 5.0. Manipulations 
at alkali pH were carried out as fast as possible. Finally modified 
Ehrlich’s reagent (Mauzerall and Granick, 1956) , 2 M with respect to 
perchloric acid (3.2 ml) is added, and. readings were taken 25 minutes
later at 556 nm in a Cecil 212. spectrophotometer. Blanks and 
standards of 6 - amino 1 ae vul ini. c acid (60 nMoles) were carried out tk^ oi 
the same procedure.
Transhydrogenase: Pyridine nucleotide transhydrogenase was first
demonstrated in extracts of Pseudomonas fluorescens Colowick et al, 
1952; Kaplan et al, 1952) and was shown to catalyse the reaction:
NADPH + NAD* ->• NADP* + NADH •
The reaction involves transfer of hydrogen and not phosphate 
and also catalyses other interactions of the pyridine nucleotides:
e.g. NADH + des amino-NAD* -> NAD* +, desamino-NADH
Subsequent work demonstrated the existence of the enzyme in 
animal tissues (Kaplan et al, 1953; Humphrey, 1957). The enzyme was 
mainly found in heart and to a smaller extent in skeletal muscle 
kidney and liver. It is mainly localized in the mitochondria. The 
above workers found no evidence for the presence of any flavine or 
metal prosthetic group in .the enzyme.
In the present study the reverse reaction was studied
NADH + NADP'1" NADPH + NAD+
Hie method of Humphrey (1957) was slightly modified.
Fig. 2.5
Absorption spectrum of reduced cytochrome
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Fig. 2.6
Estimation of amount of NAD+ formed by transhydrogenase
340 nm'
4 4
Addition! p!f: NADH
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The following were added to two 1 cm quartz cuvettes:
Reference Test
Sodium phosphate buffer .. .. , .. 
pH 6.3 (190 yMoles)
1.5 ml 1.5 ml
NADP (0.5 mg/ml) . . . . 0.2 ml 0.2 ml
NADH (0.15 mg/ml) . . . . . .  .. - 0.4 ml
Sucrose 0.25 M .. 0.4 ml -
Mitochondrial suspension 1 g e 1 ml 
(Mitochondria were washed twice)
0.2 ml 0.2 ml
Total volume 2.3 ml. 2.3 ml
Reaction commenced with addition of NADH and incubation was
‘ ■© 
carried out for 1.0 minute at room temperature. 'Hie reaction was
terminated by addition of a saturated solution of Tris base containing
25% (V/v) ethanol (0.2 ml). This provided a suitable pH 10 and
substrate for alcohol dehydrogenase which was then added with- a
Hamilton syringe (50 yl of 0.25 mg/ml). The increase at 340 nm was
followed until it reached a maximum in a Pye Unicam SP 1800 dual
recording spectrophotometer. This gave a measure of the amount of
NAD*" formed in 1.0 minute (Fig. 2.6).
Incubation was carried out for 1.0 minute as it is linear only
for 1.5 minutes, under the experimental conditions used (Fig. 2.7),
+
.-Amount of NAD formed was estimated from a Beer’s plot which was 
linear up to 4.0 yg of NAD"*" in the incubation mixture. All results
"I*
are expressed as yg of NAD formed/mg protein/hour.
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(£) Enzymes of cytosomal fraction
Glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase:
Both enzymes are involved in the oxidative pathway of the carbohydrate 
metabolism.
NADPH
A
NADP
/ \’ "<31ucose-6 
phosphate 
dehydrogenase
H20
++
CH2OPO3
glucuno 
lactas e
D-glucono-S-
lactone-6-
phosphate
COO
| NADP NADPH CO9
.H-C-OH T  7*
OH-C-H  } +
| 5 phospho- .CH2OH
H-C-OH gluconate [
| dehydrogenase C= 0
H-C-OH I
I H-C-OH
CH2OPO3
6 phospho-D-gluconate
H-C=OH
CH2PO32'
D-ribulose-5-
phosphate
Both enzymes are widely distributed and are found in 
erythrocytes, yeasty micro-organisms, mammalian tissues, lower 
plants and animals and also higher plants (Cohen, 1950; Dickens 
and Glock, 1957; Gibbs, 1952). Both dehydrogenases are exclusively 
located in' the soluble fraction (Glock and McLean, 1953) and are 
botli activated by magnesium, calcium and manganese.
In the present study, glucose-6-phosphate dehydrogenase • 
activity was taken as the difference between the dehydrogenase 
enzyme activities measured separately at pH 7.6 in the presence 
of 6-phosphoglucona.te and a solution containing both 6-phospho 
gluconate and glucose-6-phosphate (Glock and McClean, 1953).
Test 
0.5 .ml
0.5 ml
0.1 ml
1.0 nil
0.2 ml 
2.3 ml
Glucose-6-phosphate was omitted when 6-phophogluconate 
dehydrogenase was estimated. The reaction was started with addition 
of substrate to both cuvettes after a base line was drawn. Reaction 
was followed at 340 nm in a Pye Unicam SP-1800 dual beam recording 
spectrophotometer (Fig. 2.8). The determination was carried out 
at room temperature and initial velocities were considered in 
activity calculations.
In two 1 cm glass cuvettes the following were added:
Reference
Glycyl glycine buffer • .. .. .. .. ., 0.5ml
pH 7.6 (125 yMoles)
MgCl2 (50 yMoles) .. .. .. * .. . 0.5 ml
Glucose-6-phosphate (5 yMoles) |
V .. .. 0.1 ml
6-phosphogluconate (5 yMoles) J  ' .
NADP (1 mg/ml) .. .. .. .. .. ..
KC1 .(1.15%) .. .. .. .. .. .. 1.0 ml
Liver soluble fraction (25%) .. .. .. 0.2 ml
Total volume 2.3 ml
' \
Fig. 2.8 . |
' f
Estimation of glucose-6-phosphate dehydrogenase and 6-phospho- I
gluconate dehydrogenase £
A = 6-phosphogluconate + Glucose-6-phosphate 
B = 6-phosphogluconate
Fig. 2.9
Estimation of alcohol dehydrogenase
.1 [340 j nmAddition of Alcohol
Nr XlLi
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Alcoho1 dehydrogenase: Alcohol dehydrogenase (EC 1.1.1.1) is one of 
the most intensively studied enzymes and catalyses the reaction:
CH CH20H + NAD+ NADH + CH CHO
This reaction is considered to be the rate limiting step in 
the total ethanol degradation (Lundquistand Wolthers, 1958; Wes’terfeld, 
1961). Horse liver-enzyme contains four atoms of zinc per molecule, 
two of which are involved in the activity of the enzyme (Drum et al,
1967). The human liver enzyme appears to contain only the two 
functional atoms of zinc (Blair and Vallee, 1966). The enzyme is 
remarkably unspecific and it can catalyse the interconversion of 
a broad group of primary and secondary alcohols and their respective 
aldehydes and ketones (Theorell, 1965). Hie method used is basically 
the one described by Theorell and Bonnischsen, 1951).
In two 1 cm glass cuvettes the following were added:
Reference Test
Glycine-NaOH buffer .. .......... 1.9 ml 1.9 ml
pH 9.6 (190 pMoles)
NAD (10 mg/ml) ..........  .. .. 0.2 ml 0.2 ml
Alcohol (absolute) .. .......... - 0.1 ml
KC1 (1.151) .. 0.1 ml -
Liver soluble fraction (25%) 0.2 ml 0.2 ml
Total volume 2.4 ml 2.4 ml
Cuvettes were incubated at room temperature for approximately 
10 minutes before alcohol was added to allow for all NAD dependent 
dehydrogenases to be utilized. A base line was obtained and reaction 
was started by addition of alcohol and followed at 340 nm on a Pye-
'60.
Fig. 2.10
.Effect of enzyme concentration on initial velocity 
of alcoh.pl dehydrogenase
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Unicam SP-1800.dual beam recording spectrophotometer (Fig. 2. 9).
Substrate and cofactors were not limiting (Fig. 2.10).
fe) Ptotein determination
The method used in the present project was developed by Lowry 
et al (1951).
(An aliquot (0.5 ml) of tissue in 0.5 M-NaOH containing protein 
(< 300 yg) is added to 0.5 M-NaCH (0.5 ml). Freshly prepared copper 
solution (5.0 ml) is added and the mixture thoroughly mixed and left to 
stand for 10 minutes. F’olin-Ciocalteau phenol 2% agent (diluted 1:2) is 
finally added and tube is immediately mixed. Blue colour is read at 
720 nm, 30 minutes later in a Pye-Unicam SP-600 automatic, spectrophotometer.
Suitable blank and standards (0-250 yg of bovine serum albumin) 
are carried through the same procedure.
The copper reagent was prepared by mixing 1% CuSO^St^O (0.5 ml) 
with 2% potassium tartrate (0.5 ml) and 2% Na^CO^ (50 ml)
In vivo studies
Hie effect of a drug on drug metabolism can also be demonstrated 
in vivo in the .intact animal.
(a) Hexobarbital sleeping time
Hexobarbital is metabolized by hydroxylation, demethylation and 
ring scission (Cooper and Brodie, 1955).
Hie duration of the pharmacological action of hexobarbital, i.e. 
the-sleeping time can be taken as a measure of the metabolism of the 
drug (Conney et al, 1960). Hexobarbital is used as it is a short acting 
barbiturate (Chapter 4), it has a quick onset and it is metabolized to 
pharmacologically inactive products.
Animals were injected intraperitoneally with 103 mg/kg of 
hexobarbital. Duration of sleeping time is taken as the time between 
loss and regain of righting reflex (animal must be able to rise for 
at least three times in 30 seconds).
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(b) Zoxazolamine paralysis time
Zoxazolamine (2-amino--5-chlorbenzoxazole) has a central action and 
causes, muscle relaxation by inhibiting reflex pathway within the spinal 
cord although the precise action is not yet known (Geiger et al, 1958). 
In man and in the Wistar strain of rats it is metabolized to 6-hydroxy- 
zoxazolamine, which is excreted as the glucuronide and to a minor extent 
to chlorzoxazone (Conney et al, 1960a)
6-Hydroxyzoxazolamine
Chlorzoxazone
Animals were administered zoxazolamine dissolved in equivalent amount 
of 0.2 NHC1) intraperitoneally (100 mg/kg). Paralysis time is taken as 
the time between loss and regain of righting reflex (animal must rise for 
at least three times in 30 seconds).
(c) Urinary excretion of ascorbic acid
In rats the urinary excretion of ascorbic acid may be used as an 
index of enzyme induction. Enzyme inducers stimulate the metabolism of 
glucose and galactose via the glucuronic acid pathway (Bums et al, 1960).
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D-glucose ~> D-glucuronic acid — L-gulonic acid >> L-ascorbic acid
A
\/
pentose cycle D~xylulose — ■— —  L-xylulose
(Conney and Bums, 1959).
Animals were kept in individual cages designed to collect urine. 
Twenty four hour samples were collected and used for ascorbic acid 
determination.
Urine was passed through muslin and then through a cation exchange 
res5-ri. (Zeo-Karb 225, mesh size 52-100) to eliminate compounds interfering 
with ascorbic acid determination (Hughes, 1964),- The glass column was 
30 cm in length and 2 cm in diameter and 10 cm was packed, Activation 
was carried out by washing first with 30 ml 2 M-NaOH and then with water 
until washings were not alkaline. The column wTas then washed with 30 ml 
of 2M-HC1 and water until washings were neutral.
Urine aliquots (5.0 ml) containing 2% metaphosphoric acid were 
added to the column through a pipette and eluent was collected in a 
graduate cylinder containing 2 ml of 201 metaphosphoric acid. Column was 
washed with water until the effluent was no longer acid. The final volume 
ranged 20-30 ml.
Aliquots of eluent (2.0 ml) were titrated against the redqxs 
dye, 2,6-dichlorophenolindophenol (Harris and Ray, 1935). All titrations 
were carried out in triplicate. Dye was standardized using a known amount 
of ascorbic acid (0.075 mg),
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Statistics
All results are expressed, as the arithmetical means +_ S JAM. and 
means were compared by student’s t test. To obtain the value of P a 
■degree of freedom + N2” 2 was assumed in all calculations.
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Chapter Three
QUANTITATIVE DETERMINATION OF BARBITURATES AND OTHER 
COMPOUNDS BY A MODIFIED GAS LIQUID-CHROMATOGRAPHIC METHOD
QUANTITATIVE DETERMIFIAT ION OF BARBITURATES AND OTHER
COMPOUNDS BY A MODIFIED GAS LIQUID CHRQMATOGRAPHIC METHOD_
The first techniques for the Quantitative and qualitative analysis
of barbiturates made use of the physico-chemical properties of the molecule
and required substantial amounts in pure form not always obtainable from
biological specimens. Separation and determination of barbiturates before
the 1960's were carried out by paper chromatography, a slow, inefficient
and insensitive technique. Quantitative determination of barbiturates was
carried out by considering ultraviolet absorption spectrum at different pH
values, and although it is a’useful method for pure solutions is of little .
use in analysis of biological materials without prior chromatography to
* &  ‘
distinguish the barbiturate from its metabolites (Broughton, 1956). 
Fluorimetric procedures capable of determining barbiturates at a level 
greater than 3 yg/ml have also been described (Perez, 1938; Udenfriend, 1957) 
but suffered from the same disadvantages as spectrophotometry.
Gas-liquid chromatography was introduced in 1960 when the sodium salts 
of the barbiturates were subjected to controlled pyrolysis in a stream of 
carrier gas and the products were then separated and identified by gas-liquid 
chromatography (Janak, 1960). The products are assumed to be closely related 
to the parent compound, provided reaction between the original compound and 
its decomposition products can be prevented during the pyrolysis. But if 
more than one compound is present the method becomes very difficult.
Gas-liquid chromatography was extensively investigated in early 60’s 
(Parker and Kirk, 1961) and was used purely for identification purposes and 
results were co-ordinated with spectrophotometrie estimations. However, a 
linear response of the detector to increasing barbiturate concentrations-was 
shown.
Columns and detectors
Most workers have used flame ionization-detectors (Leach and Toseland, 
1968; Welton, 1970) but argon ionisation detectors have also been used 
(Brochmann-Hanssen and Svedsen, 1962) and also an ionization, 3~ray Sr90 
detector (Parker and Kirk, 1961). These appear to provide the same 
sensitivity although electron capture has been claimed to be more sensitive, 
(Gudzinowicz and Clarke, 1965). Analysis of the free barbituric acids could 
be carried out at concentrations 0.1-0.8 yg/yl,'with linear detector response 
to concentrations 0.1-1.0 yg/yl.
Ihe gas-liquid chromatography of barbiturates has been extensively 
studied using a series of different columns ranging from non-polar to - 
extremely polar materials (Brochmann-Hanssen and Svedsen, 1962). By using a 
combination of two columns, a non-polar e.g. Apiezon L and a polar e.g. a 
polar polyester, most of the commonly used barbiturates can be separated. 
However, there are disadvantages as some barbiturates have long retention times 
e.g. phenobarbital has a retention time of 15-20minutes on ApiezonL, and 
approximately 60 minutes on polyethylene glycol adipate, giving rise to diffuse 
peaks whidi are difficult to quantitate (Cook, et al, 1961). Excessive 
loading increases the retention time even more but improves separation 
(Leach and Toseland, 1968). Mixtures of liquid phases have also been used 
(Parker, et al, 1968), and this resulted in more symmetrical peaks which were 
easier to quantitate.
Problems of adsorption •
The main problem encountered is the adsorption of the barbiturate on the 
solid support giving rise to peak-tailing which leads , to asymmetrical peaks 
the effect being more pronounced at low barbiturate concentrations. Since, 
in most cases, submicrogram quantities are involved the solid support 
adsorption must be eliminated or at least reduced.
The main forces responsible for adsorption are the weak Van der Waal’s 
forces and the stronger bonds due to hydrogen bonding. The former are 
annulled in all liquid.phases, and do not present any problem. The adsorption 
sites in diatomaceous earth involve hydroxyl groups or electron rich centres. 
These will be Si-OH and Si-O-Si groups which give rise to two types of 
hydrogen bonding: (a) where Si-OH acts as the proton donor, (b) where
Si-O-Si acts as a proton acceptor. Therefore, even if Si-OH groups are 
chemically eliminated,, adsorption is still possible by those compounds which 
can donate a proton to the Si-O-Si groups., such as alcohols. These hydrogen 
bonds are believed to be much stronger than those formed by Si-OH. To 
overcome this effect many workers coated the diatomaceous earth with polyhydric 
alcohols which would form hydrogen bonds with Si-O-Si and leave free C-OH 
groups which could be eliminated by silanization. This gives better results 
although a few C-0-Si groups still remain. This technique, however, is 
limited to compounds of low7 molecular weight since with larger molecules the 
temperature has to be increased up to a level where the alcohol is unstable 
and breaks down. -The problem of adsorption can be dealt with in two ways:
(a) Reduction of the polarity of support material.
(b) Formation of a suitable barbiturate derivative.
Reduction of polarity of solid support
The performance on columns of diatomaceous earth is increased by 
addition of concentrated FJC1, which reduces the adsorption of polar compounds 
such as the barbiturates (McMartin and Street, 1966; Street, 1968; Welton,
1970). The function of washing, with acid was claimed to be the removal of 
metallic-oxides (James and Martin, 1952).
The most common method, for deactivation of the support material is by a 
reaction of active sites of the support material with dimethyl 'dichlorosilane ;
or hexamethyldisilazane, the process being known as silanization (Boheiiien, 
et al, 1960; Brochmann-Hanssen and Svedsen, 1962; Anders and Mannering, 1962; 
McMartin and Street, 1966). Reaction with the active sites, eliminates 
hydroxyl groups. .
i i i I !
- S i - O - S i -  + SiCl2(CH3)2   V  - S i - O - S i  i
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Tins reaction occurs in the presence of adjacent hydroxyl groups. When, . ■ f
however., only one hydroxyl group is present a different fe act ion takes place.- \
.1 I ! I f !s j
- Si - 0 - Si - • + SiCl2(CH3)2 - — ) - Si - 0 - Si - 0 - SiCl +HC1 i
I I I I I I
OH Cl !3 ■
i
Hie Si-Cl group can still react with solutes. If, however, hexamethyldisilazane \
is used then there is a quantitative reaction with hydroxyl groups j
according to the reaction: j
i I • I |
- Si - 0 - Si - + Si2(CH3)6 NH £ Si(CH3)3 - 0 - Si - 0 - Si - 0 - Si i
OH 1 1 1 + j
This reaction proceeds in tiro stages: First, j
1 "  1 !
- Si + Si2(CH3)s Mi — ;-- -) Si(CH3)3 - 0 - Si - + Si(CH3)3 iiH2 !
I ! !
OH ' ■ j
and tlien either, ;
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- Si + Si (CH3) 3NHj>
I
OH
} Si (CI13) 3 - 0 - Si - ■+ NH3
or,
2 Si (CH3) 3 NH2 Si2 (CIi3) 6NH ' + ■ NH3'
so adjacent hydroxyl groups are not necessary.
Silanization has also been reported to reduce barbiturate ’adhesion’ to glass 
(Blackmore and Jenkins, 1968; Blackmore, 1969). Solid support materials can 
also be deactivated by treatment with the thermal degradation products of a 
silicone gum rubber such, as SE-30 or SE-52 the process being carried out at 
400°C (Street, 1971).
Derivative formation
The second way of reducing adsorption is by modifying the barbiturate 
itself to give a suitable derivative of lower polarity for analysis (Cook, 
et al, 1961; Parker, et al, 1968; Brochmann-Hanssen and Oke, 1969; Baylis, 
et al, 1970; Neville, 1970; Street, 1971; Fiereck and Tietz, 1971). The 
derivatives generally give shorter retention time on SE-30 columns and the 
difference in retention time from that of the free barbiturate, which is 
known as the ’peak-shift’, can be used for the positive identification of the 
barbiturate. .
The procedures used for the modification of barbiturates are of two 
main types, employing either alkylation or silylation. 'Methylation can be 
carried out using diazomethane (Cook, et al, 1961; Gilbert, et al, 1970), or 
dimethyl sulphate (Martin and Driscoll, 1966; Baylis, et al, 1970); the
1,3-dimethyl derivatives are formed and can be used for gas liquid 
chromatography and the simultaneous determination of mass spectra for
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identification, if required (Gilbert, et al, 1970). Since the amide portion 
of barbiturates can tautomerise to give the enol form, N-methylation and/or 
0-methylation can occur giving rise to different derivatives with different 
retention times (Neville, 1970). The major disadvantage of this technique is 
that barbiturates with one methyl group on one of the nitrogen atoms give 
the same dimethyl derivatives as the barbiturate with no methyl group on the 
nitrogen atom and the same grouping at the 5 - position. Flash-heater 
methylation has also been reported (Brochmann-Hanssen ■ and Oke, 1969).
Injection of a methanolic solution of t rime thy lanilinium salts of 
barbiturates produced thermal decomposition in the injector giving rise to 
thermal decomposition products suitable for quantitation. Although 
trime thy lanilinium hydroxide gives instantaneous methylation, thiobarbiturates 
and bromobarbiturates give rise to two peaks due to decomposition. 
Tetramethylammonium hydroxide has also been successfully used (Parker, et al,
1968). .
On-column derivative formation has also been studied extensively 
(Anders and Mannering, 1962; Stevenson, 1966; Brochmann-Hanssen and Olce, 1969 
Kallberg, et al, 1-971). Anders* and Mannering first prepared esters by 
following the injection of the parent compound .with an injection of either 
acetic or propionic anhydride. Both acetates and propionates can be formed by 
simultaneous administration of a mixture of the anhydrides and in this way 
compounds with similar retention times can be separated. However mixed 
products are formed when the .compound contains more than one hydroxyl group. •
The use of tetramethylammonium hydroxide for on-column methylation 
(Stevenson, 1966) achieved separation of pentobarbital and-amobarbital. which 
were not separable by other.methods (Martin and Driscoll, 1966). However, 
all 5-phenyl substituted barbituric acids gave double peaks even at
temperatures of 360°C. This is probably the result of alkaline degradation 
of the barbiturates, or if the products are acidic these are probably their 
methyl esters. Mother possibility is that the phenyl ring might also be 
methylated. Injection of the parent compound together with 
N,0-bistrimeth.ylsilyiacetamide to form the trimethylsilyl derivatives achieves 
symmetrical peaks and better sensitivity (Street, 1969). On-column methylation 
can also be formed by injecting the parent compound together with
trimethyl anil ini um hydroxide to form the dimethyl derivative (Kallberg, et al,
1971).
In conclusion, on-column methylation is not always complete and gives' 
rise to secondary peaks. (Stevenson, 1966; Brocjimann-Hanssen and Oke, 1969).
It is advisable to me thy late barbiturates before injection mainly because the 
derivatives are formed more consistently and quantitatively. It should be
noted that derivative, foimation is of no practical use if the nature of the
sample content is unknown.
Column sensitivity
In the submicro gram level, sensitivity of the column becomes the limiting 
factor. Using a combination of two columns, the non-polar SE-30 and the polar 
QF-1 phase, both containing tristearin, detection was possible down to a 
level of 0.04 yg/yl (McMartin and Street, 1966a) . Using a 3.8k SE-30 loading 
samples could be analyzed even down to a level of 0.05 - 0.1 yg/yl.
Sensitivity was found to be increased by addition of dimer or trimer acids on 
high efficiency polyesters (Cieplinski, 1963; Blackmore, 1969). With 
on-column methylation detection was possible down to 0.01 - 0.05 yg. It 
should be noted that concentrations below 1 yg/yl may affect the retention time 
of the barbiturate (Braddock and Marecj 1965; Gudzinowicz and Clarke, 1968; 
Blackmore,- 1969). Finally, it is not always possible to reproduce the results 
of one column by another one similarly packed.
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Recent advances in barbiturate 'analysis by gas-liquid chromatography
Working on the gas-liquid chromatographic analysis of fatty acids, 
Ackman and Burgher in 1963 used formic acid vapour along with the carrier ga 
and observed improvement in their column performance. Formic acid is not 
detected by flame ionization detectors. This technique was used in 
barbiturate analysis using an Apiezon L column and it was observed that 
adsorption is eliminated, more symmetrical peaks are obtained and retention 
times of barbiturates are independent of sample size (Weiton,- 1970).
The present work investigates this technique with a 10% SE-30 column 
using a variety of drugs including barbiturates. An attempt is made to 
quantitate this effect and also to present evidence for possible mechanisms.
MATERIALS AND METHODS 
Materials
Barbiturates were donated by May and Baker Ltd., free acids were 
dissolved in chloroform and sodium salts were dissolved in alcohol.
Orphenadrine (Arthur H. Cox and Co., Brighton, Sussex), benzylcarbamate 
(Ralph Emmanuel, Middlesex), glutethimide (C.I.B.A., Horsham) and A.R. solvents 
(British Drug Giemicals Ltd., Poole, Dorset) were used as.'supplied,.
Replicate was obtained from Hopkins and Williams Ltd.
Apparatus used
Gas-liquid chromatography was carried out on a Pye-104 series 
chromatograph equipped with a flame ionization detector; amplified signals 
were observed on a ” Servos crib e" recorder. The chromatograph was equipped with 
a glass trap containing formic acid at room temperature, and through which 
carrier gas was allowed to flow without actually bubbling through the acid.
The formic acid-saturated carrier gas was then connected to the g.l.c. 
injector and was allowed to flow through the column for one hour, before 
sample injection. The amount of formic acid in the trap was kept constant. •
Column dimensions
A glass column was used as this can. be silanized to prevent barbiturate
adsorption on the glass. Hie column was 5 ft. in .length with an overall
diameter of 0.25 inch.
Preparation of column
Hie column was packed with 101-methylsilicone gum E-30 with Diatomite C, 
100-120 mesh as the solid support obtainable from "Pye-Unicam”, Cambridge.
This column has a maximum operating temperature of 250°C. Hie solid support 
was treated with dilute HC1 to remove mineral impurities and 
dimethyldichlorosilane was added to deactivate any surface active silanol
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groups on the support, material by forming silyl etliers. This process reduces 
the peak--tailing encountered with highly, polar compounds such as barbiturates.
' During packing, one end of the column is blocked with glass wool and 
attached to a water pump. At the open end packing material is added in small 
quantities through a funnel, while the column, is continuously tapped to ensure 
a uniform packing. On completion of packing, another piece of wool is attached 
to the column which is then connected to the chromatograph for conditioning.
' The column was conditioned at 240°C for 24. hours with oxygen free
nitrogen (20 ml/min.), as the carrier gas. A standard solution is then
injected into the chromatograph and the column is reconditioned. The column
* ■& '
is ready for use when further conditioning does not improve the response to the 
same standard solution. If during conditioning the level of packing material 
falls then additional amounts are added and the column is retapped carefully.
Column condi t i ons•
The following conditions were used during chromatography:
’■’Oxygen-free" nitrogen: 15 lbs/in2 and 18 lbs/in2 corresponding to 40 ml/min
and 60 ml/min respectively .
Air flow: 13 lbs/in2 corresponding to 300 ml/min.
•Hydrogen flow: 15 lbs/in2 corresponding to 60 md/min.
Column temperature: 200°C unless otherwise stated.
Injector temperature: No injector heating was used.
Detector temperature: 250°C.
Attenuation: x 500.
Recorder: Recorded was driven at 10 mV with a chart speed of
60 cm/hr.
Gas flews were measured with a Pye soap-bubble flow meter.
Continuous use of column, especially with plasma and urine extracts, may 
result in a deterioration of column performance as observed by peak shape 
(Fig. 3.1). The column can be recovered by removing 3 - 4  inches of the 
packing material from the injection end of the column, which is heavily 
contaminated, and repack it with fresh material. The column .is then tapped 
gently to ensure uniform packing and is then conditioned as previously 
described.
Chromatography solvents
Chloroform is the preferred solvent as it.produces a narrow peak which 
does not interfere with' the chromatography of compounds with short retention 
times, then chloroform was not used, compounds were dissolved in absolute 
ethanol. Ethanol is a less satisfactory solvent as quantitation is rendered 
difficult with compounds of short retention time (Figure 3.2).
Samples were introduced into the chromatograph with a glass, stainless 
steel, 10 pi, Terumo Syringe. All injections were carried out in the same 
manner to eliminate any variations in retention time or peak shape.
Chemical structure of compounds used is shown (Fig. 3.3).
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Structure of Compounds Used
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Barbital 
(5,5-diethylbarbituric acid)
Hip
CH2CH = CH2
\
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N O
H
Allobarbital 
(5,5-diallylbarbituric acid)
O
c h2c h 3
HN
Ij
IX
O N 
H
O
c h c h2c h2c h 3
3
Pentobarbital
(5-ethyl-5-( 1 -methyl butyl) 
barbituric acid)
CH2CH = CH2
X  / X
c h c h2c h2c h 3
c h 3
Secobarbital
(5-ally 1-5- ( 1 -methylbutyl) 
barbituric acid)
S
H
Thiopental
(5-ethyl-5(1 -methyl butyl)-2- 
thiobarbituric acid)
H
Phenobarbital 
(5-phenyl-5-ethyl barbituric acid)
CH 3
Hexobarbital
(5— ( 1-cyclohexen- l l-yl~) -1,5 
dimethylbarbituric acid)
0
c h2c h 3
\  /
c h 2c h 2cfi
XX \
N o 
I-I
c h 3
c h 3
Amylobarbitone
(5-ethy1-5-i s openty1 b arb ituric 
acid)
82*
o
CH2CH3
\ / = \  
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0 p °
ch3 ;
HN
o
Mephobarbital
(5-ethy1-1-me thy1~ 5-phenyl 
barbituric acid)
Glutethimide 
(a-Ethyl-a-phenyl glutarimide)
Benzyl carbamate
HsC
\ n / CH3
Dimethylaniline
<CH3
CH ■
Orphenadrine
(N,N-dimethy1-2- (O- me thy1-a-
phenylbenzyloxy) ethylamine)
OH
CH3
\ V ^ s^ y C H 3
2/6-Xylenol
CH.3 (CH9 ) 1 ^ CH3 CII3 (CH2)i6 CH3
Hexadecane Octadecane
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RESULTS
To investigate column performance a series of commonly used drugs, 
mainly barbiturates were used. The structures are given in Figure 3.3.
Effect of formic acid on retention time and peak shape
The retention time of a series of compounds was estimated before and 
after addition of formic acid to the carrier gas, at two different flow rate 
Octadecane and hexadecane were used as markers.
* Volumes of each 'compound'not greater than 2 yl were injected into the 
chromatograph. The .amount injected into the chromatograph was kept constant 
so that a direct comparison is valid. The amounts injected onto the 
chromatograph are shorn on Table 3.2. Two nitrogen flow rates were used.
40 ml/min. and 60 ml/min.
Retention time (t^ ) is taken as the time between injection time and 
peak maximum of compound as shown below.
o
Retention time is measured in minutes. When resolution and 
efficiency of the column are to be determined t^ is measured in centimetres.
To investigate the constancy of column performance the following 
experiments were carried out. The retention time of four compounds was 
estimated on four consecutive days at two different flow rates. During the 
first two days the carrier gas was nitrogen and during the last two days 
nitrogen saturated with formic acid vapour was used. Table 3.1 shows that 
column performance is not altered even when- the carrier gas is saturated with 
formic acid vapour. When reproducibility was being established the retention 
time of all the compounds was measured before and after addition of formic 
acid at two different flow rates.;
Formic acid does not alter the retention times of any of the .compounds-
-c* ‘ *
to any significant degree (Table 3.2).
Effect of formic acid on -column-efficiency
The efficiency of the column is characterized by the broadening of the 
peak which for a given column can be expressed by the number of theoretical 
plates. The concept of theoretical plates was first described by Martin and 
Synge in 1941 who imagined a chromatographic column divided along its length 
into a .number of zones which they termed "theoretical plates", and each zone 
is of.such a length that within it there is complete equilibration of the 
vapour between the gas and stationary phases. This model helps to define the 
efficiency of the column under a standard set of conditions. Column efficiency 
and the number of theoretical plates depend on the column operating conditions, 
so they should be accurately defined when efficiency is being determined. A 
satisfactory column should have a number of theoretical plates ranging between 
500-5000 for one metre.
To estimate column efficiency all compounds studied were injected before 
and after addition of formic acid to the carrier- gas. For each compound, the 
same amount was always injected contained in the same volume. Experiments 
were carried out at two nitrogen flow rates.
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Table 3.2
Retention time of a series of compounds before and after addition
of formic acid
Compound ! Amount 
injectec
I (vg)
q‘ Flow rate 45 ml/minj-
1
Flow rate 60 ml/min
Before formic 
acid
After formic 
acid
Before formic
I acid f
After formic 
acid
Allobarbitone 0.5 2.85 2.85
J .. . . . . . . . . . . . . . . . . . . . . —  . . . . . . . . . . . . . . . . . . . . . . . . . .. . . .
| 2.4 2.45
Barbitone 0.5 2.0 .. 2.0 1.7 1.75
Phenob arb i tone 0.5 9.8 9.85 8.1 8.35
Secobarbitone 0.5 5.4 5.4 4.5 4.65-
Pentobarbitone 0.5 4.55 4.55 3.8 3.9
Hexobarbitone 0.5 7.0 7.05 5.8 6.0
Amylob arb itone 0.5 4.3 4.25 3.55 3.6
Thiopental 0.5 7.! 7.1 5.95 6.1
Orphenadrine 1.0 9.8 9.9 8.15 8.45
Bei l zy ]. c a rb ama t e 0.1 1.5 1.5 1.3 1.3
Glutethimi.de 0.5 6. 75 6.8 5.7 5.8
Octadecane 0.125 5.85 • 5.95 5.0 5.05
Hexadecane 0.065 3.0 3.0 2.5 2.6
*D ime thy1ani1ine 0.040 1.0 •1.0 - -
*Xylenol 0.006 1.0 1.0 - - . >
Column temperature: 200°C
Detector temperature: 250°C
Alternator: x 500
* Column temperature: 180°C. Other conditions as above.
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The number of theoretical plates can be derived from many expressions.
In this work the most commonly used methods were utilized. The number of
tR
theoretical plates (N) is given by the expression, N = 5.54 (p-)2
where m is the peak width at half height (as shorn below) and 1r is the 
retention time as previously defined (Littlewood, 1970). This expression 
is also recommended by the international nomenclature committee of IUPAC 
(Scott, 1960).
I
The efficiency of the column is not significantly altered when formic acid 
is added to the carrier gas. Examples are given in Table 3.3. An 
increased column efficiency was seen with amylobarbitone sodium after 
addition of formic acid to carrier gas. This is probably the result of 
liberation of free acid which is better chromatographed since it is less 
adsorbed (Figure 3.4). Orphenadrine hydrochloride showed similar behaviour 
to amylobarbitone sodium.
The number of theoretical plates can also be expressed by the method
recommended by Desty, et al, in 1956. The number of theoretical plates
is given by: t •
N = i6 ( JL.) 2 where tR is retention time as previously defined and
co is the distance on the base line between tangents at inflection points of
the peak. Although this technique involves a larger personal error in
drawing the tangents it is widely used.
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Table 3.4 shows examples of the changes in the number of theoretical plates 
before and after addition of formic acid at the two nitrogen flow rates. 
Results obtained using this expression are similar to the ones previously 
described. Amylobarbitone sodium shows an increased column efficiency 
at both carrier gas flow rates, an addition of formic acid to the carrier 
gas.
The'above.two expressions used in calculating the number of theoretical 
plates , do not give any-measure of the reduction in peak tailing due to 
formic acid. To account for these changes the^expression recommended 
by Desty was used but u was defined as the peak width on the base line, i.e.
t - 2
N ~ 16 ) 'where w is as show below
co
\
Table 3.5 shows the changes in number of theoretical plates before and after 
addition of formic acid to the carrier gas at two flow rates. As expected, 
barbiturates being polar compounds are highly affected by addition of formic 
acid while octadecane and hexadecane show only slight changes. The increase 
in the column efficiency seen with the barbiturates is the result of a 
decrease of the peak tailing as retention times are unchanged. The column 
efficiency for orphenadrine hydrochloride and benzylcarbamate is also 
increased at both flow rates while glutethi-mi.de is not greatly affected.
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Column resolution
Resolution can also be used to give a measure of the'column’s' 
efficiency. To characterize the separation of two compounds a simple method 
was suggested by. the nomenclature committee of IUPAC (Szyanski, 1962).
Resolution (Rs) between' two compounds is given by the expression
2(t - t )
Rs = 'w~ p~— ‘ where t^ and t^. are the retention times of the
compounds and ojj and u)2 the differences on the base line between the tangents 
at• the inflection points. .
Table 3.6 shows examples of the changes in resolution before and after 
addition of formic acid, to the carrier gas at'tyro different nitrogen flow 
rates. Octadecane is used as the reference compound. Since retention times 
are practically identical before and after addition of formic acid, any 
changes in the resolution must be the result of changes in "w".
The resolution between octadecane and amylobarbitone sodium is greatly 
increased at both flow rates while orphenadrine hydrochloride-octadecane 
resolution is increased by more than 1001 at the slow flow rate. The 
resolution of hexadecane-octadecane was not affected.
The above expression was used to estimate the resolution by defining 
w as the peak width on the base line as previously explained. The results 
at two nitrogen flow rates are shown on Table 3.7.
Hie resolution of all barbiturates with reference to octadecane is 
highly increased. Orphenadrine hydrochloride and benzylcarbamate also show 
increased resolution with reference to octadecane while glutethimide and 
hexadecane are unaffected. ‘
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Peak tailing before and after addition of formic acid to the carrier gas
To account for the reduced adsorption and decreased peak tailing the 
following expression is utilized.
. Peak tailing: (PT) =  ^ ------
AB - (AC - BC)
A C B
Thus when tailing is decreased, ACB tends towards the Gaussian form and AC 
becomes equal to CB and peak tailing factor reaches unity.
Table 3.8 shows, the changes in the degree of peak tailing before and 
after addition of formic acid to the carrier gas at two nitrogen flow rates.
At both flow rates peak tailing is reduced in all compounds except the 
hydrocarbons which are not adsorbed by the solid support. Benzylcarbamate 
at 45 ml/nrinbecomes isosceles showing the great extent of peak tailing 
reduction. Amylobarbitone sodium and orphenadrine .hydrochloride show 
reductions of 801 and 601 respectively at a flow7 rate of 45 ml/min. At 
60 ml/min orphenadrine hydrochloride shows a reduction of 801. Generally, the 
reduction in peak tailing is.higher at faster nitrogen flow rates compared 
with slower rates. Figure 3.5 shows the chromatograms of a mixture of 
barbiturates before and after addition of formic acid to the carrier gas.
The improvement of peak shape is particularly evident in the case of 
phenobarbitone where the peak approaches the Gaussian- Form. Figure 3.6 shows 
reduction of peak tailing with phenobarbitone and Figure 3.7 with 
orphenadrine hydrochloride. Octadecane and hexadecane exhibit no peak tailing
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to Carrier Gas
After formic acid * Before formic acid
temperature: 200°C; Detector temperature: 250°C; Carrier gas flow: 60 ml/min;. 
tion. x 500. Barbiturate mixture contains 0.43 jig of each barbiturate.
barbitone. T: Thiopental. S: Secobarbitone.
PH: Phenobarbitone.
itone. H: Hexobarbitone. P: Pentobarbitone.
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(Figure 3.8).
Dependence of'amount injected on retention time and peak shape before and
after addition of formic acid
Many workers have encountered significant variations in retention times 
with barbiturate concentrations below 1 pg, using both polar and non-polar 
columns such as Apiezon L and Silicone gums (Braddock and Marec, 1965; 
Gudzinowicz and Clarice, 1965; Blackmore, 1969). Using an Apiezon L. column, 
and having nitrogen gas saturated with formic acid no significant changes were 
obtained in retention times of hexobarbitone when 20-200 ng were injected 
(Weiton, 1970).
In the present study pentobarbitone, 10-500 ng, was injected into the 
chromatograph before and after addition of foimic acid to carrier gas. In all 
cases 1 pi was injected.
At all concentrations no significant changes in the retention times 
were observed. (Table 3.9). The peak shape was also unaffected (Fig. 3.9).
Removal of formic acid from carrier gas •
To investigate if the effect of formic acid is irreversible, formic 
acid was removed from the carrier gas by emptying the trap and washing it out 
thoroughly.
Figure 3.10 shows the chromatogram of a mixture of barbiturates, 
chromatographed just before formic acid was removed. Formic acid was then 
removed and nitrogen was allowed to flow through column for at least an -hour.’ 
The same mixture was then chromatographed with nitrogen as carrier gas 
(Figure 3.11) . Only one of the barbiturates appeared in the chromatograph. 
This was found to be hexobarbitone. Thiopental having the same retention time 
as hexobarbitone did not appear in the chromatogram. It can be seen that
103.
Table 3.9
Effect of Sample Size of Pentobarbitone on Retention Time
Before Formic Acid After Formic Acid
Pentobarbitone Rt Pentobarbitone Rt
concentration (mins) concentration (mins)
500 ng 3.9 500 ng 3.9
100 n g 3.9 100 ng 3.9
50 ng 3.9 50 ng 3.9
10 ng 4.0 10 ng 3.9
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there is a high degree of peak-tailing when hexobarbitone is chromatographed 
without formic acid in carrier gas. Thus the effect of formic acid is 
reversible only for hexobarbitone in this mixture of barbiturates. All other 
non-barbiturate compounds previously used were chromatographed with the same 
retention times as previously described. Therefore barbiturates, except, 
hexobarbitone, are not chromatographed when formic acid is removed from 
carrier gas.
It should be noted that hexobarbitone is the only barbiturate used 
which has a methyl group on the 1!-N position. To confirm if substitution of 
the hydrogen of the nitrogen atom with an alkyl group has any significance in 
this behaviour of formic acid, another methylated barbiturate, methylphenobar- 
bital, was injected and found to behave like hexobarbitone. Thus it is 
likely that the hydrogen of the nitrogen atoms of the barbiturate ring 
participates in bonding with the column material. Removal of hydrogen by 
substitution with an. alkyl group destroys the bonding. When a large amount 
of barbiturate was injected (20 yg of pentobarbitone) this was found to 
chromatograph.
It is possible that formic acid decreases peak tailing by reducing 
the number of adsorbing sites of the solid support. To.investigate if formic 
acid has a permanent effect on the solid support, 5 yl of replicote, a 
silanizing agent, was injected in the 'chromatograph. This was followed by 
the mixture of barbiturates previously used. It can be seen that following 
silanization the barbiturates are partially chromatographed with expected 
retention times (Fig. 3.12). Phenobarbitone is not chromatographed probably 
due to the small concentration in the mixture (0.42 yg). Mien a higher 
amount 1 yg was Injected this was also found to chromatograph with .expected 
retention time. Formic acid (2 yl) was then introduced into the 
chromatograph followed again by the barbiturate mixture. Hexobarbitone was
found again to be the only barbiturate to appear on the chromatogram.
Column temperature: 
Detector temperature 
Nitrogen flow rate: 
Attenuation:
A: Allobarbitone
.13: Barb i tone
P: Pentobarbital
S: Secobarbitone
T: Thiopentail
H: Hexobarbitone
DISCUSSION
Formic acid was first used in gas liquid chromatography in the 
analysis of fatty acids (Ackman and Burgher, 1963) and subsequently in 
barbiturate analysis (Welton, 1970). Although many laboratories use this 
technique the quantitative effect of formic acid on column performance has 
not yet been studied. .
Strongly polar materials, such as barbiturates, present difficulties in 
gas liquid chromatography due to physical adsorption onto active sites of 
the. support phase. Introduction of formic acid, into carrier gas was shown to 
reduce.this adsorption (Welton, 1970).
Hie retention time of a series of compounds on a 10% SE-30 column 
was not altered by addition of formic acid to carrier gas. Similar results 
were reported with a 4% Apiezon L column (Welton, 1970). This observation 
suggests that formic acid does not react with the barbiturates to form a 
less polar derivative which is less adsorbed. Thus formic acid has a direct 
effect on the solid support and since retention times are unaltered any 
change in column efficiency and resolution of column must be the result of 
changes in peak width. .
Column efficiency was determined by the standard recommended procedures 
utilizing peak-width and peak-width at half'height. Addition of formic acid 
to the carrier gas had no significant effect on column efficiency (Tables 3.3 
and 3.4). However, use of formic acid increased columi efficiency of 
amylobarbitone sodium at both flow rates. This is probably due to liberation 
of the free acid by the action of formic acid on the sodium salt. The 
hydrocarbon markers, hexadecane and octadecane were not affected by the use 
of formic acid. These methods of estimation of column efficiency do not 
represent the true effect of formic acid in reducing peak width and then 
increasing efficiency. When the peak width on the base line is considered
1.10.
(Table 3.5) the column efficiency of all barbiturates is markedly increased. 
Similar results were obtained with orphenadrine hydrochloride and 
benzylcarbamate while the non-polar hydrocarbons were unaffected. In most 
cases use of formic acid caused large reduction in peak width resulting in 
more than two-fold, increase in column efficiency.
The degree of efficiency as determined above cannot be critically 
considered due to the high degree of error involved in measuring distances.
A small error in measuring a distance is amplified as the factor is squared 
and then multiplied. When tangents have to be drawn, the errors are even more 
magnified as in the practical chromatography of barbiturates the peaks are • 
not strictly of the Gaussian form and this asymmetry may produce an error of 
10-201 itself.
The determination of the "number of theoretical plates" assumes that 
the signal from the detector changes linearly with the concentration, 
otherwise the calculated "number of theoretical plates" cannot be correlated 
to column efficiency. Hie plate theory assumes that deviation from 
equilibrium is small, retention time is long compared to the time required for 
equilibration and, a Gaussian distribution occurs although this is not the 
true case. But although the plate theory may be considered obsolete it 
still provides the closest approximation to column performance.
Resolution between two compounds can also be assumed to represent the., 
performance of a column under specified conditions. When peak-width is 
defined as the distance between the tangent at inflection points, the changes 
in resolution due to addition of formic acid to the carrier gas are only 
important in the case of amylbarbitone sodium, again due to liberation of the 
free barbituric acid. If, however, peak-width is considered to be the width 
on the base line then there is an improvement in the degree of resolution as 
the result of decreased peak tailing. Glutethim ide and. hexadecane are not 
affected.
A direct measure of the reduced adsorption brought about by addition of 
formic acid to the carrier gas is described by the expression "peak-tailing" 
as previously defined. All compounds investigated showed a marked decrease 
in peak tailing especially at the fast flow rate. In some cases reduction of 
peak-tailing gave rise to isosceles and strictly Gaussian peaks. Peak-tailing 
of hydrocarbons is unity both before and after addition of formic acid to the 
carrier gas as there is no adsorption.
The concentration of the acid in the carrier gas was found to have no 
effect on the peak-height ratio or the retention time of barbiturates when a 
4% Apiezon column was used (Welton, 1970). This was not investigated in this 
project but it was noted that changes in temperature resulted in the base‘line 
being shifted. In the present work the formic acid trap was maintained at 
ambient temperature and no variations in either peak-height ratios or retention 
times were noted in the course of the present work.
Retention times were found to be independent of sample size, and peak 
shape was also unaffected. Similar results have also been reported with a 41 
Apiezon L column (Welton, 1970).
Function of formic acid
It has been shown'that formic acid addition in the carrier gas reduces 
the adsorption of polar compounds • onto the solid support of the liquid phase 
in the column system.
Ideally the support in a packed column is considered to be inert; but 
in practice it may cause chemical reaction of the vapours either between 
themselves or with the stationary liquid, it may produce tailing or it may 
influence retention times. These effects are attributed to the adsorptive 
properties of the support. It should be noted that solid supports are largely 
composed of silica which is activated and used as an adsorbent in gas
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adsorption chromatography.
Hie main forces responsible for the observed adsorption of 
barbiturates onto the solid support are due to hydrogen bonding. These are 
brought about by Si-OH and Si-0-Si groups. Hie former are mostly eliminated 
by silanization and do not present any problem. However, the Si-0-Si groups 
can act as proton acceptors and form hydrogen bonds which are stronger than 
those produced by the Si-OH bonds.. Barbiturates are very prone to forming 
hydrogen bonds and intramolecular hydrogen bonding is known to occur. This 
hydrogen-bonding is also important in the biological system. Barbiturates 
have been shorn to form hydrogen bonding with proteins and also to form 
strong specific hydrogen bonds with adenine derivatives (Kyogoku, e_t al, 1968) 
Therefore it is reasonable to assume hydrogen bond formation between the 
barbiturates and the Si-O-Si groups of the form shown below.
- Si - 0 - Si - 0 - Si
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Formic acid also has a great tendency for hydrogen bond formation. 
Electron.diffraction studies showed that the acid exists as the dimer 
(Pauling and Brockway, 1934). Thus when formic acid is continuously being 
flushed into the column all the Si-CKSi groups able to form hydrogen bonding 
are occupied by the formic acid so that when barbiturate is introduced into 
the column, sites of adsorption are eliminated giving rise to reduced
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barbiturate tailing and a more symmetrical peak.
When formic acid is withdrawn from the carrier-gas adsorption recurs, 
resulting again in peak tailing. Contrary to expectation, all barbiturates 
except the 1-methyl derivatives do not appear on the chromatogram when 
formic acid, is withdrawn from carrier gas. However, chromatography does 
occur when a large sample size is introduced into the column. Thus the system 
is capable of removing a greater amount of barbiturate when formic acid is 
withdrawn from carrier gas. This suggests an increase in the number of active 
sites capable of hydrogen bonding with the barbiturates. On injection of a 
silanizing agent, however, the chromatography of the barbiturates is partially 
■restored, indicating that formic acid destroys silanization leading to the. 
formation of active Si-OH groups responsible for the additional adsorption.
If formic acid is used in the carrier gas, these sites are occupied by formic 
acid through hydrogen bonding, as shown below, so that barbiturates are 
chromatographed without adsorption.
- Si - 0 - Si
i i
0 H
1 >H 0 \
OH '
When a large amount of barbiturate is passed into the column, the sites are 
occupied by part of the barbiturate and the excess is chromatographed.
When the solid support is resilanized the chromatography of the 
barbiturates is partially recovered. Following, however, injection of foimic 
acid, solid support is again destroyed, preventing the proper chromatography 
of the barbiturates.
Methyl phenobarbitone and hexobarbitone chromatograph even when formic 
acid is removed from carrier gas. This indicates that for adsorption both
of the nitrogen atoms of the barbituric ring must have hydrogens capable of
forming hydrogen bonding. Methylation of the nitrogen atoms results in 
diminished adsorption. This.is confirmed by the observation-that 
glutethimide, which lias a similar structure to barbiturates but only one 
nitrogen atom, can be chromatographed even when formic acid is removed from 
carrier gas. Thus, the primary role of formic acid is the occupation of 
adsorbing sites on the solid support so that adsorption of polar compounds is 
eliminated. If formic acid is discontinued the silanization destruction can 
be reversed by resilanizing solid support in the usual procedure. -
The property of formic acid to destroy silanization can be used.to 
separate and determine the barbiturates, thiopental and hexobarbital, which 
is not possible under normal conditions as they both have the same retention
time. When, however, formic acid is removed only hexobarbitone can be
chromatographed.
In conclusion, addition of formic acid to the carrier gas improves 
column performance as observed by column efficiency and resolution. Adsorption 
is greatly reduced facilitating quantitation at submicrogram level 
estimations. The present work suggests that formic acid can be used in gas . 
liquid chromatography of all polar compounds provided that there is no 
chemical reaction between the formic acid and the solute or solvent.
• . Chapter Four 
PHARM/VCOKINETICS OF SOME BARBITURATES
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PHARMACOKINETICS OF SOME BARBITURATES
The major reason for determining drug concentrations in plasma and 
for studying the factors affecting drug absorption, metabolism and 
excretion is the realization that the intentsity of the pharmacological 
effect at a specified time is often related to the amount of drug in the 
plasma.
In biopharmaceutics, the biological half-life is the time required for 
one half of the amount of drug absorbed to be eliminated, whether by 
excretion, metabolic decomposition or other natural processes following 
the establishment of equilibrium. Using this ferm we imply that the loss 
of'unchanged ding follows a first order reaction kinetics. Plasma half-life 
depends on drug transfer through and across the different membranes and 
barriers, metabolism and urinary excretion of unchanged drug (Wagner, 1968).
The plasma half-life is not a constant factor and variations occur 
due to (a) dosage effects, (b) variations in urinary excretion, (c) inter­
subject variations, (d) effect of age, (e) effects of other drugs, (f) 
differences in protein and tissue binding, and (g) disease.
Increasing the drug concentration may alter the biological half-life 
due to saturation of one of the processes such as active transport, metabolism 
and distribution. Multiple doses may also affect the half-life of the drug 
as drugs may induce their, own metabolism. The tolerance of barbiturates 
after prolonged administration-is being observed in both humans and animals 
(Koppanyi and Dille, 1934; Remmer, 1962). Changes in urinary pH may change 
■reabsorption by the kidneys since the latter depends on the amount of lipid- 
soluble non-ionised form of the drug.
Inter-subject variations of the plasma levels of lipid-soluble 
drugs have been widely reported. In a group comprising eleven patients 
there was a 36-fold variation in the steady state plasma level of desmethyl- 
imipramine (Hammer et al, 1969). Similar results have also been described 
in the use. of phenylbutazone, antipyrine and dicoumarol (Vessel and Page, 
1968a, b, c.). Inter-subject variations are most often found in the case 
of lipid soluble drugs which are not readily excreted by the kidney and 
which undergo extensive oxidation mainly in the liver. Therefore, plasma 
levels of such drugs must depend to a large extent on the activity of 
drug oxidising enzymes in the liver. Supporting evidence, concerning 
hexobarbital plasma half-lives in different species, showed that they were 
related to liver enzyme activity; there was an inverse relationship between 
the rate of biotransformation of hexobarbital and the duration of its 
hypnotic effect (Quinn et. al, 1958). If reduction of cytochrome P-450 
is the rate limiting step in the oxidation of drugs then individual 
differences in rates of metabolism in man may be. due to variations in 
cytochrome P-450 reductase (Davies et al, 1969). Inter-subject variations 
may also be the subject of different diets, different amounts of water intake, 
physical activity and other factors.
Age can influence the plasma level to a great extent as a result of 
different metabolic capacities. Newborn animals have lower metabolic 
capacity hence requiring a smaller dose to achieve a desired therapeutic 
concentration (Kato _et al, 1964). Because antipyrine is completely 
metabolized and distributed evenly in the body water it has been suggested 
that by estimating changes in the biological half-life of this compound, 
information could be obtained concerning the relative activity of the 
drug metabolizing enzymes in an animal before and after chronic exposure 
(Welch et al, .1967).
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Drugs are reversibly bound to plasma proteins chiefly albumin, 
by electrostatic forces, hydrogen bonding and Van der Waal's forces 
(Teresi& Luck,1952).. They are slowly released to become active at 
receptor sites and to be metabolized, the rate of metabolism being 
proportional to the amount of free drug. Therefore, protein binding may 
alter biological activity and drug distribution within the body which in 
turn influences biological half-life. However, binding is not a.fixed 
parameter or absolute value since by increasing drug concentration in the 
blood, the decree of binding will decrease in most cases due to saturation 
of available protein. Binding to tissue proteins is very likely but it 
has not been fully, investigated. Several drugs have been shown to displace 
other drugs from their protein binding sites (Goldbaum and Smith, 1958).
Interaction between drugs is discussed in detail in Chapter 
6 with regard to ethanol-barbiturate interactions. Biological half-lives 
may also be influenced by changes-in physiological conditions (stress) 
and pathological conditions (disease).
The importance of the biological half-life of a drug, in medicine 
and pharmacy, lies in prescribing correct dosage regimens and avoiding 
poisoning .from overdosage. Many workers have estimated the rate of 
barbiturate disappearance in humans (Brodie, 1952; Brodie et al, 1953- 
Lous, 1954; Fazelcas et al, 1956; Brand et al, 1959; Brilmayer and 
Loennecken, 1962; Brand et al, 1963). However, the techniques they 
employed were unspecific colour reactions and spectrophotometric methods 
which measure the biological half-life of the pyrimidine ring rather than 
of the parent barbiturate and do not distinguish between parent drug and 
its oxygenated metabolites.
Hie present work determines biological half-life in the rat 
of a series of commonly prescribed barbiturates using a sensitive gas- 
liquid chromatographic, technique, which .measures specifically the 
unchanged barbiturate.
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Materials and apparatus
Barbiturates wrere a gift from May and Baker, Dagenham, Essex; 
sodium salts were dissolved in saline (50 mg/ml) or free acids were 
dissolved in M-NaOH and then adjusted to pH 8.5. All organic solvents 
were of the "Analar" grade and obtained from B.D.H., Poole, Dorset.
Heparin was obtained from Sigma Chemical Co., and was dissolved in 
saline (1000 unit/ml).
The standards and biological samples were chromatographed in a 
Pye-104 series isothermal chromatograph with single flame ionization 
detector equipped with a trap filled with formic acid (see Chapter 3).
• The column was packed with 101 silicone gum, SE-30, and conditioned 
as previously described (Chapter 3). For the estimations of barbiturates 
the following conditions were used: "Saturated with formic acid
vapour flow = 45 ml/min, flow = 60 ml/min, air flow - 300 ml/min, 
column temperature = 200-230°C, oven temperature = 250°C, attenuator x 500. 
The recorder was used at 10 mv and chart speed was driven at 1.0 cm/min 
(see Chapter 3).
Hie ratio of the barbiturate to internal standard response plotted 
against the amount of barbiturate injected was found to be linear 
(Fig. 4.1).
Methods
In the present study the fate of the barbiturate in the plasma 
was studied utilizing a large group of animals, as opposed to following 
the rate of plasma disappearance in individual animals, in order to 
eliminate changes in metabolic rates due to stress. Previous work has 
shown that stress may increase (Ripe et al, 1963; Driever and Bousquet, 
1965) or decrease metabolism (Stitzel and McCarthy, 1971).
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In all experiments 40 day old male Wistar albino rats were used, 
and for each drug 24 animals each received an intraperitoneal dose of 
75 mg/kg of the barbiturate. Blood was withdrawn at six regular 
intervals, taking approximately 2.5 ml of blood by cardiac puncture 
using heparinized needles and syringes while the animal was still under 
barbiturate anaesthesia. With long acting barbiturates, e.g. barbitone 
the animal was not fully anaesthetized so it was rendered unconscious 
with a mild blow on the neck and blood was immediately withdrawn from 
the heart while it was' still beating. Blood was collected in glass 
vials containing 200 units of heparin, and then centrifuged in an M.S.E. 
Mistral 6L centrifuge at 2500'up.m. for 20 minirt.es and the plasma 
removed. For barbiturate estimation 1.0 ml of plasma was taken.
Extraction of barbiturate was carried out on the.same day as 
shown (Fig. 4.2). Plasma pH was adjusted to 6.5 and the barbiturate 
was extracted with ethyl acetate. The organic layer containing the 
barbiturate was kept in stoppered tubes overnight. The next day the 
solvent was evaporated off and the barbiturate redissolved in 0.1 ml 
chloroform containing the internal standard. Allobarbitone (0.2 mg/ml) 
was used as internal standard for all barbiturate estimations. In 
the case of allobarbitone estimations, pentobarbitone was used as the 
internal standard (0.3 mg/ml). Samples 1-3 yl.were injected in the 
gas chromatograph.
Quantitative determination was carried out by considering the area 
under each peak (Fig. 4.3). Blank plasma extracted according to the 
method described showed one peak, (Fig. 4.4) and no attempt was made 
to identify the compound. This peak interfered, only with the 
determination of thiopental; however this was still possible and
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Plasma extraction of barbiturates
1.0 ml of plasma
2.0 ml of 0.2 M KH2P04
5.0 ml of ethyl acetate
Extract in a mechanically 
driven rotor for 5.0 minutes 
and separate phases by 
centrifugation in an MSE 
Mistral 6L centrifuge at 
2000 r.p.m. for 5.0 minutes
Remove 3.5 ml of organic 
layer and evaporate acetate 
in a' 70 C water bath under 
a low stream of air
Inject 1-3 yl samples 
in the chromatograph
aqueous layer
Redissolve in 0.1 ml 
of chloroform containing 
the internal standard
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Quantitation of barbiturates
-i
H— I
Peak area (PA) .= H x to 
where H = peak height and 
ai = peale width at half height
C - Chloroform 
A = Allobarbitone 
S = Secobarbitone
6 4 2
(mins)
0
Fig. 4.4
Extraction of plasma from control animals
C = Chloroform .
P = Plasma peak present 
in all samples
1.0 ml of plasma was extracted 
as described (Fig. 4-Z) and 
1 yl was injected in the 
chromatograph
For conditions see text
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was carried out as shown (Fig. 4.5). For each estimation standard 
curves were made by extracting known amounts of barbiturate from 
plasma and drawing a plot of the amount added against the amount 
extracted; this was used for the subsequent estimations (see Appendix). 
A standard curve for the chromatographic method wras obtained by 
injecting different amounts of barbiturate and same amount of internal 
standard. All graphs were found to be linear in the region required 
for estimations (see Appendix).
127.
i I ! ! ! !  i i N : N ! I
tmi!
! i.! m m !
rrrrrnT!
LO'
o-
LOH
. rH
cd
•P
P
0
P-o
•H
rP
H
U •> L(_J
• O
P
bl o
■rH •H
PH •P
cd
■p
•rH
-P
P
cd
3
O'
moJho
0
£O4-J
•H
'Scd
oI—I 
rH
rHCTS
■P
PJ0
Pho
•H
6  <  H
I I I
CJ <  H 3X
E
I
cd0Pcd
cd
0P.
128.
Results
The plasma levels-were determined at six regular time intervals, 
which were chosen according to the duration of the ■ pharmacological 
action of the barbiturates. Four animals were used for each time 
interval and the mean was calculated (Table 4.1) . The means were 
plotted on semilog paper and the straight line was extrapolated to 
give concentration at zero time. Plasma half-lives were taken as the 
time required to reach half of initial plasma concentration (Figs. 
4.6-4.12). The half-lives are given in Table 4.2.
When animals were sacrificed at the first time interval they had 
already reached maximal plasma concentration (Fig. 4.6-4.12). thus 
diffusion into the blood stream after intraperitoneal administration 
was complete,
The structures of the barbiturates investigated are given in 
Table 4.3.
129.
H'
0 t—f■a
E— 1
(f) 
0 
P 3 
p  
3 
P • H'S3
.Q
m
o
0
u
u
&
0PL3c/i
•rHT3
ctj
S
33
rHCP
W
OO
+ I
to
§
t/3cd
0
Pcd
nd
0
P
3
0
t/3
0
PCP
to
P
rH
3
to
0
bO
bO
6
LO
o-
X
rHi—i
cd
0
3
O
P
•H
P
0
P
P
3
•H
■XJ
0
P
0
Pto
•H
3
3
0 
P 
3  
P 
3 
P 
• H  
rQ P 3 
*Q
'U3
M
CTi t-O
LO rH
oo ch to to to
•H
rp
+1
N N CO tO \0
LO H- CM 03 CO rH
O rl Ol O 't
LO H" LO
rH
rH i—I i—I i—f
oo 'O' t"-|H
+1
LO LO ooooOJ
CO 03 O03
rH
rH
O ’
to C—  rH i— I
03 03 rH rH rH
rH
LO rHCO
tO H" 03 \D b'-
H* H" H v  CM 03LO
LO tO CM r— i rH
i—I
LO CO 03 LO
H- tO tO 03 03
LO tO rH 
CM CO H"
LO
LO
03 03 tO H* LO CO•H
rH
to
130.
ul
ts
 
ex
pr
es
se
d 
in 
mg
/1
00
 
ml
 
ox 
pl
as
ma
. 
i 
Ea
ch
 
va
lu
e 
is 
th
e 
me
an
 
of
 
fo
ur
 
de
te
rm
in
at
io
ns
Table 4.2
Plasma half™lives of barbiturates in the rat
Barbiturate Plasma half-life (hrs)
Barbitone 7.2'
Phenob arbi tone 2.8
Allobarbitone 1.7'
Pentobarbitone 1.3
Secobarbitone 0.9
.Thiopental 0.5
Hexobarbitone 0.3
The barbiturates (75 mg/kg) were administered intraperitoneally. 
Animals used were 40 day old male Wistar-albino rats.
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TABLE 4.3 
Structure of Barbiturates
:EL€H
HE
H
Barbital 
(5,5-diethylbarbituric acid)
j? chV c h.
^  ' \  ! 2 3 
HN |— ^HCH2CH2CH3
Jv C H U  
°’ O
H
Pentobarbital
(5-ethyl-5- (l1 -methylbutyl) 
barbituric acid).
Ell CHCE.QEL CH
H
Secobarbital
(5-allyl-5- Cl1-methylbutyl 
barbituric acid)
HKT
:H2CH3
— ^CHCH CH CH \ z z z>
CH3 ■
H
Thiopental
(5-ethyl-5(11-methylbutyl-2- 
thiobarbituric acid)
CIl CH
HN
H
Phenobarbital 
(5-phenyl-5-ethyl barbituric acid)
9
CH CH=CH
T ‘CH CH=CH2
H
Allobarbital 
(5,5-diallylbarbituric acid)
j
I
CH3
Hexobarbital
(5- (ll-cyclohexen-^-I-yl)-l/5 dimethyl barbituric acid)
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Pentobarbitone half-life
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Discussion
The determination of the biological half life from plots of plasma 
concentration on semilog paper implies the assumption of a one compartment 
model. In pharmacokinetics the one compartment model assumes that any 
drug entering the body is instantaneously distributed into the available 
space (Gibaldi,1971). In estimating the half-life of a cirug.,
absorption and distribution processes are completed before ‘that part of 
slope from which we estimate the half-life is reached. It must be pointed 
out that the biological half-life represents the time when half of the 
absorbed amount of a drug, after equilibrium is reached, is eliminated. 
Pharmacokinetic studies have shown that elimination of a ding in man 
is not an apparent first order process, except when the drug is below'the. 
usual- therapeutic range (Gibaldi, 1971).
After ingestion, barbiturates appear in all organs, tissues and
fluids throughout the body (Brodie et al, 1950; Brodie et al, 1953).
They are weak acids having pK values of 7.8-8.1 except for phenobarbitonea
which has a pK of 7.3 (Waddell and Butler, 1957) (Table 4.4). Thus, a
at physiological pH they exist largely in the form of undissociated 
molecules and in this form they pass through lipid membranes. So the 
rate of transfer will depend on the lipid solubility of the-undissociated 
molecule (Mark, 1963). This partly explains the half-life found for 
phenobarbitone. At physiological pH values, phenobarbitone exists in 
the dissociated form which is poorly absorbed. Since microsomal 
oxidative systems are protected by lipoid membranes (Gaudette and Brodie, 
1959) the rate of phenobarbitoiBtransfer to the site of metabolism is 
slow. Thiopental presents a special case due to its high lipid solubility. 
After thiopental administration maximum drug concentration is observed
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in the liver immediately after administration (Brodie, 1952).
Tie lipid solubility of the thiobarbiturates is 10-11 times greater 
than the value for the corresponding oxygen analogue (Table 4.4).
Hie dominant factor in barbiturate distribution and metabolism 
is therefore the lipid solubility. Ihen administered intravenously 
the rate of drug uptake by a certain tissue depends on the rate of 
blood flow to the tissue. Barbital with the smallest partition 
coefficient is the most poorly absorbed barbiturate. It cannot readily 
reach the site of metabolism (Table 4.5) and thus is very poorly 
metabolized. Metabolites of barbital in the urine of humans and 
animals accounts only for 5V of dose administered (Ebert, et al, 1964; 
Goldschmidt and Wehr, 1957). Phenobarbitone, also poorly metabolised, 
never reaches high concentration in the liver and compares poorly with 
the more lipid soluble barbiturates which have liver concentrations three 
times higher than the plasma level. Barbital and phenobarbital are 
excreted slowly in the urine in spite of their good renal clearances 
because they are so resistant to metabolic alteration. Lipid soluble 
barbiturates have virtually zero renal clearances but their rates of 
metabolism are appreciably higher than phenobarbitone. The more lipid solubl 
barbiturates are also more protein bound with subsequent reduction in 
the concentration of free, diffusible barbiturates in both plasma water 
and glomerular filtrates. Increased lipid solubility also facilitates 
reabsorption across the wall of the kidney tubule, which behaves like 
a lipoid barrier, with resultant decrease in excretion of the drug in 
the urine.
Protein binding follows the same order as lipid solubility (Table 4.6) 
barbital being the most poorly bound. Tissue protein binds to the same
Table 4.4
Physicochemical properties of barbiturates
Barbiturate ^ P K a ^  Lipid
Solubility
^Duration 
of action
^Plasma half-life 
(hrs)
Barbitone 7.8 0.26 Long 7.2
Phenob arb i tone 7.3 1.0 Long 2.8
Allobarbitone - - Long 1.7
Pentobarbitone• 8.0 5.8 Medium 1.3
Secobarbitone 7.9 - Short 0.9
■Thiopental • 
■
7.4 63.0 Ultra-short 0.5
Hexobarbitone 8.2 - Ultra-short 0.3
_______________  ..
(a) From Bush, 1963.
(b) Distribution o£ 4.0 mg of barbiturate between 5.0 ml of peanut oil 
and 20 ml of phosphate buffer pH 7.4. From Mark et al, 1958.
(c) From Williams, 1959.
(d) In 40 day old male Wistar-albino rats
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Table 4.5
Plasma and liver levels of barbiturates
Barbiturate ^plasma level 
mg/100 ml
^liver level 
• mg/100 g.
ratio
plasma/
liver
^half-life
Barbitone 9.4 9.8 0.92 7.2
Phenobarbital 7.0 10.0 0.70 2.8
Allobarbital ~ - - 1.7
Pentobarbital 3.8 11.6 0.33 1.3
Secobarbital 5.0 13.0 0.33 0.9
Thiopental 3.4- 10.7 0.36 , 0.5
Hexobarbital - - - 0.3 .
(a) Levels 5 minutes after administration of 50 mg/kg of barbiturate in 
rabbits (GoIdbaum and Smith, 1958).
(b) Half-lives in 40 day old male Wistar-albino rats.
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Table 4.6 
Protein binding of barbiturates
J Barbiturate fa) t—* j • ^inaction
bound
■
Liver
binding
^Half-life.
Barbitone 0.05 0.11 7.2
Phenobarb itone 0.20 0.32 2.8
Allobarbitone - - 1.7
Pentobarbitone 0.35 • 0.41 1.3
Secobarbitone 0.44 0.54 0.9
Thiopental 0.65 0.66 0.5
Hexobarbitone - - 0.3
(a) Binding of 0.001 M substituted barbituric acids by 1%
. bovine, serum albumin in M/15 phosphate buffer pH = 7.4 
(Galdbaum and Smith, 1958).
(b) Half-lives in 40 day old male Wistar-albino rats.
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extent as plasma protein (Goldbaum and Smith, 1954). About 25% of 
thiopental present in plasma during anaesthesia is free in the plasma 
water, available for pharmacological action while the rest is protein 
bound (Brodie et al, 1950). Strongly bound barbiturates give higher 
•levels in the liver compared "to plasma, while weakly, bound barbiturates 
tend to give more equal concentrations.. Since thiopental also displaces 
an appreciable fraction of secobarbital and pentobarbital from plasma 
protein, it is possible that barbiturates and their analogues are bound 
partially at the same site.
Thiopental is known to be an ultrashort acting barbiturate 
(Williams, 1959) but it exhibits a half-life in the rat of approximately 
15 minutes (Fig. 4.9). However, this is probably not the result of 
metabolic degradation. Three minutes after intraperitoneal administration, 
thiopental has reached maximum plasma levels, then after ten minutes there 
is a sudden drop': to almost 50% of the-previous plasma level. The 
decrease continues and gives a biological half life of 30 minutes.
Similar results in the rate of plasma disappearance of thiopental were 
obtained by other workers.(Brodie et al, 1950; Goldstein and Aranow,1960). 
This phenomena can be attributed to .the high lipid solubility of the 
thiopental molecule, which leads to equilibration of the high plasma 
level with the brain, .since-the'l’ipoid blood-brain barrier is virtually 
absent for such a highly lipid soluble molecule.
The systemic plasma level is also rapidly falling as a result of 
distribution to other tissues/mainly skeletal muscle as this has a high 
blood flow. This plasma with a lowered thiopental concentration again 
comes into the brain and the brain thiopental rapidly diffuses back into 
the plasma thus diminishing the brain concentration. Thus although
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brain levels are initially high these drop rapidly due to distribution 
to other tissues and this explains the short anaesthetic properties 
of thiopental. With increasing blood circulation the thiopental level 
in fat can exceed that of plasma by 6-10 fold (Brodie et al, 1950). 
Thiopental is slowly released from the body fat into the plasma and the 
following disappearance from the plasma is a result of metabolic 
degradation by the microsomal drug metabolizing enzyme associated with 
the hepatic smooth endoplasmic reticulum. The oxy-analogue of thiopental, 
pentobarbitone, does not exhibit a similar picture (Fig. 4.7). The 
disappearance-of this barbiturate is mostly a result of metabolism, with 
a biological half-life of 76 minutes. Previous work (Brodie, et al, 1950; 
Goldstein and Aranow, 1960) has shorn that pentobarbital penetrates the 
brain much more slowly and tissue distribution is also -less, giving rise 
to high plasma levels. With pentobarbital equilibrium is delayed and 
thus brain concentration rises to a plateau while the plasma level is 
falling and so a rapid fall in the plasma concentration is not observed.
One of the pathways of thiopental metabolism is the desulphuration 
at the 2-position to the corresponding oxy-analogue, pentobarbital, which 
can be further metabolized to inactive products. This pathway has been 
demonstrated to occur in man (Bush et al, 1961; Mark et al, 1965), in 
rats (Winters et al, 1955) and in cattle, sheep and swine (Sharma and 
Stowe, - 1970). In the present study, however, no pentobarbitone was 
detected in the rat plasma up to at least 30 minutes after administration. 
This is in accordance with previous work using human blood (Furano and 
Greene, 1963). This seems to suggest that this pathway of desulphuration 
is a very minor pathway and so pentobarbitone does not accumulate to
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detectable amounts. This was supported by the observation that after 
awakening from thiopental anaesthesia, pentobarbitone formation does 
not reach, brain in large enough concentrations to anaesthetize the 
animal for a second time, although pentobarbital is itself a medium 
acting barbiturate. It is also possible that any pentobarbitone formed 
is bound to tissue proteins and cannot enter the blood stream.
Pentobarbitone could also be rapidly metabolized further to its polar 
metabolites -which are then excreted, although this is unlikely as unchanged 
pentobarbitone has been isolated from the urine of humans (Mark et al,1965) • 
and urine of cattle, sheep and swine after thiopental treatment (Sharma
-c*
and Stowe, 1970).
Hie biological half-lives obtained for barbiturates* in the rat 
comparewith those obtained in man by other workers (Table 4.7), and 
are in the same order as in man. The difference in absolute values is 
the result of different activities of the drug metabolizing enzymes.
This is supported by evidence showing direct correlation between half-life 
and relative enzyme activity in hexobarbital oxidation (Quinn et al, 1958) 
and amidopyrine demethylation (Bums, 1966) in different species.
In conclusion, the biological half-lives of the barbiturates, and 
probably of other drugs, depend largely on the lipid solubility of the 
compound, as this also determines the extent of protein binding and the 
rate of metabolism.
Table 4.7
Biological half-lives of barbiturates in man and rat
■
Barbiturate
: '
Barbitone 7.2 hrs 4.8 days
Phenob arb i tone 2.8 hrs 3.4 days
Allobarbitone 1.7 hrs 2.0 days
Pentobarbitone 1. 3 hrs 1.8 days
Secobarbitone 0.9 hrs 1.2 days
Thiopental 0.5 hrs 8.0 hrs
Hexobarbitone 0.3 hrs 5.0 hrs
(a) From Parke, 1971; and Low and Sonne, 1956.
(b) In 40 day male Wistar-albino rats
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Chapter Five
BARBITURATES AS INDUCERS OF 
HEPATIC DRUG METABOLISM
BARBITURATES AS INDUCERS OP HEPATIC DRUG METABOLISM
Introduction
Barbiturates were introduced clinically in 1903 with the synthesis
of barbital (diethylbarbituric acid), followed in 1912 with the synthesis of
phenobarbital (5-ethyl-5-phenyl barbituric acid). Since then about 2500 
barbiturates have been synthesized and studied and about 12 are now widely
used. Although barbiturates have been in use for more than half a century,'
their pharmacological action is far from being understood. Their metabolic 
fate is inadequately documented, often semiquantitative and in some cases 
non-existent.. • .
Pharmacological action of barbiturates
Barbiturates are classified as hypnotics and sedatives. They act to 
depress the central nervous system, the degree of depression depending on the 
barbiturate used, the dose, route of administration, degree of excitability of 
the nervous system at the time of administration and on previously acquired 
tolerance. In small doses they relieve tension and ;anxiety but with larger 
doses selective activity is lost, while the depressant action spreads to all 
parts of the central nervous system around the spinal cord causing drowsiness, 
sedation and sleep. Barbiturates are not analgesics and in small concentrations 
they can even behave as anti-analgesics. However, they enhance the analgesic 
activity of other drugs such as salicylates and in medical practice short-acting 
oxybarbiturates may be given in' conjunction with analgesic drugs to enhance 
relief.. In anaesthetic doses they all inhibit convulsions; phenobarbital has 
a selective anticonvulsant action and is used in grand mal epilepsy.
Considerable evidence has suggested that the pharmacological action of 
barbiturates is related to the inhibition of biological oxidation (Aldridge, 196
Barbiturates inhibit the oxidation of NADH in the flavoprotein region of the 
mitochondrial electron transport chain although the precise site of action has 
not yet been definitely located (Emster, et al, 1955). Other fla.voenzymes 
have also been shown to be inhibited by barbiturates, including cerebral NADH 
dehydrogenase (Giuditta and Strecher, 1962; Giuditta and Casola, 1965).
Work with infrared techniques has shown that barbiturates have high 
selective affinity for forming a hydrogen bonded complex with adenine 
derivatives (Kyogoku, et al, 1968; Kim and Rich, 1968), Subsequent work with 
nuclear magnetic resonance techniques demonstrated a selective hydrogen bond 
formation between barbiturates and the adenine part of RAD and NAD in solution 
(Kyogoku and Yu, 1970). The amino group of FAD is involved in the association 
with the enzyme protein (Yagi, et al, 1961). Barbiturates might inhibit the 
formation of the FAD-protein complex by blocking the binding site of FAD, and 
although the role of adenine in RAD is not clear it may probably function in 
binding to the enzyme protein or'to the co-enzyme FAD. Riboflavin derivatives 
have been shown to compete with barbiturates for the formation of hydrogen 
bonded complexes with adenine derivatives (Kyogoku and Yu, 1968: 1969).
Barbiturates, thus, might inhibit interaction between substrate and flavoenzyme.
According to their rate of elimination barbiturates are subdivided into; 
(a) long-acting; (b) short-to intermediate-acting and (c) very short-acting 
(ultrashort).
Barbiturate toxicity
In high concentrations barbiturates are strong depressants of 
respiration. They depress smooth muscles of the ureter and urinary bladder and 
may affect the renal tubular transport system resulting in severe oliguria or 
anuria as a result of hypotension. During labour they can cause respiratory
depression in the infant since the placenta offers no significant barrier to 
their passage into the foetus.
The lethal dose depends very much on the individual and variation may be 
•up to 50% (a 63 year old woman survived 68.5 mg/100 ml of blood). Withdrawal . 
symptoms in barbiturate addicts are.severe and often fatal; symptoms include 
weakness, violent tremors, anxiety, temperature rise, rapid pulse and 
epileptic seizures. Psychosis may also occur resembling schizophrenia.
Sites of barbiturate metabolism
Generally, metabolism of barbiturates leads to the formation of 
metabolites which are pharmacologically inactive. However, in some cases e.g. 
3-hydroxyhexobarbital, the pharmacological effect of the metabolite is reduced 
but not completely eliminated (Irrgang, 1965). Metabolism of thiobarbiturates 
and N-methyl barbiturates may lead to deactivation, activation or change in 
pharmacological activity depending on the kinetics of the alternative pathways 
available for metabolism.
By far most of the metabolism of barbiturates occurs in the liver. 
Isolation of the liver from the circulation in dogs produced anaesthesia which 
resulted in failure of the animals to awaken within the normal period (Meyers 
and Peoples, 1954). Partial hepatectomy leads to an increase of barbiturate 
sleeping time (Shideman, et al,1947 )• Bilateral nephrectomy increases 
barbiturate anaesthesia in animals indicating that significant metabolism also 
occurs in the kidney (Richards, et al, 1953). Other tissues including brain, 
heart, intestines, muscle and spleen, have also been shown to metabolize 
barbiturates but to a lesser extent (Gould and Shideman, 1952).
The liver enzymes metabolizing barbiturates are located in the 
endoplasmic reticulum and. require NADPH and O2 and have been identified with 
the enzymes known to metabolize a variety of other compounds and. termed mono­
oxygenases (Brodie, et al, 1955). The classical inhibitor of the microsomal 
drug'metabolizing enzymes, SKF 525A, blocks barbiturate metabolism (Kato, et al, 
1964b) However, not all enzymes are situated in the microsomes. A 
3-hydroxyhexobarbital'-dehydrogenase was isolated from a crude soluble fraction 
In rabbit, catalysing the conversion of 3-hydroxyhtxobarbital to the 
ketoderivative. Hydroxysecobarbita 1 does not serve as a substrate of this system 
(Toki & Tsukamoto, 1964). The 1-isomer of hydroxypentobarbital in the presence 
of NAD is oxidised to ketopentobarbital by the soluble fraction (Kuntzman, et al,
1967). Similar results have been reported with respect to hydroxysecobarbital 
(Ide,.et al, 1967).
Pathways of barbiturate metabolism
Barbiturates are metabolized through four pathways (Williams, 1959).
(a) Metabolism of substituents at position 5.
One or both substituents of the 5-position can be metabolized. Complete 
removal of the side chain is also possible.
(1) Oxygenation. This occurs preferentially in the longer side-chain
at the ultimate (w) or penultimate (w-1 ) carbon atom giving rise 
to primary and secondary alcohols respectively (Fig. 5.1). This.
is seen in the metabolism of secobarbitone . (Tsukamoto, et al, 1963). 
If oxygenation results in the formation of an asymmetric centre, 
optical isomers of the hydroxy barbiturates are formed as in the 
metabolism of hexobarbital (Ftimer, et al, 1969).
(2) Oxidation. The primary and secondary alcohols are further
metabolized by enzymes to carboxylic acids and ketones (Fig. 5.1).
(3) Complete removal. One of the two substituents may be completely
removed (Fig. 5.1)*
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(b) Dealkylation of the nitrogen atom: Removal of the alkyl group, usually 
methyl s does not result in deactivation. This pathway competes with
■o
oxygenation as observed in hexobarbital metabolism (Williams and Parke, 1964).
(c) Desulphuration. The pathway converts thiobarbiturates to the 
corresponding oxy-analogues which are also pharmacologically active e.g. 
thiopental is desulphurated to pentobarbital (Soehring and Dietz, 1956).
(d) Ring scission. The barbiturate ring is relatively stable in vivo and 
scission of the ring to produce substituted malonylureas is a minor pathway. 
Thiopental is metabolized in rats to give 3% of the dose as thiourea (Taylor, 
et al, 1952).
■The-nature and location of the enzymes responsible for ring scission are 
still unknown. It is possible that gut microflora attack barbiturates or their 
metabolites.
A number of barbiturate metabolites are excreted as glucuronides but this 
system has not been studied.
The metabolic pattern of barbiturates varies in different species. The 
importance of a metabolic pathway varies among species and some -animals may be
devoid of an enzyme system carrying out a particular pathway. However, due to 
lack of experimental procedures a quantitative picture cannot be realised at 
present.
Factors affecting the metabolism of barbiturates
Many factors are known to affect the metabolism of barbiturates and other 
drugs, including the following:
Species and strain differences : Both qualitative and quantitative 
differences in the metabolism of barbiturates occur among different 
species. This essentially reflects different activities of the 
drug-metabolizing enzymes. The metabolism of hexobarbital in different 
species has been correlated with the activity of the drug metabolizing 
enzymes (Quinn, et al, 1958).
Differences in the rates of metabolism of hexobarbital have been 
shown in different strains of rats ('Fumer, et cQ, 1969) and rabbits 
(Cram, et al, 1965). Differences in the individual response to 
barbiturates and appearance of toxic effects is due to genetically 
determined defects, which alter the pattern of metabolism.
.. \
Physiological factors ; Newborn rabbits, mice and guinea pigs appear to 
lack the hepatic microsomal enzyme system which in the adult is 
responsible for the metabolism of a wide variety of drugs (Fouts and 
Hart, 1965). Newborn animals and humans metabolize barbiturates less 
readily than adults and so barbiturates are more toxic to the newborn 
(Yeary, et al, 1966).
Male rats metabolize a number.of drags more readily than females.
Hexobarbital is oxidised more rapidly.by liver microsomes of male rats
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than by those of females (Quinn et al, 1958). Administration of 
testosterone to female rats results in an increase of the metabolism 
of hexobarbital to a level comparable with that of male animals 
and administration of oestrogens to male animals results in the 
opposite effect. 'The sex difference in the metabolism of 
barbiturates has not been observed in any other animals than rats 
and probably does not occur in humans.
Barbiturate metabolism is influenced by administration of 
hormones. Adrenalectomy markedly impairs the enzymes that metabolize 
hexobarbital in male rats but has little effect on the enzyme in 
the female rats (Remmer, 1958). Furthermore, the duration of the 
pharmacological action of pentobarbital and hexobarbital is reduced 
in stressed animals while barbitone, which is mostly excreted 
unchanged, is unaffected (Driever and Bousquet, 1965). Thyroidectomy 
reduces the rate of metabolism of hexobarbital but administration of 
thyroxine stimulates metabolism in female rats and decreases this 
in male rats (Kato and Takahashi, 1968).
Impairing effects of starvation occur sooner in males than in 
females and in the latter the drug-metabolizing enzymes are enhanced 
after fasting (Gillette, 1965).
Disease can also alter the rates of metabolism of barbiturates 
and human patients with liver disease may exhibit sensitivity to many 
other drugs due to impairment of their liver detoxication mechanisms.
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Pharmacodynaniic factors : Barbiturate metabolism can be affected
by a number of pharmacodynamic factors such as plasma and tissue 
protein binding, excretion etc. which are discussed in detail in 
Chapters 4 and 6.
Environmental factors : Hie microsomal mono-oxygenase system is
markedly influenced by dietary anutrients, food additives, pesticides 
and industrial chemicals. These can either stimulate or inhibit the 
microsomal'drug-metabolizing-.enzymes resulting in alteration of 
barbiturate metabolism.
-o
Barbiturates as inducers of their own metabolism; It is a well 
laiown fact that barbiturates become less effective .when they are 
administered repeatedly for a long period. The decreased pharmaco­
logical response of barbiturates after prolonged administration, known 
as tolerance, was found to be the result of stimulation by the 
barbiturate of its own metabolism Jpemmer and Siegert, 1962; Remmer,
1962). Using a series of barbiturates the above workers showed 
that all substituted barbiturates could stimulate their own and the 
metabolism of other barbiturates (e.g. Cross tolerance). Barbituric 
acid, which, is'known to have no hypnotic properties, also has no effect 
on the.microsomal enzyme system. However, chronic barbital administration 
results in tolerance although this barbiturate is mainly excreted 
unchanged, so its effect cannot be totally ascribed to metabolism. 
Therefore alteration of sensitivity of the drug at receptor site is 
also a possibility to be investigated (Ebert et al, 1964).
IS 8.
Inhibition of barbiturate metabolism Barbiturate metabolism can 
be inhibited, as a result of competitive inhibition, by a variety of 
compounds which serve as substrates for the same enzyme system that 
metabolizes barbiturates. After an interval of approximately 12 hrs 
the inhibitory phase ceases and barbiturate metabolism may be 
stimulated (kato et al, 1962b;Rogers et al, 1963).
Barbiturates as inducers of.the microsomal drug-metabolizing enzymes 
Barbiturates have been shown to induce a variety of drug 
metabolizing enzymes both in vivo and in vitro (Remmer, 1962; Kato 
and Vassanelli, 1962 ; Mark, 1963; Remmer and Me.rker, 1965). Hie 
degree of stimulation depends on the dose administered until a 
maximum is reached after approximately 4 days of pretreatment (Kato 
and Vassanelli, 1962). Barbital also stimulates microsomal drug 
metabolism although it is not metabolized to any significant extent.
By far the most extensively studied barbiturate is the long-acting 
phenobarbitone which is at present used as the model inducing agent.
Hie inductive effect is caused by the parent compound, since p-hydroxy- 
phenobarbital, the major metabolite of phenobarbital, was found to 
be inactive (Minegishi et al, 1968). Pretreatment of rats with 
phenobarbital did not enhance the activity of pentobarbital oxidase 
in the lung, 'nitro-reductase, in kidneys, or aminopyrine N-demethylase 
in the kidney, heart, spleen, brain, muscle or lung (Conney, 1972) but 
increased the activity of other drug-metabolizing enzymes in the kideny 
(Uehleke and Greim, 1968)..
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.The effects of barbiturates on steroid metabolism
The microsomal mono--oxygenase system also metabolizes a variety of 
endogenous substrates including cholesterol and steroid hormones, therefore 
barbiturate administration will disturb their metabolism. Phenobarbital 
pretreatment has been shoivn to enhance cholesterol biosynthesis (Mitoma et al,
1968), stimulate metabolism of testosterone, A^-androstene-3-17-dione 
(Comiey and KTutch, 1963), androsterone (Garreu et al, 1961), oestradiol- 
17-3-nydrox)7"!ase (Conney et al, 1965) and cortisol (Conney et al, 1965; 
Burnstein et al, 1967). . Thus barbiturate administration may lead to changes 
in the hormonal balance with subsequent physiological consequences.
The mechanism of hepatic enzyme induction by barbiturates
Stimulation of drug metabolism has been shown to occur with a 
diversity of compounds with different pharmacological activities and 
chemical structures. The mechanism of stimulation of microsomal metabolism 
is not the same with all inducing agents. Barbiturates and other drugs 
are similar to halogenated insecticides and cause a non-specific induction 
of microsomal enzymes which is -accompanied by proliferation of the endo­
plasmic reticulum. The effect is obvious shortly after drug administration 
but chlorinated insecticides require prolonged treatment. In contrast, 
polycyclic hydrocarbons give rise to a more specific stimulation of micro­
somal enzymes arid do not stimulate proliferation of the endoplasmic 
reticulum (Fouts and Rogers, 1965).
Phenobarbital-like inducers stimulate RAJJPH-cytochrome c reduction 
and cytochrome P-450 (Conney, 1967), and increase the affinity of cytochrome 
P-450 for type I and type II substrates and also. increase its reduction
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(Gram et al, 1969). Polycyclic hydrocarbons, such as methylcholanthrene 
induce formation of a new form of cytochrome P--450, (Chapter 1), which' 
has an affinity for substrates different from that of the usual form of 
cytochrome P-450 -(Mannering et al, 1969). It has increased affinity for 
type II substrates but decreased affinity for type I substrates. This 
cytochrome may be a modified cytochrome P-450 or a new related cytochrome 
(Kato and Takanaka, 1969; .Shoeman et al, 1969). Polycyclic hydrocarbons 
do not induce NADPH-cytochrome c reductase or the rate of cytochrome P-450 
reduction (Conney, 1967; Gram et al, 1969). In female rats the anabolic 
steroid spironolactone .increases NADPH-cytochrome- c reductase activity and. 
rate of cytochrome P-450-substrate reduction but has little or no effect 
on the amount of cytochrome P-450. Glucocortoids show similar effects 
(Castro et al, 1970). .
Enzyme induction was shown to be the result of increased protein 
synthesis and is inhibited by puromycin and actinomycin D (Conney and 
Gilman, 1963; Kato et al, 1965). Phenob arbi tone has been shown also to 
decrease rate of enzymic protein breakdown (Jick and Shuster, 1966;
Kurijama et al, 1969). Methylcholanthrerie increases total protein content 
of liver without altering protein content per gram of liver, whereas 
phenobarbital and other drugs increase both .and also increased 'the 'micro­
somal protein per gram of wret liver (Conney et al, 1960). Both phenobarbital 
and methylcholanthrene stimulate hepatic RNA-polymerase activity (Gelboin, et al 
1967) giving rise to a nuclear chromatin which is a more efficient template 
for RNA synthesis than that from control animals. Increased protein 
synthesis could be 'the result of increased translation as the result of 
decreased turnover of messenger- and other RNA. Phenobarbital has been 
demonstrated to inhibit ribonuclease activity which parallelled the micro­
somal metabolism of aminopyrine (Stolman and Lou, 1970; Louis-Ferdinand
and Fuller, 1970).
Other workers suggested that phenobarbital primarily affects the 
transcription of ribosomal RNA whereas 3-methylcholanthrene produces an 
increase in the transcription of RNA resembling messenger RNA (Wold and 
Steele, 1969).
Effects of barbiturate on other liver enzymes
Phenobarbitone and barbitone do not affect glucose-6-phosphatase, 
another enzyme situated in the liver endoplasmic reticulum, showing that 
barbiturates have a selective effect inducing only the enzymes involved in 
drug metabolism (Feuer et al, 1965; Platt and Cockrill, 1967). However, 
the activities of some cytoplasmic enzymes are increased e.g. UDP-glucose 
dehydrogenase (Touster et al, 1961), glucose-6-phosphate dehydrogenase 
and 6-phosphogluconate dehydrogenase (Platt and Cockrill, 1967), some 
transaminases (Remmer, 1969) and conjugases (Remmer, 1964).
Barbiturates also induce mitochondrial enzymes (Chapter 8) one of 
the most prominent being S-aminolaevulinic acid synthetase resulting in 
an increase of porphyrin biosynthesis (Wada et al, 1968, Chapter 8).
Barbital and phenobarbital stimulate the biosynthesis of 1-ascorbic
acid from glucose through the. glucuronic acid pathway (Bums et al, 1957;
14 ■ *Eisenberg et al, 1959). Using C glucose it was found that barbital
produces a marked increase in the conversion of ^C-D-glucose to D-glucuronic
acid and ascorbic acid. Since barbital is not extensively metabolized
this effect occurs independently of any known detoxication mechanism.
Barbiturate stimulation of ascorbic acid and glucuronic acid production
may be due to - induction of uridine diphosphate glucose (UDPG) dehydrogenase
or of microsomal glucuronyl transferase activity (Zeidenberg et a_l, 1967).
Factors affecting enzyme induction of microsomal metabolism by barbiturates
Phenobarbital stimulates several microsomal enzymes in botli the foetal 
and newborn rabbit (Hart et al, 1962). Treatment of -pregnant mice with 
barbital increases the activity of the bilirubin conjugating enzyme, in the 
liver of the newborn (Catz .and Yalfe,: 1962).
■ Phenobarbital administration gives rise to a greater extent of 
induction in growing rats. Female rats are more susceptible to barbiturate 
induction than male rats reducing the difference observed in the activities 
of the unstimulated animals (Furner et al, 1969a).
Implications of barbiturate Induction in drug therapy
Barbiturates stimulate the.metabolism of other drugs, pesticides 
and toxic chemicals. If metabolism leads to detoxication of the compound 
then induction causes a decrease in the pharmacological activity, e.g. 
strychnine (Kato et al, 1962c) If, however, metabolism leads to active 
products, barbiturates increase the pharmacological or toxicological 
effect e.g. acetylsalicylic acid (Coldwell and Solomonraj, 1968).
The inductive properties of barbiturates are exploited in therapeutics. 
For example, administration of barbiturates to animals enhances the 
enzymic glucuronide formation of bilirubin by liver microsomes and 
accelerates the in vivo metabolism of bilirubin. .Thus barbiturates 
have been used therapeutically in the treatment of hyperbilirubinaemia 
(Crigler and. Gold, 1969).
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Barbiturates stimulate their own metabolism and the metabolism of 
a diversity of compounds. The extent of induction varies among barbiturates, 
some having little or no effect. However only phenob arbi tone has been 
thoroughly studied although many other barbiturates are used in clinical 
practice. Although it has been suggested by many workers that the degree 
of induction depends on the rate of metabolism and thus on the physical 
properties of the molecule no work has been done to prove its validity.
The present study involves the determination of the enzyme-inductive 
properties of a group of commonly used barbiturates and attempts to provide 
evidence supporting the above suggestion. •
MATERIALS AND.METHODS
Barbiturates were a gift from May and Baker Ltd. Sodium salts 
were dissolved in saline (50 mg/ml)., free acids were dissolved in M-NaOH 
and the pH was adjusted to pH 8.5-9.0 with dilute hydrochloric acid.
In each experiment 18 male Wistar-albino rats , 37 days old, were 
randomly divided into six groups. Test groups received daily intra- 
peritoneal administration of one barbiturate (50 or 75 mg/kg) for three 
days while the control group received the corresponding volume of saline. 
Animals were-killed 24 hrs after last injection, the livers were removed 
and subcellular fractions were prepared as previously described (Chapter 2). 
Each .experiment was repeated at least twice and the results were comb hied. 
When b arbi tone was investigated, three groups of five animals were used.
One group served as control, one was treated'with phenob arbi tone and the 
other with barbitone.
The following determinations were carried out on the microsomal 
supernatant fraction (9,000 x g supernatant): biphenyl-4-hydroxylase,
ethyMorphine demethylation and p-nitrobenzoate reductase. Enzymes 
determined in the microsomal'fraction (suspension of 105,000 x g pellet) 
include NADPH-cytochrome-c reductase, glucose-6-phosphata.se, cytochrome 
P-450, cytochrome b^ and microsomal-protein.. Using the soluble fraction 
(105,000 x g supernatant) glucose-6-phosphate dehydrogenase, 6-phospho- 
gluconate dehydrogenase and soluble protein were determined (Chapter 2).
Binding of barbiturates to hepatic microsomes was carried out as 
previously described (Chapter 2).
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Rinding of barbiturates to hepatic microsomal cytochrome ■ P-450
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RESULTS
All barbiturates studied interact with cytochrome P--450 to produce 
a type I spectral change (Fig. 5.2) having a trough near 420 run and a 
peak near 390 nm. Thiopental (Fig. 5.21) mid allobarbitone (Fig. 5.2.F) 
show only a'minimum at 420 nm and were still classified as type I.
Barbitone and barbituric acid gave no binding spectra (Fig. 5.2G, 5.2D).
Intraperitoneal administration of barbiturates at both dose levels 
of 50 mg/kg and 75 mg/kg resulted in stimulation of the microsomal drug 
metabolizing enzymes (Tables 5.1,.5.2, 5.3). There was also an increase 
in liver wt and the liver/100 g body wt ratio especially after pretreatment 
with intermediate and long acting barbiturates. The effect on liver wt 
was dose dependent.
Barbiturates enhanced the activities of all microsomal drug 
metabolizing enzymes studied. Hydroxylation of biphenyl was enhanced 
by all barbituric acid derivatives and with the exception of thiopental 
extent of induction was dependent on the plasma-half life of the barbiturate 
(Fig. 5.3). When the barbiturate dose was increased the biphenyl metabolism 
was enhanced even more (Fig. 5.4). .
The NADPIi-reduction of cyrtochrome c follows , the same pattern 
(Fig. 5.3), phenobarbitone being the best inducer. Increasing the dose 
resulted in no further enhancement of the enzyme activities'(Fig. 5.4).
Demethylation of ethylmorphine and reduction of p-nitrobenzoate 
were also induced by barbiturate pretreatment the long acting barbiturates
177.
being the better inducers (Fig. 5.4).
Phenobarbitone markedly increased ‘the level of cytochrome P-450 
in the microsomes (Fig. 5.3). Other barbiturates also elevated, the 
amount of the cytochrome but the effect was less pronounced. Cytochrome 
bg was also increased by all barbiturates (Fig. 5.3). Increasing the 
dose showed no further increase in the level of the cytochromes (Fig. 5.4).
Hexobarbitone sleeping times after barbiturate pretreatment were
significantly lower compared to controls and with the exception of
thiopental the decrease in sleeping time was reversely correlated to the
■© ' ■
plasma half life of the barbiturate, (Fig. 5.5).
Barbiturate administration did not significantly change the 
activities of glucose-6-phosphate dehydrogenase and 6-phosphogluconate 
dehydrogenase in the soluble fraction or microsomal glucose-6-phosphatase 
(Table 5.4).
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Stimulation of in vivo drug metabolism by barbiturates
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DISCUSSION
Interaction of barbiturates with hepatic microsomes
All barbiturates,.'except barbital and barbituric acid have been 
shown to interact with 'ey to chrome P-450 to give a type. I spectral change 
■ which is in agreement with previous reports (Topham, 1970). Thiopental, 
a sulphur containing barbiturate, forms a trough at 420 nm but has no 
absorption maximum at 390 ran. At the range of 350-420 nm it has a high 
absorption probably due to interaction of the sulphur with the haemo- 
protein-cytochrome P-450 or with a component of the lipid environment 
of 'the cytochrome. Barbiturates having the same substituents at the
5-position, e.g. diethylbarbituric acid (barbital) and diallylbarbituric 
acid (aliobarbital) and the unsubstituted barbituric acid give abnormal 
or no spectrum at all. Aliobarbital (Fig. 5.2F) gives a spectrum 
characterised only by a trough near 415 nm but has no absorption maximum.
It was still classified’as 'type I spectrum. Other workers (Jansson et 
al, 1972)' observed that with increasing barbiturate concentration, 
barbiturates containing an allyl substituent gave rise to a modified 
type II spectral change. This suggests that these barbiturates may 
interact in more than one way with cytochrome P-450 or with more than 
a. form of the enzyme. Barbituric acid (Fig. 5.2D) and barbital (Fig. 5.2G) 
gave no spectrum at all. Hie possibility that these compounds bind to 
both type I and type II sites to the same extent so that resultant 
difference spectrum is zero was investigated by blocking type II binding 
site prior to addition of barbital. Large amounts of ethanol were added 
to both test and reference cuvettes. However, addition of barbital to 
test cuvette again produced no spectrum suggesting that the compound 
is unable to bind to cytochrome P-450 which is compatible with its low 
metabolism (Goldschmidt and Wehr, 1957; Conney et al, 1961).
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Barbital has a pK of 7.2 and at physiological pH is ionised and in this 
form .is unlikely to penetrate the lipoid environment of the drug metabolising 
enzymes of the endoplasmic reticulum (Gaudette and Brodie, 1959). Hie 
binding of the remainder of the barbiturates indicates that they may serve 
as substrates of the microsomal oxygenase system.
Stimulation of the in vitro microsomal drug metabolism by barbiturates
M l  barbiturates studied stimulated the in vitro activities of a 
variety of drug metabolizing enzymes and also increased the microsomal 
cytochrome content. Since all barbiturates can act as stimulators of 
microsomal drug metabolism, it can be concluded «that inducing ability 
is-a property of the barbiturate ring. However, the extent of induction 
is dependent on the substituents at the 5-position. All barbiturates 
enhanced aromatic hydroxyl at ion of biphenyl, demethylation of ethyl- 
morphine, reduction of p-nitiobenzoic acid and NADPH reduction of 
cytochrome c. There was also an increase in the liver wt as previously 
reported (ICunz et al, 1966). The same workers showed that after chronic 
pretreatment phenobarbital increased liver/100 g body wt ratio while other 
barbiturates had less pronounced effect and barbituric acid had no 
.effect. Kunz et al (1966) also showed that liver enlargement was the 
result of hypertrophy with a disproportionate change in .the compartments 
and not due to hyperplasia. The same workers observed that phenobarbital . 
increase of protein, lipid and RITA almost parallelled the increase in 
liver.wt. In the present study barbiturates with long pharmacologic 
acitivity are the most potent inducers of drug metabolism. Secobarbital, 
a short acting barbiturate, has little or no effect. Thiopental 
presents a special case and will be di.scussed later in this chapter.
Barbitone having a long pharmacologic activity is a potent inhibitor
but not to the degree of phenobarbitone, probably the result of the inability
of the compound to reach the enzyme system.
All barbiturates increased the microsomal content of cytochrome.
P-450 and cytochrome b^, phenobarbital having the most potent and 
secobarbitone the weakest effect. Increasing the dose from 50 mg/kg 
to 75 mg/kg did not result in significant changes'of the extent of 
.increase of cytochromal content and NADPH-cytochrome c reductase showing 
that saturation has been reached. Hie increase in cytochrome content 
parallels the biological half-life of the barbiturate. However, alio- 
barbitone stimulation of cytochrome P-450 is lower when compared to 
pentobarbitone at both dose levels (Figs. 5.3, 5.4). -This is probably 
the result of the destruction of cytochrome P-450 by an aliobarbital 
metabolite (Abritti and De Matteis, 1971^/l972). Other ally 1 containing 
compounds have also, been shown to destroy cytochrome P-450, e.g. allyl- 
isopropylacetamide (De Matteis, 1970, 1971). Secobarbitone also has a 
similar effect which may contribute to its weak stimulation of cytochrome 
P-450.
Many endogenous compounds such as steroids serve as substrates of 
the same mono-oxygenase system. It is reasonable to assume that the 
active sites of the enzymes are always occupied by these endogenous 
substrates so that on barbiturate administration these must compete with 
the endogenous substrates for the active sites of the enzyme. When all 
active sites of the enzyme are occupied, further administration of 
barbiturate will.' not enhance the degree of induction.
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Effect of barbiturates on in vivo drug metabolism
The inducing ability of barbiturates has been confirmed by in vivo 
studies. Iiexobarbitone sleeping time was shortened after barbiturate 
pretreatment (Fig. 5.5). Excluding thiopental the decrease in sleeping 
time caused by barbiturates was directly correlated to the biological half- 
life of. the barbiturate in the rat plasma (Chapter 4).
Possible mechanism of enzyme induction
The increase in cytochrome P-450 content is appreciably higher than 
stimulation of metabolism suggesting that the newly synthesized P-450 
is less active. It is also possible that barbiturates stimulate the 
formation of more than one form of cytochrome P-450 but only one of 
these is actively involved in the metabolism of drugs.
Phenobarbitone is known to act as an enzyme inducer of drug 
metabolizing enzymes both by stimulating microsomal protein synthesis 
and by decreasing the rate of breakdown of pre-existing enzyme (Jick 
and Shuster, 1966). Although the incorportion of aminoacids into protein 
after barbiturate pretreatment was not investigated in the present 
work it would be reasonable to assume that all barbiturates which can 
act as inducers do so in the same mode as phenobarbitone.
Compounds with slow rate of metabolism are good inducers of drug 
metabolism suggesting that formation of the enzyme-substrate complex may 
be a dominant factor in the induction of microsomal drug metabolism. 
Phenobarbitone with a long half-life is a potent inducer while 
secobarbitone with a short half-life is a poor inducer. Barbital, although 
only slightly metabolized, still acts as a potent inducer of the mono- 
oxygenase system. These observations indicate that the duration of
association of the enzynic-substrate complex is the important factor in 
induction of drug metabolism and not the amount of enzyme-substrate' complex 
formed. Hexobarbitone, an ultrashort acting barbiturate (Chapter 4) 
does not activate microsomal drug metabolizing enzymes when administered 
once a day but given In'/ice a day it activates microsomal metabolism on 
the fourth or fifth injection (Reminer, 1962).
Thiopental as an inducer of microsomal drug metabolism
Thiopental is a potent inducer of the mono-oxygenase system although 
its biological half-life is very short (Chapter 4). Thiopental is known 
to be metabolized partially to its oxyanalogue pentobarbital which is . 
itself a potent inducer of the microsomal mono-oxygenase system and also 
has a longer biological half life (Chapter 4). Thus the stimulation of 
microsomal drug metabolism by thiopental is due to its metabolite, pento­
barbitone, and not to thiopental itself. Although this pathway is minor 
it still produces sufficient pentobarbitone to interact with the enzyme.
On formation pentobarbitone is immediately bound to the enzyme as it is 
already inside the microsomal lipoid barrier and there is no problem in 
reaching the enzyme system.
Correlation between enzyme induction and chemical structure of compound
Recently reports appeared where lipid solubility and rate of 
metabolism were correlated (Martin and ITansch, 1971) while also lack of 
correlation has been described (Mazel, 'et aJL 1966). It
was reported that the more lipophilic the barbiturates are, the faster 
they are metabolized and hence the shorter the duration of their 
pharmacological action (Hansch, 1972). Contrary to the above workers
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Jansson et al (1972) observed only a rough correlation between lipid 
solubility and rate of metabolism of barbiturates. Hie same workers 
also observed that there was no good correlation between lipid 
solubility and binding affinity to cytochrome P-450. Their results 
suggested that lipid solubility determines the availability of a drug- 
at the active site but is not involved in the formation of the enzyme- 
substrate complex. In contrast, action of barbiturates on mitochondrial 
NADH-oxidase, revealed strong correlation with lipid solubility suggest­
ing that although lipid solubility is required for a substrate to reach 
the microsomal cytochrome P-450, other properties of the molecule are 
involved in determining the binding to the cytochrome while in mitochondria 
lipid solubility alone determines the efficiency with which barbiturates 
inhibit the respiratory chain. In view of these results they suggested 
that barbiturate ring structure is important for barbiturate interaction 
whereas the substituents are directly involved in 'the interaction with 
cytochrome P-450 and the final hydroxyl acceptors. Evidence for the 
possibility that the side-chain substituents are.of importance has also 
been previously described (Topham, 1970).
The magnitude of the type I spectral change is thought to be 
directly related to the concentration of cytochrome P-450 that interacts 
with added substrate. All barbiturates, except barbitone, produce 
spectral interactions with cytochrome P-450 but the maximal size varied 
with the different barbiturates and was roughly correlated to lipid 
solubility (Jansson et al, 1972). those barbiturates with low lipid 
solubility produce a spectral change with cytochrome P-450 of smaller 
magnitude than the more lipid soluble compounds, these observations 
support the suggestion that degree of induction of drug metabolism is
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determined, by. the duration of the association and not by the amount of 
enzyme-substrate complex.
Products of metabolism can also bind to cytochrome P-450 as 
observed in the metabolism of imipramine (von Bahr and Orreriius, 1971).
On formation, the product competes with parent compound .and other 
metabolites for the enzyme site. If product displaces parent compound 
it gives rise to product inhibition. Thiopental metabolizes to pento­
barbitone which binds to cytochrome P-450.and gives rise to the high 
degree of stimulation of drug metabolism.
Barbital as inducer of.microsomal drug metabolism
Barbital is known to be metabolized to a small extent in the 
liver of rats (Goldschmidt and Wehr, 1957; Ebert et al, 1964) and in the. 
present work it has been shown to act as a potent stimulator of microsomal 
drug metabolism. These findings indicate. that at least a small amount 
of barbital can reach the. microsomal enzyme system to form the enzyme 
complex which is necessary for it to be metabolized. However, barbital 
addition to liver microsomes- gave no binding spectrum. Ethanol gives 
rise to a binding 'spectrum but is itself not metaboli zed by the microsomal 
mono-oxygenase system (Chapter 6). These observations suggest that 
binding to cytochrome P-450 is not indicative of metabolism or inducing 
ability of a compound and vice versa. However, it is possible that 
amount of barbital interacting with cytochrome P-450 is small and its' 
binding cannot be detected with presently available 'techniques.
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Effect of barbiturates on other liver enzymes
Barbiturates clo not induce any cytoplasmic enzymes or enzymes of
the microsomal fraction not involved in drug metabolism. Glucose-6-
phosphatase, a microsomal marker, was not affected by barbiturate pre-
treatment. This is in accordance with previous reports (Feuer et al
1965). However, other workers showed a significant inhibition of glucose-
6-phosphatase by phenobarbitone (Kunz et al, 1966). These results
show that barbiturates are selective in carrying out. their stimulative
effect in the microsomes. Glucose-6-phosphate dehydrogenase and 6-phospho-
gluconate dehydrogenase are also -unaffected in accordance to previous
reports (Feuer et al? 1965) although results to the contrary have also
* <?
been reported (Kunz et al, 1966). •
In conclusion,
(a) Lipid solubility is the dominant factor in determining. .tl\e 
availability at the enzyme site since it also determines degree 
of protein binding.
(b) Once compound reaches the enzyme it competes with 'endogenous or 
diet derived compounds for the active site of cytochrome P-450.
(c) Lipid soluble compounds appear to bind more easily to cytochrome 
P-450 as observed by the magnitude of their spectral changes.
(d) The duration of the association of enzyme-substrate complex and 
not the amount formed is the dominant factor determining the 
extent of induction.
(e) When product is formed it may compete with parent compound and 
other metabolites for the enzymic active site.
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(£) We are in error in assuming that binding of a compound to cyto­
chrome P-450 indicates that this compound can be metabolized by 
this system and vice versa.
(g) Barbiturates selectively stimulate only the drug metabolizing 
enzymes in the microsomes.
More work is required to establish if barbiturates can act in
v
more than one way. It is not yet clear what factors regulate the 
binding of a compound to the enzyme and how the formation of this 
complex triggers off the formation of new enzymic protein
Chapter Six 
METABOLISM OF ETHANOL AND BARBITURATES
METABOLISM OF ETHANOL AND BARBITURATES
Chronic alcohol abuse is the most widely known chemical injury to 
which’ man is exposed. In the United Kingdom the consumption of beer 
alone averages 98.4 litres per head per year, and the U.K. ranks only 
eighth in the list of world beer consumers. In the United States there 
are at least 6 to 8 million alcoholics and in England and Wales the 
admission of alcoholics rose from some 2000 in 1959 to over 8000 in 
1969., In terms of addiction therefore, ethyl alcohol is of far greater 
social and medical importance, than all other drugs combined (Zacune and 
Hensman, 1971). Thus an understanding of the pharmacological and 
biochemical implications of alcohol consumption^is of major importance 
if this problem is to be dealt with effectively.
Ethanol is known to be metabolized by three different systems, 
namely: •
. Cl) Alcohol dehydrogenase (ADH)[NAD-oxidoreductase EC 1.1.1.1.]
(2) Catalase [EC 1.1.1.1.6]
(3) A recently described hepatic microsomal enzyme system 
(microsoma 1 ~ethano 1 -oxidising system, MEGS).
Also a small amount of ethanol is excreted unchanged (Lieber and 
Davidson, 1962)' find as the glucuronide and sulphate conjugate (Kamil, 
et al, 1952; Bostrdm and Vestermark, 1960). Hiese pathways are described 
in detail.
(1) Alcohol dehydrogenase (ADH) is a ubiquitous enzyme occurring 
in many animals including invertebrates, microorganisms and also in 
plant tissues. It is a. zinc-containing enzyme located mainly in the
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liver of mammals, where it is responsible for 90-98% of ethanol metabolism 
(Thompson, 1956; Morrison and Brock, 1967). Extrahepatic ethanol metabolism 
also occurs and this enzyme has been demonstrated in the kidney (Jacobson, 
1952; Spencer, et al, 1964; BUttner, 1965; Mezey, et al, 1968), seminal 
vesicles, gastrointestinal tract (Spencer, et al, 1964; Mezey et al, 1968; 
Wartburg, et al, 1964; Mis tills and Garske, 1969). Recently an enzyme 
similar in kinetic properties and response to inhibitors to hepatic 
ADH, has been demonstrated, in the brain (Raskin and Sokoloff, 1968). The 
presence of ADH has also been shown in human jejunum, colon and stomach 
(Spencer, et al, 1964).
Ethanol, being water soluble would be expected to be metabolized
by enzymes of the soluble fraction of the liver rather than by enzymes
of the endoplasmic reticulum. Alcohol dehydrogenase is mainly located
in the cytoplasmic fraction of the liver but considerable activity is
also found associated with the mitochondria (BUttner, 1965). In the 
+
presence of NAD it oxidises ethanol to acetaldehyde, which is further 
metabolized by another NAD-dependent enzyme to acetate and thence into 
the various metabolic pools.
Studies on purified enzymes revealed that the oxidation of ethanol 
to acetaldehyde is the rate limiting step in this sequence of reactions, 
the critical points being the dissociation of the enzyme-NADH complex 
and the hepatic NAD /NADH ratio (Theorell and Bonnischsen, 1951; Smith, 
et al, 1957; Smith-and Newman, 1959; RUihli and Oura,
1962). 'Alcohol'dehydrogenase- also metabolizes methanol which, explains 
the rationale of the use of ethanol in methanol poisoning (Zatman, 1946; 
Bartlett, 1950).
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(2) Catala.se is a widely distributed enzyme found in high 
concentration in mammalian liver and .erythrocytes and capable of 
metabolizing both ethanol and methanol (Tephly, et. al, 1964; Watkins, 
et al, 1970). It is a very powerful catalyst for converting hydrogen 
peroxide to water and oxygen (Jammer and Somers, 1947). However, its• 
importance in ethanol metabolism, in vivo appears to be negligible 
(Bartlett,-1952; Kinard, et al, 1956; Tephly, et al, 1964).
(3) Recently a new7 system has been described which is present 
in the hepatic microsomes, and is similar to the system known to 
metabolize a variety of dmgs and xeriobiotics (Orme-Johnson and 
Ziegler, 1965; Lieber and De Carli, 1968; Roach, et al, 1969; Khanna, 
et al, 1970). This system which is known as the microsomal ethanol 
oxidising system (MEOS), metabolizes both methanol and ethanol but 
not higher primary or secondary alcohols.
The Microsomal Ethanol Oxidising System (MEOS)
This ethanol-metabolizing enzyme system is distinguished from 
ADH by its localization in the microsomal fraction, its optimal 
functioning at physiological pH (ADH has a pH optimum of 10-11) and 
its requirements for NADPH and 0^ . Like the hepatic' microsomal mixed 
function oxidase system, which metabolizes drags, its activity is inhibited 
by carbon monoxide. Although in this microsomal system NADPH cannot 
be replaced by H^O^ it may be replaced by BaO^ (Khanna, et al, 1970) 
or a H202~generating system, e.g. glucose plus glucose oxidase (Roach, 
et al, 1969; Isselbacher and Carter, 1970). It is therefore, probably, 
not completely identical .with the xenobiotic, mixed-function oxidase 
system of the liver (Roach, et al, 1969). 'Die MEOS has little activity
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in the absence of NADPH, and this may not be substituted by NAD*1 , NADP'‘
nor NADH. However, acetyl pyridine .(AP-NAD ), a very good cofactor
for ADH, has the same activity in the MEOS as NADPH, suggesting that [
ethanol metabolism by the microsomal fraction is probably due to A
contamination of the microsomes with both ADH and catalase (Carter and j-
Isselbacher, 1971). Repeated washing of the microsomal pellet with
Tris-acetate buffer reduces the MEOS activity, and also similarly. i
reduces catalase. The.washings contained both ADH and catalase ■*"
activities but were not capable of oxidising ethanol under MEOS
conditions. Mien added back to the twice-washed microsomal-pellet the £
y!
MEOS activity was completely restored (Carter and Isselbacher, 1971).
. . .  '  • • . r  .
Addition of crystalline ADH and catalase similarly stimulated MEOS
' ■ ■ ■ . ■ ' ■ ■ ' I
activity in the washed microsomal pellet. .
£
It was demonstrated that under physiological conditions, both I
i1:
in vivo and in the isolated perfused liver, rat liver ADH was sufficient t
- I
to. account for the whole of ethanol metabolism (Papenberg, et al, 1970). i
f
In some of the work presenting evidence for MEOS activity the 9,000 (g.av.) .
i
supernatant was used (Lieber and De Carli, 1970) rather than the isolated . h
V
microsomal fraction (105,000 g.av. pellet). This fraction contains (
!
most of the ADH and about 401 of the catalase activity of the liver ?
(Nyberg, et al, 1953). Furthermore, inhibition of MEOS by carbon monoxide }
has not been shown to be reversed by irradiation with monochromatic f
light of wavelength 450 nm, which is a feature of cytochrome P-450, the 
terminal microsomal mixed-function oxidase (Tephly, et al, 1969). The 
above evidence all seems to suggest that even if a system for the 
oxidation of ethanol is present in the microsomal fraction, it does not 
have identical properties to the microsomal enzyme system known to
metabolize a variety of foreign compounds.
Inhibitor studies
To examine this complicated system many workers have studied the 
effects of a variety of inhibitors of catalase and ADH, Pyrazole 
blocks ethanol metabolism by inhibiting ADH but not catalase (Watkins, 
et al, 1970). It competes with ethanol for the ethanol binding site of 
ADH (Theorell and Yonetani, 1964). . Pyrazole was also found to inhibit 
the in vivo metabolism of ethanol in rat (Goldberg and Rydberg, 1969; 
Lester, et al, 1969; Reynier, 1969). Moreover,, in the perfused liver 
inhibition was found to parallel the decrease in ethanol utilization 
(Papenb'erg, et al, 1970). However, these results are to be treated with 
caution as some workers have shown that pyrazole inhibits the in vitro 
activity of bothMEOS, and of the microsomal drug-metabolizing enzyme 
system (Lieber, et al, 1970; Isselbacher and Carter, 1970; Rubin, et al, 
197]) although other workers have found the contrary (Khanna and Kalant, 
1970).
Addition of azide or cyanide in vitro (at concentrations not 
affecting the microsomal drug-metabolizing enzyme system) and addition 
of 3~amixio-l,2,4“triazole in vivo and in vitro inhibited the MEOS. 
However, ail the above compounds are known also to be catalase inhibitors 
and it has been suggested that catalase may be involved in the observed 
MEOS activity (Margoliash, et_ al, 1960; Khanna and Kalant, 1970; 
Isselbacher and Carter, 1970). Aminotriazole has also been shown to 
inhibit a variety of microsomal enzyme activities (Kato, 1967).
However, Lieber and De Carli (1970) failed to show any■inhibition of . 
MEOS by these substances under conditions in which catalase was inhibited
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and concluded that catalase does not participate in the MEOS.
The classic inhibitor of drug-metabolism, SKF-525A ($-diethyl- 
aminoethyl diphenylpropyl acetate), does not inhibit MEOS in vitro 
(Roach, et al, 1969; Tephly, et al, 1969; Khanna, et al, 1970) and 
has also no effect on the rate of blood ethanol disappearance (IChanna 
and Kalant, 1970). However, Lind and Parker in 1967 showed a prolongation 
of ethanol sleeping time in mice treated with SKF--525A. Another 
inhibitor of the microsomal drug-metabolizing enzymes, deoxycholate, 
has been shown to inhibit the in vitro oxidation of ethanol (Khanna, 
et al, 1970) thus suggesting the presence of MEOS. However, inliibit ion 
of both microsomal drug metabolism and MEOS by ■ deoxycholate does , not 
prove identity of these systems since cholate is a non-specific 
disrupter of microsomal structure.
Spectral evidence for ethanol metabolism by MEOS
Ethanol binds to microsomal" cytochrome P-450 suggesting that it 
could serve as a substrate of this mixed function oxidase enzyme system 
(Imai and Sato, 1967; Rubin, et al, 1971a). A compound may bind to 
cytochrome P-450 to induce a type I spectrum, characterised by a trough 
at 420 nm and a peak at 385-390 nm, or a type II spectrum, characterised 
by a trough at 385-390 nm and a peak at 420-425 nm, or may induce no 
spectrum at all. Organic solvents such as alcohols having short carbon 
chains produce a spectral change similar to that of aniline, with a peak 
at 420 nm and a trough at about 392 nm. This type of interaction is 
termed modified type II or Reverse type I (RI) and represents the 
interaction of lipid soluble compounds with the substrate bound form 
of cytochrome P-450 at a site other than the type I (Diehl et al, 1970;
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Rubin,'et al, 1971a; Schenkman, et al, 1972). Hie binding of ethanol 
to microsomes is inhibited by compounds which produce a type II 
binding spectrum, such as pyrazole, but is unaffected by those which 
produce a type I spectrum,-'such as hexobarbitone (Rubin, et al, 1971). 
Furthermore, ethanol inhibits the reduction of cytochrome P450, a known 
property of type II and Reverse type I compounds (Gigon, et al, 1969; 
Scherikman, et al, 1972). From studies of the 10 of ethanol, it was 
shown, that ethanol is a better inhibitor of the type II aniline hydroxyl at; ion 
than of type I pentobarbitone hyaroxylation (Rubin, et al, 1968). Ihe 
hepatic microsomal preparation from animals pretreated with ethanol 
exhibits an enhanced binding spectrum with ethanol (Rubin, et al, 1971,. 
1971a), a general property of substrates of the mixed function oxidase 
system. This behaviour of ethanol does not show conclusively that it is 
oxidised by a system similar to the microsomal drug-metabolizing enzyme 
system, as other alcohols such as isobutanol, 2-propanol and isoarnyl 
alcohol also induce spectral changes similar to that of ethanol (Imai 
and Sato, 1967) but no microsomal metabolism of these compounds is known.
In vivo evidence for ethanol metabolism by MEOS -
It is well known that after ethanol ingestion by alcoholics the 
blood disappearance of ethanol is more rapid than in normal subjects 
(Mendelson and Mello, 1964; Kater, et al, 1968; Iber, et al, 1969;
Lieber and De Carli, 1970; Mezey, 1971; 1972; Tobon and Mezey, 1971). 
Theoretically this acquired tolerance could be due to (a) stimulation 
of MEOS, (b) stimulation of ADH or catalase, (c) increase in NAD the 
hydrogen acceptor, (d) increase in urinary excretion and/or respiratory 
elimination.
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Ethanol has been demonstrated to induce its own. metabolism in 
vivo (Lieber and De Carli, 1968; Kater, et al, 1969; Tobon& Mezey, 1971; Mezey 
1972) thus explaining the observed tolerance of alcohol in alcoholics, 
although an adaptive process at receptor sites cannot be excluded 
(Westerfeld and Schulman,. 1959; Mendelson, et al, 1965; Khanna, et al,
1972) „ However, there is no correlation between the rate of ethanol 
metabolism and blood ethanol disappearance suggesting that other 
factors may also be involved (Mezey, 1971).
Ethanol does not affect catalase activity (Hawkins, et al, 1966;
Lieber and De Carli, 1970) although the contrary has also been reported 
(Wartburg and Rbthlisberger, 1961; Carter and Isselbacher, 1971). However, 
the in vivo significance of catalase is thought to be negligible (Bartlett, 
1952; Kinard9 et al, 1956; Tephly, et al, 1964).
The effect of ethanol metabolism on ADH is a highly conflicting 
issue. Stimulation of ADH activity has been reported (Carpenter, 1940; 
Figueroa and Klotz, 1962; Dajani and Orten, 1960; Dajani, et al, 1963; 
Mendelson, et al, 1965; Mirone, 1965; Hawkins, et al, 1966; Albertini, 
et al, 1967; Mistilis and Birclfall, 1969), while other workers reported 
no significant changes (Aull, et al, 1956; Kinard, et al, 1960;
Greenberger, et al, 1965; Lieber and De Carli, 1968; Hillboin and 
Pikkarainen, 1970; Carter and Isselbacher, 1971; Singlevich and 
Barbonak, 1971), and still others reported inhibition (Morrison and 
Brock, 1967). However, changes in ADH do not parallel ethanol metabolism 
(Singlevich and Barbonak, 1971).
Another possible mechanism for the increased alcohol clearance.
+
in alcoholics is the enhancement of NAD concentration, e.g. pyruvate
-f
increases metabolism by re-oxidation of NADH to NAD (Westerfeld, et al, 1942)
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or an enhancement of respiratory elimination '(Newman and Tainter, 1936).
Ethanol-barbiturate metabolic interactions
If ethanol is metabolized by the same system known to metabolize 
barbiturates then ethanol pre-treatment should induce the activity of the 
microsomal drug metabolizing enzyme(s). Ethanol has been shown to 
induce these enzyme(s) for a variety of these substrates in vivo and 
also to inliibit in vitro (Rubin and Lieber, 1968; Rubin, et al, 1970). 
Proliferation of the hepatic, smooth, endoplasmic reticulum, has also 
'been shown to occur after ethanol administration (Iseri, et al, 1966; Lane 
and Lieber, 1968; Rubin, et al, 1968; Rubin, etwal, 1970). 'Hie increase 
of .smooth endoplasmic reticulum may not be a direct effect of alcohol, 
but conceivably is a response to accumulation of lipids which are in 
part processed in the -smooth endoplasmic reticulum.
Pretreatment'with ethanol has been shown by many-workers to 
increase the activity of the drug-metabolizing enzymes, and the contents 
of cytochromes and microsomal protein (Nelson, et al, 1967; Rubin and 
Lieber, 1968; Rubin, et al, 1968; Lieber and De Carli, 1970; Meldolesi, 
1967; Dioguardi, etal, 1970; Carter and Isselbacher, 1971; Ideo, et al, 
1971a, 1971b; Singlevich and Barbonak, 1971; Mezey, 1972). As the 
increase of microsomal protein produced by ethanol is delayed compared 
to the induction of the enzymic activity it is possible that the increased 
enzyme activity is due more to enzyme stabilization than to synthesis 
of new enzyme. Studies in vivo have shown that ethanol pre-treatment 
shortens pentobarbital induced sleeping times9 (Kalant, et al, 1970). 
Ethanol also induces the mitochondrial enzyme 6-ALA synthetase, the 
limiting step in porphyrin biosynthesis (Rubin, et al, 1970), and
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hence explains the enhanced urinary coproporphyrin excretion (Zieve, 
et al, 1953; Sutherland and Watson, 1951) and the porphyric crises 
that ethanol precipitates in individuals with congenital hepatic 
porphyria (De Matteis, 1967). This induction presumably also involves 
the endoplasmic reticulum since the 6-ALA synthetase is organized 
there before transport to the mitochondria . (Hayashi. et al, 1969).
The effect of classical inducers of drug metabolizing enzymes on 
the MEOS activity is very confusing and reports are very much at variance. 
Phenoharbitone has been shown by some workers to induce microsomal 
alcohol metabolism in vitro (Conney, 1967; Roach, et al, 1969; Lieber 
and De Carli, 1970; Reinhard and Spector, 1970; Mezey, 1971) although 
other workers observed no significant difference (Koff, et al, 1970;
Ideo, et al, 1971a). Aromatic hydrocarbon inducers such as 3,4-benz(o)pyrene 
and 3-methylcholanthrene also present the same conflicting picture.
Both 3-methylcholanthrene and phenobarbitone administration 
do not alter the rate of blood-alcohol disappearance (Klaassen, 1969;
Mezey, 1971) although the opposite observations have also been reported 
(Fischer and Oelssner, 1961; Fischer, 1962). However, both inducers have 
been shown to antagonize the effects of ethanol (Reinhard and Spector,
1970) and a decrease of ethanol sleeping time was-observed-in mice 
pretreated with phenobarbitone , chlorpromazine, ami~ triptyline or 
imipramine given before the ethanol (Tipton, et al, 1961; Schleyer and
Jani.tzki, 1963; Khanna. and Kalant, 1970) .
Effect of alcohol on lipid metabolism
One of the most pronounced actions of alcohol is the interference 
with lipid metabolism, giving rise to a fatty liver.(Di Luzio, 1958;
Koff & Fitts, 1972). These toxic effects were first thought to be a result of 
the sub-optimal nutrition usually accompanying acute ethanol intoxication. 
However, subsequent.work has shown that ethanol is toxic per se to the 
liver when consumed at high dose rates (Rubin and Lieber, 1967, 1968a;
Lieber and Rubin, 1968). Hie lipids accumulating in liver can be 
derived from three sources: (a) dietary lipids entering blood stream 
from gut as chylomicrons, (b) adipose tissue lipids transported as 
free fatty acids, (c) lipids synthesized in liver. The possible 
mechanisms leading to fatty liver are fourfold (a) increased fat 
mobilization, (b) decreased hepatic lipoprotein release, (c) decreased 
hepatic lipid oxidation, and (d) increased hepatic lipogenesis.
Current views are that at low- dose rates alcohol is largely metabolized 
by ADH but at higher dose rates accumulates in the cell, including 
the endoplasmic reticulum where it would bind to cytochrome P-450 and 
possibly adversely affect the metabolism of fatty acids by inhibiting 
co-oxidation (Popper, personal communication).
Effect of ethanol on cellular organelle structure
Ethanol disturbs cellular organization causing ultra-structural 
modifications the most striking effect being the enlargement and 
disfiguration-of mitochondria with disorientation of cristae and 
appearance of crystalline inclusions. Mitochondria also tend to 
clump together (Rubin and Lieber, 1967a). Human mitochondria exhibit a 
similar condition during chronic alcohol intoxication (Lane and 
Lieber, 1966); Hepatic mitochondria isolated from ethanol-pretreated 
rats have decreased oxidative properties. However^ ethanol even 
accelerates the incorporation of labelled.alanine into glucose 
suggesting the presence of an adequately functioning gluconeogenic
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pathway. Recent work has shown that chronic, ethanol administration • 
results in a persistent defect in mitochondrial membrane biogenesis 
which, can cause further mitochondrial damage. Mitochondrial respiration 
is also depressed by ethanol, and is probably more a result of mito­
chondrial injury than to a metabolic effect of ethanol. Fatty acid 
oxidation by mitochondria is also diminished.
In conclusion ethanol exerts a multiple effect on liver structure 
and- function, but the mechanisms are not yet fully understood.
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Ethano1-Barbiturate Interaction
Owing to the widespread and increasing use of pharmaceutical 
agents, the interaction of drugs is becoming a major hazard. The 
high incidence of alcoholism, magnifies the importance of this problem 
and many social accidents and clinical crises are the result of 
synergism between alcohol and commonly ingested drugs. Although the 
use of tranquillizers has risen immensely in the last decade, 
barbiturates are still the most commonly prescribed drugs of those 
acting on the nervous system. There are over 15 million prescriptions 
yearly in England and Wales constituting approximately 6% of the total 
prescriptions (Zacune and Hensman, 1971), Roughly about one night's 
sleep in every ten in the U.K. is barbiturate-induced (Dunlop, 1970).
Thus the likelihood of an alcohol barbiturate interaction is being 
steadily increased.
The effect of barbiturates is enhanced when they are simultaneously 
administered with ethanol, but in alcoholics who are not under the 
immediate effect of alcohol there is an increased resistance to the 
action of barbiturates (Soehring and Schuppel, 1966; Forney and Hughes, 
1968; Gebhart, et al, 1969; Wiberg, et al, 1969; Coldwell, et al, 1970). 
The term ’interaction' inplies two different events, (a) changes in the 
effects of alcohol by barbiturates (1)) changes in the effects of 
barbiturate by alcohol. •
Although few drugs may interact chemically in vivo, most interact 
by interfering with some pharmacodynamic mechanism. Absorption may be 
altered by changes in pH (Downer, et_al, 1970), changes in the transport 
system by complex formation (Goto, et al, 1969), or by altering the
blood flow to the site o£ absorption (Frey and Kampmann, 1966). One 
drug can modify the concentration of another at a receptor site, 
either directly by displacing the other drug from its receptor site 
(reduced biological activity), or indirectly by displacing the other 
drug from plasma proteins and thereby increasing the receptor concentration 
of the first drug (increased activity) (Solomon, et al, 1968; O ’Reilly, 
and Levy, 1970). Displacement - 'from tissue proteins is also very likely.
Hie competition of drugs at receptor site may be competitive if they
act on same receptor or non-competitive if drugs act at different receptor
sites.
Interference with the metabolism of drugs may lead to - change in 
pharmacological action (Cucinelli,et al, 1965; Yeung and Field, 1969). 
Changes in the pH can also influence the rate of excretion (Beckett, 
et al, 1969; Myschetzky and Lassen, 1971). The degree of interaction 
is also affected by physiological factors such as age, sex, strain, 
nutritional and physiological status.
Both ethanol and barbiturates are highly lipid soluble compounds 
readily absorbed, so it is unlikely that interaction results from 
interference in the absorption process, The transport of barbiturates, 
however, maybe disturbed by. ethanol.. Considerable work has been 
carried.out on the brain levels of barbiturates in animals pretreated 
with ethanol but the results are conflicting. A decrease in the brain 
concentration of barbiturates fifteen minutes after administration to 
rats pre-dosed with alcohol has been reported by many workers (Seidel, 
et al, 1964; Kalant, et al, 1970; Coldwell, et al, 1970), but others 
have claimed that no significant differences occurred (Graham, i960), 
and even raised, brain levels have also been reported (Ratchliffe, 1969; 
Leslie, et al, 1971).
If we assume the existence of a system in the liver microsomes 
capable of metabolizing ethanol then the cross-tolerance of ethanol 
and barbiturates can be explained by virtue of their metabolism by 
the same enzyme system. Alcoholics in the sober state have their 
microsomal drug-metabolizing enzymes elevated,-thus accelerating 
deactivation of barbiturates and decreasing their pharmacological 
activity. However, if they are under the immediate effect of ethanol 
a coupetition between ethanol and barbiturates for the enzymic active 
site results in potentiation of the pharmacological action of 
barbiturates.
. This cross-tolerance may also be the result of changes in the 
sensitivity of the nervous system and not upon changes in the metabol 
pattern. Furthermore, altered permeability of cell membranes by 
ethanol is also possible, and it should be noted that ethanol is 
capable of changing the permeability of the blood-brain barrier to 
many drugs other than barbiturates (Newman & Richardson,1937). The v 
variations in previous results have been attributed to different 
experimental conditions. -The present work therefore aims at a 
series of experiments under identical conditions so that direct 
comparison of them is valid.
Experimental Design and Results
Repeated doses of a drug may have metabolic and pharmacological 
effects which differ from the acute effects of a single large dose.
With respect to alcohol, small repeated doses produce different effects 
on the liver, e.g. on lipid metabolism, than does a large single dose 
(Iseri, et al, 1966); chronic administration has also been shown to 
interrupt the biogenesis of mitochondrial membranes while a single 
dose has no effect (Rubin, et al, 1972). Therefore, the effects of 
both acute and chronic doses of ethanol on drug metabolism are 
investigated in this project.
A* Short term administration
In all experiments male Wistar-albino rats, fed on an adequate 
diet were used. The different pretreatments are described at the 
beginning of each experiment.
Acute intraperitoneal administration of ethanol: Two groups comprising
of six 18-day old animals were used. The test group was treated with 
ethanol for six days by intraperitoneal administration of 1000 mg/kg 
body wt, and control animals received the equivalent volume of saline.
Two animals died on the fourth day- from ethanol toxicity. The remaining 
animals were sacrificed twenty four hours after the administration of 
the last dose, the liver was removed, homogenized and its drug metabolizing 
activity determined in vitro as described in Chapter 2. Table 6.1 shows 
that the only significant changes produced by this treatment were 
reductions in the hepatic hydroxylation of biphenyl.
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Table 6.1
Effect of acute intraperitoneal administration of
ethanol on microsomal drug metabolizing enzymes
Parameter examined Control Test
Liver wt/lOOg. body wt. 4,2 + 0.1 4.! + 0.2
Total liver protein (mg/g.liver) 166 + 5 166 + 40
Microsomal protein (mg/g.liver) 28 •{- 2 25 + 2
Biphenyl-4-hydroxylase (yMol/mg pt/h.) 0.11 + 0.01 0.07 + 0.011
• (yMol/g. liver/li,.) 3.9 + 0.2 !.8 ' + 0. 2
Biphenyl- 2-hydroxy 1 ase (nMol/mg.pt/h.) 20 + 2 9 + 1 1
(iiMol/g. liver/h) 0.55 + 0.06 0.23 + 0.031
Ethylmoiphine-N- (yMol /mg. pt /h.) 0.49 ■+ 0.08 0.50 + 0.04
demethylase
(pMol/g.1iver/h) 13 + 1.0 12 1
nJL
Cytochrome-c-reductase (0. D.units/
g.liver/rmn) 21 + 2 20 + 1
Cytochrome P-450 (O.D.units/mg/pt) 0.07 + 0.01 0.06 + 0.01
(0.D.units/g.liver) 1.8 + 0.2 !. 6 + 0.1
Cytochrome b^ (O.D.units/mg/pt) 0.07 +■ 0.01 0.°7 ± 0.01
(O.D.units/g.liver) 1.9 + 0.4 1.6 '■ + 0.1 
......
Animals were pretreated with 1000 mg/kg alcohol daily for six days'. 
Results are N.S. unless otherwise stated.
1. P < 0.01 2. P < 0.02
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Effect of different concentrations of ethanol administered intrape ritone ally
To investigate if there are threshold concentrations for the metabolism 
.of ethanol by the hepatic microsomal enzymes and hence threshold 
concentrations for its interaction with drug metabolism (a biphasic 
effect), increasing amounts of ethanol ranging from 10-100 mg/kg were 
administered intraperitoneally to different groups, each of three 
animals. Table 6.2 shows that there are no changes in the contents 
of cytochromes or microsomal protein at any dose level but there is a 
slight increase in the enzyme activities of biphenyl-4-hydroxylase, 
ethylmorphins demethylation and NADPH - cytochrome c. reductase at the 
low dosages. The levels of these enzyme,activities returned to the 
control values with increasing doses of ethanol (Fig. 6.1). Dosage in 
the region of 10-25 mg/kg was re-examined in 22 day old rats in groups 
of six animals. Pretreatment was carried out for one day and for three 
days. In the former experiment (Table 6.3) there was a slight but 
significant increase in biphenyl-4-hydroxylase activity at the 25 mg/kg 
level only. In the latter experiment (Table 6.4) elevation of biphenyl- 
4-hydroxylase occurred only in the 10 mg/kg group and was also accompanied 
by an increase in the/ cytochrome-c-reductase activity. There were no 
changes in the microsomal content of the cytochromes P-450 and b,- or 
in microsomal protein.
Each group consisted 
of four 21 day-old rats. The test group received a single oral dose 
of ethanol 5g/kg body wt by gastric intubation while controls received 
the corresponding volume of saline and animals were sacrificed 17 hours 
after pretreatment. None of the hepatic parameters examined was affected 
by the pretreatment (Table 6.5).
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Table 6.3-
Effect of intraperitoneal administration of different
ethanol concentrations on hepatic microsomal drug metabolism
Parameter - Control 10 mg/kg 25
-
mg/kg
Liver wt/100 g body wt. 4.5 + 0.1 4.6 + 0.1 4.8 +
i
0,2 !i
Total liver protein mg/g liver 161 + 9 169 + 3 176 + 12
i
Microsomal protein mg/g liver 25 + 1 23 +■ 2 17 + i 2 1i
Biphenyl-4-
pmol/mg pt/hr 0.18 + 0.02 0.16 -h 0.02 0.24 + o.oi M
i
hyaroxylase ymol/g liver/hr 4.5 + 0.1 3.4 j. 0.1 3.7 0.1
Biphenyl-2-
nmol/mg pt/hr 21 + 2 18 + 3 29 +
i
1
hydroxylase
ymol/g liver/hr 0.53 + 0.05 0.39 + 0.04 0.48 4- 0.03
Cytochrome-c-reductase 
O.D. units/g liver/min 38
+ 2 32 + 1 1 36 *>- 5
Cytochrome P-450
O.D.units/mg pt. 0.06 + 0.01 0.05 + 0.01 0.06 0.01
O.D.units/g live]~ 1.4 + 0.1 1.1 + 0.14 0.9 +' 0.13
Cytochrome b^
O.D.units/mg pt. 0.10 + 0.01 0.09 -f 0.01 0.09 + 0.01
i
O.D.units/g liver 2.5 
1
+ 0.2 2.0
...
+ 0.1 i.5 0.31
1 P <0.02
2 P < 0.001
3 P < 0.01
4 P < 0.05
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Table 6.4
Effect of intraperitoneal administration of different 
ethanol concentrations on hepatic microsomal drug metabolism
Parameter Control 10 mg/kg 25
%
mg/kg |
Liver wt/100 g body wt 4.4 + 0.1 4.3- * 0.1 4.6 + 0.04 j
Microsomal protein mg/g liver 21 . + TJ. 22 + 2 21 ' + 1 I
P-nitrobenzoate reductase 
■,ymol/g liver/h. 4.5
+ 0.3 4.4 + 0.2 4.5 +
1
0.2 j
jnol/mg pt/h. 0.19 + 0.01 0.31 + .■ 0.031 0.20 •!- 0.02 !
jDipiienyi-^  i
hydroxylase ;Jmol/g liver/h. 4.0 + 0.3 6.7 + 0.61 4.1 + 0.4
Biphenyl-2-
ynol/mg pt/h. 15 + 1 11 + i 16 + 3
hydroxylase
jnol/g liver/h. 0.31 + 0.03 0.23 + 0.03 0.3 + 0.04
Cytochrome-c-reductase 
O.D. units/g liver/min.
33 . + 3 46 + 21 35 + 3
Cytochrome 
p a
O.D. units/mg pt 0.06 + 0.01 0.07 4- 0.01 0.06 *T* 0.01 '
Jr
O.D. units/g liver 1.2 + 0.1 1.4 -i- 0.1 1.2 + 0.1
Cytochrome O.D. units/mg pt 0.10 + 0.01 0.09 + 0.01 0.08 + 0.01
5 O.D. units/g liver 1.9 + 0.1 1.8 . + 0.1 1.6 + 0.1
1 P < 0.01
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Table 6.5
Effect of ethanol administration by gastric intubation 
on hepatic microsomal drug metabolism
Parameter Control Test |
•
Liver wt/100 g body wt 4.3 + 0.2 4.1 + 0.1 j
Total liver protein mg/g liver
...... ....
172 ± 7
■ 171 ± 10 i.
Microsomal protein mg/g liver
......  ...  .... .  ■ •
24 + 1. 26 1 2  j
P-nitrobenzoate reductase
•
•ymol/g liver/hr 3.3 +• 0.2 3.3 1 0.3
Biphenyl-4~ ymol/mg pt/hr 0.19 + 0.02 0.15 + 0.01
hydroxylase ymol/g liver/hr 4.6 + 0.5 4.0.1 0.3
Biphenyl-2- nmol/mg pt/hr 13 -i- 2 12 + 1
hydroxylase ymol/g liver/hr 0.13+ 0.01 0.12 1 0.02
Cytochrome P-450 'O.D.units/mg pt 0.06 _+ 0.01 0.05 1 0.01
O.D.units/g liver 1.4 + 0.1 i. 5 l 0.1
Cytochrome b^ O.D.units/mg pt 0.08 * 0.01 0.08 1 • 0.01
O.D.units/g liver 2.4 + 0.2
■
2j 3 1 0.1
-
Test animals received a single oral dose of ethanol 5g/kg body wt. by gastric 
intubation
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Effect of oral administration of ethanol in drinking water: .Two experiments 
were performed. In the first one, each group comprised six 18 day-old
*\7*
animals and the test group was maintained for eighteen days on 2% /v aq 
ethanol as their only drinking liquid. Again, the hydroxyl at ion of 
biphenyl was slightly increased but there were no other changes (Table 6.6). 
In the second experiment -there were four groups containing six animals 
aged 21 days. Group A served as controls; Group B was’maintained on 
aq. ethanol 101 (V/v) for five days as the sole drinking liquid; Group 
C received daily doses of 75 mg/kg phenobarbitone during the last three 
days before animals were sacrificed, but no ethanol; Group D received 
both ethanol and phenobarbitone. These experiments showed that ethanol 
alone (Group B) gave rise to a significant increase only in the hydroxy- 
lation of aniline (Table 6.7); cytochrome P-450, b^ and■ NADPH-cytochrome-: 
c reductase were unchanged. Hie expected usual increases of hepatic 
enzymes was observed with the phenobarbital treated animals (Group C) 
and similar effects to these were observed in the ethanol and phenobarbital 
treated animals (Group D). These latter results are discussed later 
in this Chapter.
Effect' of ethanol on its own binding to microsomes: In the first
experiment five animals received five daily doses of ethanol (100 mg/kg)
intraperitoneally and were sacrificed on the sixth day. In the second
\r
experiment three rats were maintained on 2% ( /v) aq. ethanol for twenty 
four days as the only drinking liquid. In both experiments there were 
no significant changes in the spectral dissociation constant Ks, maximum 
binding AEmax and ethanol binding (Table 6.8 and Fig. 6.2).
215.
Table 6.6
Effect of oral administration of ethanol
on hepatic microsomal, drug metabolism
1 . ■
|Parameter
».-..... -
Control Test
j
]Liver wt/100 g body wt
.
4.3 + 0.1 4.6 + 0.1
jlvlicrosofnal protein mg/g liver 27 + 1 26 + ' 1
Biphenyl-4- ^ol/mg pt/hr ' . 0.15 a 0.01 0.19 + 0.011 .
hydroxylase . «. J ymol/g liver/hr 3.9 + 0.2 4.9 .j. 0.1 2 •
Biphenyl-2- nmol/mg pt/hr 24
+ 3 34 . +. 3 3
hydroxylase ^ 1/g liver/hr 0.62 + 0.06 0.89 H* 0.051
Ethylmorphine l™ol/mg protein/hr 0.70 + 0.04 0.69 + 0.07
-N-demethylase _ , n. „J ymol/g liver/hr 19 + 2 18 + 2 .
O.D.units/mg pt 
Cytochrome P-450
0.06 + 0.01 0.07 + 0.01
O.D. units/g/liver 1.5 + 0.1 1.7 + 0.1
O.D.units/mg pt
Cytochrome b^
0.09 + 0.01 0.09 .+ 0.01
O.D.units/g liver 2.3 + 0.3 2.2 + 0.1
P < 0.01 
P < 0.002. 
P < 0.02
Test animals were maintained on 101 (V/v) aq. alcohol for 18 days.
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Table 6.7
Effect of oral administration of ethanol on hepatic
microsomal drug metabolism
Parameter
...  . "
Group A 
control
Group B 
ethanol
..... !
Group C 
pheno­
barbitone
Group C I 
ethanol & } 
pheno- j 
barbitone j
Liver wt/lOOg body wt 4.3 + 0.2 4.4 + 0.4 4.7 _+ 0.1 4.6 + 0.1 ;
!
Microsomal pt mg/g lr/er 37 + 2 38 + 4 36 + 1 33 + 2 2 |
i
Biphenyl-4-hydroxylase 2.6 + 0.1 
■ymol/g. liver/hr |
2.5 + 1 3.1 + Oil 3 2,8 + 0.1 | I
Ethylmo rphine-N- 
demethylase 
ymol/g liver/hr
29 + 2 34 + 2 45 + 3 ■* 40 + 3 3 j
'• i 
1
Anil ine -hydroxy 1 as e 
ymol/g liver/hr
0.9 +0.1 1.7 + 0.2 2 1.4 * 0.1 3 2.0 + 0.11* |
p-nitrobenzoate 
reductase 
ymol/g liver/hr
3.5 + 2 3.3 + 0.3 4.1 + 0.2 1
-
4.3 _+ 0.22 |
NADPH-cyt-c 
reductase 
O.D.units/g.liver / 
min.
O.D.units/mg pt/min.
2 0 + 2  
0.55 + 0.04
20 + 1 
0.54 _+_ 0.04
. 3 2 + 2  2 
0.90 + 0.05^
!
i
1
i
47'+ 5 If j 
1.42 + 0.09^1
Cytochrome b^
0.D.units/g.1ive r
O.D.units mg/pt.
2.4 +0.1 
0.07 +0.01
2.0 + 0.3 
0.05 + 0.01
2.7 + 0.2 
0.08 + 0.01
j
2.6 +0.2 | 
0.08+ O.Ol1}
Cytochrome P-450 
0.D„units/g liver
O.D.units/mg pt.
2.6 +0.2 
0.07 + 0.01
2.5 + 0.3 
0.07 + 0.01 .
5.4 + 0.4 4 
0.15 + 0.01\
1,
I
5.2 +0.4 'j
0.16+ 0.02'* j
P <0.05 
P < 0.01 
P <0.02 
P < 0.001
217.
OO
vO
(D
r—I■aH
to
CD
£otoo£u
• H
6
u•H
4->£
0 ]
,£
oft
bO
£•Hrd
a
•H
ft
toft•H
£o
ft
g
B£0£ft
0£
ft
ft
P
0
fto
po0ftft
w
c-. cn• ©CO O
P ■ + 1 ■ + |to0 rH CObO P • ©
£ C0 rH•H iH f tftr-*£•H <*> I—1 COft Io rH LOrH 1—I • •
o pH T—\ O£ -X O ■
£ r £ + 1 + |■ ft w Pp <3 £ 1-0w O •U CO OOrH
ft tOo O• •
r—\ o O10p + 1 + 1•rH P£ (0 o to. £5. 0 I—I 1—1p • •c o oQ-
2/
ft H~o o
s rH/*\ o • oCJ£ + 1 + jw P
< £ cr> ftO o  • ft(J • •o o
-
o o<vj- OOPto + 1 + I0/-N p o oCO to
s CO to
co orH O VOo vO f t£P + | + 1£O O CU tO vo
CO ft
CO
-
_ ftp ft o
£ 0 X0 £ O£ to •H U £ft 0 X £ i—1 *H ££ > £ P £ 00 •H ft £ >c P£ bO • H ^-Nft £P vO £ > ft £0 bO ££ ft £ V r crft \  O to v—/ O £boft r—t *H
£ £ o\e> £ ft' £ <NI 0 £O ft . • H • HO • £ £ -H £i—1 *H o bo ft
2
H
to S*
ftCO CO.
to 6•H to
bo bo
£ £
£ •Hft
£ £•H •H
X X
ft fto o
£
r-< £r£p P0 0 *
bO bO t£ £•H •H oP P CO
£ £ CO
ft ft
£ £ lO Uft ft O£ £ COO O to£ £ £O O Oft ft •H
rd ft 0 0
3 3
£ £ o o
paj£
P
£00
£
•H •H O
P P U£ ££ £ ft
P P q£ £0 0 c3O U r££ £ Po o- 0u U ftft ft o
§
os 0bO
r£ ft £
P P £
w W
pH CO CO
218.
Fig. 6.2
Effect of oral ethanol administration on its binding
to hepatic microsoines
/AE Control
Test
180
160
140
120
100
6.05.04.02.01.01.0 0
I x '10"2 (mM"1)
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Effect of simultaneous intraperitoneal administration of ethanol and
pentobarbitone on the biological half-life of pentobarbitone: Animals
were 40 days old and four animals were used for each time period; . The 
alcohol and pentobarbitone were administered simultaneously; animals 
received pentobarbitone (75 mg/kg) ■ dissolved, in 99.91 ethanol (1185 mg/kg). 
Plasma levels of pentobarbitone were estimated as previously described 
(Chapter 4). Ethanol had a marked effect on the plasma: levels of 
pentobarbitone and completely inhibited the progressive disappearance 
of pentobarbitone from plasma (Fig. 6.3) during the first ninety minutes 
after dosage (Table 6.9).
B. Chronic ethanol administration
In all experiments male Wistar-albino rats were maintained on 
food ad lib and 101 (V/v) aqueous alcohol as their sole drinking liquid 
for six weeks unless otherwise stated.
Effect on the in vitro metabolism of drugs: Four groups were used each
dosed as follows, Group A served as Controls, Group B received aq ethanol 
101 (Vv) for six weeks; Group C received daily intraperitoneal administration 
of phenobarbitone 75 mg/kg for three days before day of sacrifice; Group D 
received a combination of treatments for Group B and Group C.
This experiment showed that ethanol induces both type I and type 
II hydroxylation as represented by biphenyl and aniline respectively.
There was also a slight increase in the reduction of p-nitrobenzoate 
(Table 6.. 10). Phenobarbitone induced all parameters and the cytochrome 
content as expected, and in the case of aniline hydroxylase only were the . 
effects produced by alcohol and barbiturate additive (Fig. 6.4).
Fig. 6,3
Effect of. simultaneous administration of ethanol and pentobarbitone 
on pentobarbitone plasma half-life
Each point represents the average of four animals
~~— ~© Control
.
Ethanol administered simultaneous!) 
with pentobarbitone
8
7
6
2
1
40 50 60 70 8010 20 30
Time (mins)
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Effect on hexobarbitone sleeping time: . The'same four treatments as in 
the previous experiments were administered to four groups of animals 
and the hexobarbitone sleeping time was determined as previously described 
.(Chapter 2).
Ethanol did not have any effect on the hexobarbital sleeping time 
but it did. potentiate the inhibitory effect of phenobarbitone to an extent 
that six of the nine animals in Group D, receiving both ethanol and 
phenobarbitone, did not sleep at all (Table 6.11).
Effect on zoxazolamine paralysis time: Four groups of animals each
* o
were pretreated as in the previous experiment and zoxazolamine paralysis 
was estimated as described previously (Chapter 2).
Ethanol itself had no effect on the duration of paralysis due to 
zoxazolamine but again ethanol potentiated the inhibitory effect of 
phenobarbitone and none of the animals in Group D, receiving both ethanol 
and phenobarbitone, showed complete paralysis although locomotion was 
abnormal (Table 6.11).
Effect on pentobarbitone plasma half-life: In two experiments 21-day
old animals were maintained on 10% (V/v) aq. alcohol for fifteen and 
sixteen days respectively; one group (15-day treated) having one day 
without alcohol before administration of pentobarbitone. Pentobarbitone 
was administered intraperitoneally, and the plasma half-life was estimated 
as previously described (Chapter 4),
In both experiments the rate of plasma disappearance of pentobarbitone 
was unaltered (Figs. 6.5 and 6,6, and Table 6.9).
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Effect on urinary excretion of ascorbic acid: Four groups of animals
comprising four animals were dosed as described in the previous experiments.
.The animals were caged individually in cages designed to collect urine.
A 24-hour urine sample was collected after-'the last injection of 
phenobarbitone; and ascorbic acid was estimated as described previously 
(Chapter 2).
Ethanol decreased the urinary excretion of ascorbic acid but 
phenobarbitone, as expected gave rise to a very large increase. The 
conbination of ethanol plus barbiturate, however, resulted in lower 
increase in ascorbic acid excretion indicating an additive effect (Table 6.12).
Effect on alcohol dehydrogenase: Four groups of six animals were used,
dosed as previously and ADH was measured on the soluble fraction of the 
liver, as described-in Chapter 2.
Neither phenobarbitone, alcohol nor the combination of the two altered 
the ADH activity of liver cytosol (Table 6.13).
Effect on liver mitochondrial transhydrogenase: Again four groups of six
animals were treated with either alcohol, phenobarbitone or a combination of the 
two and transhydrogenase was determined as previously described (Chapter 2).
Again-no .significant changes were observed, following pretreatment 
with either ethanol, phenobarbitone or a combination of the two, on the 
levels of liver mitochrondrial transhydrogenase (Table 6.13).
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Discussion
Chronic exposure to ethanol may produce an adaptive change both in the 
rate and.pathways of ethanol metabolism resulting in alteration of the 
pharmacological effect of the drug itself. Hie contradicting results and 
conflicting intepretations found in the literature are probably the outcome 
of failure to consider the effects of the dose and duration of pretreatment 
as well as the different routes of administration. These are considered 
in the present work. -
Acute administration ' .
Animals receiving alcohol by intraperitoneal injection for six days
• o  *
at the high dosage of 1.00 g/kg showed a general reduction. of hepatic 
microsomal activity. There was a significant decrease (501) in the 
hydroxylation of biphenyl although the content of the cytochrome P-450 
and bt- was not altered. Similar results have been described by other 
workers (Ideo, et al, 1971a). The inhibition of drug metabolism is 
probably the result of ethanol toxicity since two out of six of the animals 
receiving alcohol died. Acute ethanol administration is known to reduce 
the amount of endoplasmic reticulum without affecting the amount of 
cytochrome P-450 (Porta et al, 1970). Inhibition of drug metabolism
can be due to damage to cellular organisation and especially mitochrondria
leading to uncoupling of oxidative phosphorylation (Tremolieres; et al, 1967). 
At high dosage ethanol binds to hepatic microsomes so it can interfere 
with the binding of substrate to cytochrome. P-450. Animals given a single 
dose of alcohol intraperitoneally at 10 to 100 mg/kg showed induction of 
the microsomal drug metabolisirtjenzyme syste; in the lower range of dosage, 
and the levels of activity fall again to control values with increasing 
ethanol concentration (Table 6.2). Maximal enzyme induction occurs at
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doses of 10-50 mg/kg and at this level there is an increase of 801 in 
biphenyl-4-hydroxylase, a 25% increase in ethylmorphine N-demethylation, 
cmd some 10% increase in NADPH-cyt-c-reductase (Fig. 6.1). Hues ethanol 
appears to act as a weak enzyme inducer at low dosage, but no changes 
were observed in the contents of cytochrome P-450 and b,~. This dose range 
was further.-.investigated in animals pretreated with the same low dosage 
of alcohol for one day (Table 6,3) and for three days (Table 6.4). In 
the first experiment, if results were expressed, in teims of units per 
gram of liver, there was no change, but because of a reduction in the 
level.of microsomal protein (an unexpected result) a significant increase 
in specific activity (units/mg protein/hour) was observed. In the second 
experiment (three days pretreatment) there were substantial increases 
in both biphenyl hydroxylation (60%) and NADPH-cytochrome c reduction 
(40%) at the dose level of 10 mg/kg ethanol.. Thus duration of pretreatment 
is of importance probably because animals are capable of metabolizing 
ethanol fairly rapidly (300 mg/kg/h in the rat; Lester, et al, 1969).
Since the degree of induction probably depends on the duration of the 
enzyme substrate complex (Chapter 5) it is possible that because of the 
rapid rate of ethanol oxidation by ADH the substrate does not exist for 
long enough to interact substantially with the endoplasmic reticulum, 
and thus produces a high degree of microsomal enzyme induction.
In the intraperitoneal administration of ethanol this may reach 
the liver rapidly in high concentration compared with the lower steady rate 
obtained when the alcohol is taken orally in the drinking water. Intra­
peritoneal administration can lead to peritoneal inflammation (Strubelt, 
et al, 1972) and external necrosis in the surface layers of the liver.
Thus, to eliminate this local toxic effect, further routes of administration 
were studied. Oral administration was first carried out by giving animals
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a single dose (5g/kg) of ethanol by gastric intubation. No significant 
changes in enzyme levels were observed, although other workers (Ariyoshi, 
et al, 1970) did find an induction of aniline hydroxylase which was not 
studied in this work. (Table 6.5). then animals were- kept on 2% (V/v) aq. 
ethanol for eighteen days there vTas an increase in biphenyl hydroxylation 
(Table 6.6), but after six days on 10% ( /v) ethanol there were no changes in 
the rates of metabolism of biphenyl, p-nitrobenzoate, or ethylmorphine, or 
in the contents of cytochromes and NADPH-cyt-c-reductase. In this last 
experiment, there was however, a 77% increase in the hydroxylation of 
aniline,-a type II substrate .(Table 6.7) . It can be concluded from the 
above work that at' low dosage given for long periods ethanol may act as 
an inducer of microsomal drug-metabolizing enzymes, particularly of 
aromatic hydroxylations.
Spectral interactions
Ethanol interacts with the microsomal Haemop rote in cytochrome P-450
to yield a nmodified-type II” spectrum (Fig. 6.8) characterised by a peak
at 415 my and a trough at 387 my as opposed to a peak at 430 my and a trough
at 390 my exhibited by a typical type II spectrum. Modified type II spectrum
(also known as reverse type I, RI) is considered to be due to displacement of
some pre-existing substrate, bound in vivo, from the enzyme (Schenkman, et al,
1969). This spectrum involves interaction between compounds and a non-haem
part of the mixed function oxidase. Treatment with ethanol, 100 mg/kg
intraperitoneally for six days or ca. lg/kg in the drinking water for 24
days, showed no changes in the I( or AE max as compared with control ss
(Table 6.8). Thus the affinityr of ethanol for cytochrome P-450 or the 
total amount of ethanol bound, are not altered (Fig. 6.2). The binding of 
ethanol to.cytochrome P-450 was studied by.many other workers, who reported 
that increased ethanol.binding occurred after chronic administration 
(Rubin, et al, 1971).
Fig. 6.8
Binding of ethanol to rat hepatic microsoir.es
Reference and sample cuvettes 
contained 3.0 ml of a microsomal 
suspension (approx. 6.0 mg of 
protein) prepared in Tris buffer 
0.1 M pH = 7.6. Ethanol 10]il 
was added to sample cuvette-to 
give a final concentration of 
50 mM. .
500 400 350
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Although ethanol gives a binding spectrum with cytochrome I M  SO 
this does not necessarily prove that it is a substrate since non-specific 
binding has been observed (Narasirolulu, et-al, 196 5; Imai and Sato, 1967).
Interaction of ethanol on acute administration with pentobarbital
Studies in vivo have shown that ethanol simultaneously administered 
with pentobarbital reduces the rate of the disappearance'of the 
barbiturate (Figure 6.3, Table 6.9). In non-treated animals, the 
plasma concentration of pentobarbital fell to less than half the 
original value within 90. minutes, whereas in those animals receiving 
ethanol there was no significant change in plasma concentration over 
this period. Similar results were obtained by other workers (Misra, et al,
1970; Rubin et al, 1970a). This inhibition of pentobarbital metabolism 
probably represents a non-specific binding of ethanol with the active 
site of the enzyme interfering with the binding of pentobarbitone.
Pentobarbitone is a known substrate of cytochrome P-450 and gives a type 
I binding spectrum (Chapter 5). Pentobarbitone metabolism might also be 
inhibited by prevention of the re-oxidation of NADPH due to mitochondrial damage 
by the ethanol. Furthermore, it has also been shown that ethanol inhibits 
cytochrome P-450 reduction. This is considered to be the rate-limiting 
step in drug hydroxylation (Gigon, .et al, 1969) and involves the transfer 
of electrons from flavoprotein- to haemoprotein. Thus the inhibition of 
drug metabolism by acute ethanol could be due to interference with electron 
transfer rather than to competition for the final hydroxylating enzyme, 
cytochrome P-450 (Rubin et al, 1970). Extrapolating plasma disappearance 
curves (Figure 6.3) to zero time show that -initial pentobarbitone level is 
more than 50V lower in the ethanol administered animals indicating 
' impairment of pentobarbitone absorption which could, result in the inhibition 
of metabolism. This result would explain the increased potency of
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barbiturates in intoxicated persons. •
Chronic ethanol administration
During chronic administration, animals were maintained on 101 
(V/v) of ethanol. Adult rats on a normal laboratory diet drank approximately 
8-10 ml of water per day and consumption of such an amount of 10% alcohol 
is equivalent to 6-83; alcohol/kg body wt. This is close to the animal's 
capacity for metabolism of alcohol and also supplies about 35% of the 
required calories. Higher concentrations of ethanol led to the rats 
refusal to drink, resulting in dehydration and growth retardation, as 
previously reported (Morgan, et al, 1957). Mice on 15% (V/v) aq. alcohol
o ‘
as their sole drinking liquid for periods up to one year have been reported 
to grow normally (Mirone, 1965) and if the nutritional status of
the animal is adequate, chronic alcohol administration at this level for 
as long as 5-6 months does not give rise to fatty livers, although 
mitochondrial damage may occur (Porta, et al, 1970)*
During chronic administration, there is a 100% increase in biphenyl 
hydroxylation compared to a 275% increase produced by phenobarbital 
(Table 6.10). Induction of pentobarbital hydroxylase, another type I 
substrate, lias been reported previously'but the degree of induction was 
not as great (Rubin, et al, 1968). There was also a 40% increase in 
the hydroxylation of aniline although other workers reported up to a 
7-fold increase in activity (Rubin, et al, 1968; Ariyoshi, et al, 1970;
Mezey, 1972). These workers carried out their determinations using 
purified microsomal suspensions (105,000 g pellet) while in the present 
study the 9,000 g supernatant (microsomes plus soluble fraction) was used. 
There was also a slight but significant increase in the reduction of 
p-nitrobenzoate similar to the one described by Rubin in 1968. The .present 
work, however, does not support the previous findings of increases in
cytochrome P-450 (10-1005) (Ariyoshi, et al, 1970; Rubin, et al, 1971;
Ideo, et al, 1971a; Singievich & Barb on ah, 1971;Mezey, 1972), Ariyoshi also 
reported a 205 increase in cytochrome b^. These increases in cytochrome 
P-450 found by previous workers aid not parallel the high increases 
observed in metabolic activity, which may imply sin enhanced specific 
activity of newly-synthesized enzyme, or a modification of activity of 
existing enzymes even without induced enzyme synthes is. On the basis of 
studies on rats treated with phenobarbitone, it was suggested that induced 
cytochrome P-450 may be more capable of forming the enzyme-substrate complex 
(Ullrich, 1969).
In the present work the microsomal supernatant (9,COO x g supernatant) 
was used in the in vitro study of drug metabolism. This fraction contained 
both microsomes and soluble fraction. Hie latter contained the soluble 
cofactors such as NADH. Ethanol pretreatment resulted in an increased 
level of NADH due to alcohol oxidation by alcohol dehydrogenase. Recent 
work has shown that NADH in the presence of NADPH can act as an electron 
donor for mixed function oxidation (Estabrook and Cohen, 1969). The 
observed stimulation of metabolism of biphenyl , aniline and p-nitrobenzoate 
may be the result of elevated NADH levels. However, this seems to be insignificant 
in vivo.
It can be concluded from the above experiments that aromatic hydroxylases 
are the most sensitive enzymes to ethanol administration, both chronic and 
short term. Both aniline and biphenyl hydroxyl at ions are induced whether 
results are. expressed in units per g liver wt or per mg of protein. Reduction 
of p-nitrobenzoic acid is inhibited by type II substrates by altering the 
flux of electrons through the transport system but not by type I compounds 
(Sasame & Gillette, 1969). This would seem to disagree with the accepted fact 
that ethanol is similar to type II compounds. Recent work (Kinoshita, et al,
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1972) suggested that acetaldehyde, the product of ethanol oxidation, may 
interact with the microsomal membrane and alter its physicoch.emJ.cal 
properties, finally influencing the activity of aniline hydroxylase.
Therefore, the ethanol effect is due to its metabolite, acetaldehyde, rather 
than to the ethanol itself..
Effect of ethanol in alcohol dehydrogenase
.The cytosomal ADH activity is not altered by chronic ethanol 
administration showing that accelerated blood ethanol disappearance in 
alcoholics is not due to an induction of cytosomal alcohol dehydrogenase 
(Table 6.13). Phenobarbitone also has no effect.
Effect of chronic ethanol administration on urinary ascorbic acid excretion 
Studies in vivo showed that ethanol markedly decreases the urinary 
excretion of ascorbic acid as opposed to a 9005 increase by phenobarbitone 
(Table 6.12). Similar results were reported by other workers (IVesterfeld and 
Schulman, 1959). Thus ethanol does not show all 'the properties of inducers of 
the microsomal drug metabolizing enzymes. Phenobarbitone increases the 
activity of uridine diphosphate glucose dehydrogenase present in the 
cytoplasm and also increases microsomal glucuronyl transferase (Zeidenberg, 
et al, 1967). Mien both ethanol and phenobarbitone administered the 
effect appears to be additive.
Effect of alcohol pretreatment on hexobarbital sleeping time and 
zoxazolamine paralysis
Further in vivo studies showed that ethanol has no effect on either
zoxazolamine paralysis or hexobarbital sleeping time (Table 6,11) indicating
that even if a microsomal system which oxidises ethanol exists, this is
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not important in vivo.
Effect of chronic ethanol administration of pentobarbital plasma 
disappearance
The effect of ethanol on plasma pentobarbital disappearance lias
been investigated in two experiments. In the first, animals receiving
ethanol chronically were ' intoxicated when pentobarbital was administered,
while in tlie second there was one day gap to allow for alcohol clearance.
This design was adopted to represent the two known cases where alcoholics
ingest barbiturates when sober and when under the immediate effect of
ethanol. In both cases (Figures 6.5 and 6.6) there are no significant
changes. Other workers have also reported that cl ironic administration
of ethanol failed to affect the rate of metabolism of pentobarbitone
in vivo or in vitro by liver slices (Kalant, er al, 1970).. The above
workers used gas liquid’chromatographic, techniques. In their experiments
with'human volunteers Rubin, et al, 1970 estimated the pentobarbitone
14
half-life (1q )^ by injecting C-pentobarbital and measuring the plasma 
radioactivity at regular intervals. They found an enhanced rate of 
pentobarbitone disappearance. In their extraction procedure unchanged 
pentobarbital was separated from, metabolites by using petroleum ether 
containing isoanylalcohol. They do not though mention7 the efficiency 
of separation, however.
Mechanism of induction of microsomal drug metabolism of ethanol in 
the in vitro system
Hie failure to correlate in vitro results with the in vivo situation 
led many workers to believe that cytochrome P-450 generates in vitro
suggesting that in vitro microsomal ethanol metabolism is an artefact 
(Khanna, et al, 1970) , It is known that liver microsomes contain an 
enzyme system NADPH oxidase capable of catalyzing the oxidation of NADPH
by oxygen to yield NA.UP and H^Cy (Gillette, et al, 1957). Tills prompted 
workers to investigate the possibility that the in vitro oxidation of 
alcohol is a result of a catalase oxidation (Roach, et al, 1969;
Isselbacher, and Carter, 1970; Hawkins and Kalant, 1972;
Thurman, et al-, 1972). Thus the NADPH dependent oxidation of ethanol 
by microsomes is not due to a distinct and separate membrane bound enzyme 
but a result of at least three separate enzymic reactions involving both 
catalase and alcohol dehydrogenase, both shown to be microsomal contaminants 
(Moir, et al, 1968; Isselbacher and Carter,1970; Carter and Isselbacher, 1971.
NADPH'-+0o + H+‘ NADPH-oxidase \  NADP+ + IL0o ■■ 2  —---- f 2 2 r
NADP+ .+ CILCH.OH ADH v. NADPH + H+ + CH_CH0
3 2 ------ :--- ------•>
H202 + CH3CH2OH catalase 2H20 + CIgCHO
A similar system has been described in the metabolism of indanol to indanone 
(Billings, et al, 1970). The existence of a microsomal system metabolizing 
ethanol was shown mainly by the use of inhibitors which are not sufficiently 
specific to allow for definite conclusions. Orme — Johnson and Ziegler, 1965, 
believed that catalase w/as not involved in the microsomal metabolism of 
ethanol because NADH could not replace NADPH. Since NADH rate of oxidation 
is three times that of NADPH then the higher H^O^ production should result 
in greater MEOS activity. However, more recent v:ork has demonstrated that 
NADH-oxidase does not incorporate CL into H0CL but into water, the otherZ Li Z
product being NAD* (Mackler, 1967). This may also explain why NAD and NADH 
give about the same activity when substituted for NADPH in the microsomal 
ethanol-oxidizing system (MEOS) since NAD can be utilized by alcohol 
dehydrogenase (ADH) to give NADH. then H^O^ is added to the system it can
acetaldehyde formation occurs, (Roach, et al, 1969; Lieber, et al, 1970;Carter 
'& Isselbacher, 1971). The addition in vitro of potassium cholate (an 
NADPH oxidase inhibitor) inhibits NADPH-oxidase and the microsomal ethanol- 
oxidizing system with no effect on alcohol dehydrogenase or catalase.
Addition of HgC^ and CUCI2 inhibits NADPH-oxidase, alcohol dehydrogenase 
and catalase and also completely inhibits MEOS (Isselbacher and Carter,
1970), Addition of ADP, ADP plus Fe^H, ADP plus Fe^‘ lea to a stimulation 
of both NADPH-oxidase and MEOS activities. Ferrous iron is known to 
stimulate peroxidation of ethanol by catalase (Kremer, 1970) and by-MEOS. 
Phenobarbital does not induce MEOS or NADPH-oxidase as shown both in vivo 
and in vitro (Lieber, et al, 1968; Carter and Isselbacher, 1971) although 
opposing results also appeared ( R o a c h F i n a l l y  ethanol administration 
stimulated NADPH-oxidase accounting for the enhanced ethanol oxidation due 
to ethanol pretreatment (Lieber, et al, 1970; Carter and Isselbacher, 1971). 
Recent work (Thurman, et al, 1972) lias confirmed that the MEOS system 
is in fact due to H^O^ formation. Ethanol oxidation in the presence of 
NADPH or an H ^  generating system has been shown to share similar 
characteristics, namely:
(a) The same ethanol concentration for half maximal rate,
(b) Dependency of maximal rates on H^O^ formation. Under the same 
experimental conditions the rate of acetaldehyde production after 
ethanol addition to liver microsomes was found to be two times
. higher with an generating system than with NADPH. The rate 
could be increased by increasing the H907-generating system but 
not by enhancing the activity of the NADPH-generating system.
(c) Competitive.inhibition by peroxide substrates for catalase.
In the presence of formate, a typical peroxidationsubstrate for 
catalase (Chance and Herbert, 1950) acetaldehyde production 
from ethanol with an NADPH- or H^O^-generating system was markedly
suppressed. These effects were dependent upon the 
concentrations of both ethanol and formate indicating 
competitive inhibition.
(d) Inhibition by azide, ,a catalase inhibitor, with identical 
insensitive rates. In the presence of azide, another 
inhibitor of catalase (Lemberg and Foulkes, 1946), inhibits °f 
' production of acetaldehyde from ethanol in microsomes in 
. the presence of both an NADPH- or an H^O^-generating system.
However, a portion of acetaldehyde production could not be 
inhibited by azide and.was Identical with both generating 
systems. - -
- (e) Diminished acetaldehyde production in microsomes from rats 
pretreated with aminotriazole or pyrazole, inhibitors of 
haemoprotein biosynthesis (Tschudy and Collins, 1957), with 
identical residual rates.
Also NADPH-dependent acetaldehyde formation is suppressed in the presence 
of an active H^O^ generating system. In conclusion, it has been established 
that there is a system in the liver microsomes capable of metabolizing 
ethanol in vitro but this is not similar to the system which is known to 
metabolize barbiturates. The contribution of this system to the. overall 
ethanol metabolism has been-estimated to be less than 101 and is not of 
very great significance (Tephly, et al, 1969; Lester, et al, 1969;
Klaassen, 1969; Hassinenand .Ylikahri, 1972).
Ethanol-barbiturate interaction
To investigate the biochemical aspects of interaction of ethanol with 
barbiturates, phenobarbitone was chosen, as this has a long half-life 
(Chapter 4) so that any interaction with microsomal metabolism will be more 
pronounced. Two experiments were performed to represent chronic and short
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term administration. During the short term administration animals 
were kept on 101 (v/v) aq. alcohol for six days. There were no significant 
changes in the degree of metabolism between Groups C and D but both were 
stimulated compared to controls (Group A). However, considering the 
hydroxylation of aniline, Group B receiving only ethanol showed an 
induction of 77%, while Group C receiving phenobarbitone showed a 48% 
increase. Group D, undergoing both treatments, showed an elevation of 
119% (Table 6.7). Therefore, the effect of ethanol and phenobarbitone 
seem to be additive (Figure 6.4). A very similar picture is obtained in 
animals receiving ethanol chronically (Table 6.10). Ethanol induces 
aniline hydroxylase by 38%, phenobarbital by 66%, and both pretreatments 
by 120%, again an additive response in agreement with previous reports 
(Ariyoshi, et al, 1970). In both experiments phenobarbitone induced the 
cytochrome content to a higher level in the animals receiving ethanol showing 
that these animals are mo ie sensitive to the phenobarbitone induction of the 
cytochrome (Figure 6.7). Studies 'in vivo have shown that with animals 
receiving ethanol and phenobarbitone, the hexobarbitone sleeping time was 
decreased more than in animals receiving phenobarbitone alone. Hie effect 
is very pronounced since two thirds of the animals in this group did not 
sleep. A similar effect was demonstrated with zoxazolamine as none of 
the animals in Group D were completely paralyzed (Table 6.11). Thus, 
the in vivo work parallels closely the in vitro results.
Mechanisms of ethanol-barbiturate interaction
Thus although ethanol does not stimulate the activity of the microsomal 
drug metabolizing enzymes it potentiates the effect of other inducers, such 
as phenobarbitone. This effect of ethanol has been shown to be veiy 
important in vivo, and could be the result.of an increased affinity of
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phenobarbitone for the enzyme or enhanced stabilization of the phenobarbitone- 
enzyme complex as the degree of induction seems to depend on the stability 
of this' complex (Chapter 5) . Hie longer the association of the substrate 
with the enzyme'the higher the degree of induction. Ethanol could also 
act by displacing other compounds bound to the active sites of the 
cytochrome, such as the more readily metabolized endogenous substrates, 
making more sites available for the formation of the phenobarbitone enzyme- 
substrate complex. This model can explain the observed ethanol 
potentiation of phenobarbitone as seen in hexobarbital sleeping time and 
zoxazolamine paralysis experiments.; Thus the observed resistance of 
alcoholics to barbiturates can be explained. .On administration of 
barbiturates to alcoholics the microsomal drug metabolizing enzyme activity 
is increased so that barbiturates can be further metabolized rapidly.
Ethanol is a lipophilic compound capable of passing freely through 
the lipid barrier which protects the drug metabolizing enzymes (Gaudette . 
and Brodie, 1959). ' It interacts with cytochrome P-450 but is not metabolized 
by the microsomal monoxygenase system. Imai and Sato (1967) observed that 
the molar concentration of ethanol required to give a type II spectrum 
similar to aniline is 20 to 30 times greater and they suggested that the 
interaction of ethanol with cytochrome P-450 is a. non-specific binding on 
a lipophilic phase of the microsomal membrane adjacent to .the', haemoprotein 
rather than a substrate-like binding to the hasmoprotein itself. Thus 
ethanol may act as an activator of the microsomal mono-oxygenase system 
either by modifying the membrane environment or by allosteric effects.
Ethanol can also act as a carrier of the barbiturate through the 
‘ lipoid barrier thus resulting in an increase in the formation of the 
enzyme-substrate complex.
Cofactor availability could be influenced by ethanol in many ways. 
Acute administration can prevent .reoxidation of NADP by injuring 
mitochondria and thus disturb barbiturate metabolism. Ethanol increases 
the NADH/NAD ratio through its oxidation by alcohol dehydrogenase 
.(Raiha & Our a., 1962; Forsander, et,al? 1965; Leeyy, 1967; Kahonen, 
et al, 1971; Rawat, 1972). The.concentration of NADH can affect
the metabolism of ethanol itself since dissociation of ADH-NADH is the 
slowest step in ethanol oxidation to acetaldehyde (Theorell & Chance; 1951). 
Ethanol, by increasing the NADH/NAD ratio, shifts the equilibrium of 
lactate dehydrogenase system in favour of lactate giving'rise'to a fall in 
pyruvate concentration and suppression of the tricarboxylic acid cycle. 
Ethanol may affect barbiturate metabolism by transhydrogenation of NADH 
to NADPH in the mitochondria. The mitochondrial membrane is fairly 
impermeable to NADH (Greens Crane, 1958; Lehninger, et al, 1960). Hie 
ultrastructural modifications by ethanol may allow mitochondrial entry 
of NADH by increasing the permeability, Ethanol lowers NADP levels in 
perfused rat liver (Williamson, et al, 1969). The ratio of NADPH/NADH 
increases gradually with ethanol treatment representing an NADH-NADP 
transhydrogenation (ICalant, et al, 1970). Hie present project investigated 
this possibility and found no significant changes in the mitochondrial 
transhydrogenase activity in animals chronically treated with alcohol or 
phenobarbitone, or a combination of both (Table 6.13). Therefore the 
observed decreases in NADP and the increase in NADPH/NADH is not the 
result of increased transhydrogenase activity in the mitochondria.
Interaction can also be the result of changes in pilarmacodynamic 
factors such as absorption, transport and distribution of drugs. Alterations 
in the sensitivity of the central nervous system can also account for these 
interactions seen in vivo.
Unfortunately not sufficient information on the physiological and 
biochemical significance of endogenously synthesized ethanol exists 
(McManus,’ et al, 1966; Lester, 1961). Its existence is also debatable 
due to the doubtful.-techniques utilized. Also overlooked are other 
possible pathways of ethanol that might be important in vivo. Ethanol 
was found.in urine as ethyl .glucuronide (Kamil, et al. 1952), and as 
ethyl sulphate (Bostrbm and Vestermark, 1960). Fatty acid ester 
formation has been observed in vitro and during in vivo ethanol metabolism 
(Goodman and Deykin, 1963; Newsome and Ratray, 1965), Theoretically, 
the formation of ethylene glycol is also possible although no evidence 
exists. The role of extrahepatic ethanol metabolism has not yet been 
evaluated. Chronic ethanol metabolism increases the specific activity 
of ADH in the stomach and small intestine slices (Mistilis Jl2MrcUall,t94j)) k 
The hormonal participation still has not been fully examined. Thyroid 
hormones, adrenocorticoids, catecholamines, insulin and glucagon have 
been associated with ethanol metabolism.
Only when all factors involved are fully elucidated can we look 
forward optimistically to solving the problems of drug interaction with 
ethanol and alcoholism.
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EFFECT OF IMIPRAMINE ON METABOLISM OF PENTOBARBITONE
Imipramine (N- (3-dime thylamiiiopi\opyl)iminodibenzyl hydrochloride 
is a tricyclic antidepressant, chemically related to the phenothiazines, 
but possessing an antidepressant rather than a sedative action. It 
.counteracts and even reverses the sedation and other central effects of 
reserpine (Sulser and Brodie, 1961). rfhe prescription of tricyclic 
antidepressants such as imipramine, together with a barbiturate hypnotic 
is relatively common, in the elderly patient, and has been suggested to 
contribute to a frequently observed confused mental state.
Mechanism of action' '
*
The clinical action of ■imipramine is characterized by a lag period 
of one to four weeks before signs of mental recovery can be seen (Kuhn, 
1958). The slow onset of benefit is considered to be partly due to the 
fact that imipramine owes its action to its demethylated metabolite, 
desmethy 1 imipramine (aesipramine. DMI). Imipramine has been shown to 
counteract the actions of reserpine when the brain contained little 
imipramine but high levels of desipramine (Gillette, et al, 1961;Sulser 
et al, 1962). ■
Chemical properties of imipramine and desme thy 1 imipramine
Imipramine- is a very highly lipid soluble compound and is rapidly 
absorbed and distributed (Bicke! and Weder, 1968). When administered 
intraperitoneally it diffuses directly into adipose tissue and not through 
the circulation as in the case of thiopental administration (Brodie, et al, 
1950). Of the total imipramine administered an average of two thirds is 
excreted in the urine while the rest appears in the faeces (Bickel and 
Weder, 1968)..
Desipramine is also a highly lipophilic drug, which is excreted 
metabolized as. well as unchanged, into the bile (von Bahr and Borga, 1971).
It is completely absorbed from the intestine and insignificant amounts 
are recovered in the faeces (Bickel, et al, 1967). Desme thy limipramine 
is highly bound to plasma proteins whereas there is no binding of its 
conjugated metabolites. Insignificant amounts of imipramine are excreted 
in the kidney so that plasma levels reflect the activity of the drug 
metabolizing enzymes (Hammer, et al, 1969).
Site of imipramine metabolism
Metabolism of imipramine occurs mainly in the liver and requires 
NADPH and 0^  indicating that the microsomal drug-metabolizing enzyme 
system is involved (Dingell, et al, 1962; 1964). Rat liver microsomes 
contain’ an enzyme which is relatively specific for demethylation of 
tertiary amines. This enzyme demethyl a tes imipramine to desipramine 
but does not readily demethylate desipramine. It was suggested that 
this system probably demethylates other compounds including chlorpromazine 
and amitriptyline. On the basis of imipramine metabolism it has recently 
been shown that there are at least two NADPH-dependent enzyme systems in 
the endoplasmic reticulum, one catalysing C-oxygenation and one N-oxygenation 
(Bickel, 1971). -
Pathways of imipramine metabolism
Some twenty metabolites of imipramine have been found in appreciable 
amounts varying from hydrophilic metabolites to extremely lipophilic ones. 
Imipramine metabolites appear very rapidly in tissues, the highest 
concentrations being found in lung, liver and kidney. Desmethylimipramine 
appears in the blood minutes after imipramine administration (Bickel and
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Weder, 1968). The main metabolic pathways of imipramine are given in 
Figure 7.1.
Rat -liver metabolizes imipramine in vitro by three independent 
pathways, N-oxidation, demethylation and 2-hydroxylation (Nakazawa, 1970). 
Imipramine N-oxide is reduced to imipramine and to a minor degree is 
demethylated to desmethylimipramine by blood or tissue homogenates in the 
absence of added cofactors. These reactions are partly enzymic and partly 
haemocatalytic as ferrous ions in excess stimulate this system, (Bickel, et al, 
1968). More recent work (Nakazawa; 1970) using an isotope trapping technique 
showed that imipramine N-oxide is not an intermediate in the formation of 
desmsthylimipramine. After addition of desipramine to- the rat perfused 
liver the hydroxylated product, its glucuronides and also the unchanged 
drug have been found (von Bahr, 1970). In in vitro microsomal preparations, 
glucuronides also were -formed in the presence of UBPGA (von Bahr and Bertillsen, 
1971). The same workers showed that hydroxylation of desipramine and 
subsequent glucuronide formation can also occur as a "two step reaction”, 
where the two enzyme sequences cooperate to yield greater amounts of polar 
metabolites.
In man, further demethylation of desmethylimipramine is a minor pathway 
and of little importance (Cramme/and Scott, 1966; Bickel pet al, 1967), the 
major pathway being hydroxylation which occurs predominantly at the 2- 
position with a small portion at the 10— position (Cramirerand Scott, 1966).
In the rat only the 2-.hydroxylated product has been detected (Bickel and 
Weder, 1968). The 2-hydroxylated product is a highly polar compound and is 
unable to cross the blood brain barrier. In the case of fatal overdosage 
to a patient no hydroxylated product was found in the brain (Bickel, et al,1967).
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Imipramine-N-oxide is also- formed in man and has been isolated from urine 
of patients receiving imipramine (Hermann, 1963).
Phenobarbitone treatment can reduce the plasma levels of desmethyl- 
imipramine. Phenobarbitone administration to rats has been shown to give 
rise to a two-fold increase in the activities of the enzymes that catalyze 
the formation of desipramine and its hydroxyl ated metabolite, while 
N-oxidation is unaffected. Denethylation and hydroxylation are inhibited 
by SI(F 525A, an inhibitor of microsomal drug metabolizing enzymes* while 
again N-oxidation is unaffected (Nakazawa,’1970). These observations 
suggest that the enzymes for C-hydroxylation are different from those for 
N-oxidation. However, von Bahr. et al (1972) reported inhibition of the 
hydroxylation of desmethylimipramine by phenobarbitone. They explained 
their findings by assuming that phenobarbital affects cytochrome P-450 or 
its microenvironment causing a qualitative change in the lipid interaction 
between the cytochrome and desmethyl imipramine. Hie 2-hydroxy derivative 
of desipramine in high concentrations inhibits the hydroxylation of 
desipramine, i.e. product inhibition (von Bahr and Bertillsen, 1971).
This inhibition of hydroxylation may be due to competition for the binding 
site of cytochrome P-450 since desipramine and its 2-hydroxylated product, 
like SKF-525A (Schenkman, et al, 1967) are bound with high affinity to 
cytochrome P-450. '
Sex and species difference in imipramine metabolism
Male rats have been shown to show higher activities in metabolizing 
imipramine, both in vivo and in vitro (Pscheidt, 1962; Gillette, 1963;
Moody, et al, 1967; Hammer and Sjoqvist, 1967; Bickel and Gigon, 1971).
In horses the ratio of N-oxidation to the demethylation of imipramine 
is 0..2 while in pigs it is 15.0 (Bickel, 1971) thus exhibiting a wide specie
difference. Microsomal preparations from rat liver are less active than
those from rabbit. Rat livers metabolize imipramine to desipramine and
slowly -transform this metabolite to hydroxylation products while rabbit
metabolizes both very quickly so that desmethyl imipramine does not
•accumulate. This confirms the finding that the antidepressant action of
imipramine could manifest itself in rats but not in rabbits (Dingell,
et al, 1962). These observations have also been demonstrated in vivo
by measuring the plasma levels of imipramine and desipramine. Man was
found 'to behave like the rat, whereas the mouse behaves like the rabbit
(Dingell, et al, 1964). In rat the main metabolite is desmethyl imipramine
while in rabbit it. is the 2-hydroxylated product.
« '
Individual differences
Measurement of plasma concentration of desmethylimipramine in eleven 
depressed patients resulted in a 36-fold difference between the highest and 
lowest steady state (Hammer, et al, 1966) which explained the individual 
differences in clinical response. As already discussed, phenobarbitone 
induces the metabolism of imipramine. Thus, variations in response to these 
drugs in psychiatric patients who are treated with' a wide spectrum of drugs 
may be due to altered rates of metabolism or to altered metabolic patterns.
Interactions of imipramine with other drugs
Desipramine and imipramine inhibit the hydroxylation reactions 
involved in the metabolism of certain drugs such as pentobarbital (Kato, 
et al, 1963), tremorine (Hammer and Sjoqvist, 1966), amphetamine (Consolo, 
et al, 1967) and tyramine (Lemberger, et al, 1965). These interactions 
are thought to be due to changes in the metabolic activities of the hepatic 
microsomal enzymes and cytochrome P-450.- The present work will consider the 
effect of imipramine administration on the plasma levels of pentobarbitone.
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Materials and Methods
Imipramine hydrochloride was donated by Biorex Laboratories Ltd., 
and was dissolved in saline (50 mg/ml). Pentobarbitone levels in the 
blood were measured by gas liqui d chromatography as previously described 
(Chapter 4). Two experiments were performed. In the first one, 24 male 
40-d.ay old, Wistar-albino rats received daily intraperitoneal administration 
of imipramine (50 mg/kg) for 3 days. 24 hours after the last injection
the animals received pentobarbitone (75 mg/kg) intraperitoneally and the rate 
of disappearance of the latter from the blood plasma was investigated as 
previously described (Chapter 4). In the second experiment, 24 male 40-day 
old Wistar-albino rats received a single dose of imipramine (50 mg/kg) 
followed immediately-by the intraperitoneal administration of pentobarbitone 
(75 mg/kg) and again the plasma disappearance of the pentobarbitone was 
studied. In both experiments four determinations were carried out at six 
regular time intervals.
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Results and Discussion
Simultaneous administration of pentobarbitone with imipramine 
resulted in a very marked decrease in the rate of pentobarbitone 
disappearance from the plasma. There was no significant metabolism 
of the barbiturate for at least the first 90 minutes after administration 
(Fig.-7.2, Table 7.1)’. Both pentobarbitone (see Chapter 5) and 
imipramine (von Bahr and Orrenius, 1971) interact with cytochrome P-450 
giving rise to a type I spectrum. .Thus the increased plasma levels of 
pentobarbitone may be the result of inhibition caused by competition 
between imipramine and pentobarbitone for the same active site of the 
cytochrome. Tricyclic antidepressants bind to cytochrome P-450 with 
very large affinities and imipramine is so highly-bound to smooth microsomes 
that the level in these vesicles is several hundred-fold greater than that 
found in an aqueous phase with which they are in equilibrium (Dingell, 
et al, 1961). This competition, between imipramine and pentobarbitone 
could prevail even if imipramine was completely metabolized since its 
metabolites also bind to cytochrome P-450. Desmethyl imipramine, the major 
metabolite, also has a high affinity for the cytochrome and induces a type 
I spectrum (von Bahr'and Orrenius, 1971; Bickel, 1971, Bickel and Gigon,
1971). The hydroxy derivatives of both imipramine and .desmethyl imipramine 
also bind,with high affinities, to cytochrome P-450, while imipramine N~oxide 
has low affinity. They all induce a type I spectrum. The magnitude of the 
spectral change produced by imipramine is not enhanced by addition of 
desipramine and neither is the desipramine-induced type I spectrum increased 
by 2-hydroxy-desipramine, suggesting that imipramine and its hydroxylated 
metabolites interact with a common cytochrome P-450 species. Didesmethyl- 
imipramine gives rise to a type I spectrum at low concentration but type II 
at high concentrations. If microsomes are saturated with desmethylimipramine 
the spectrum of didesmethylimipramine is of type II even at low concentrations
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Figure 7.2
Effect of simultaneous administration of 
imipramine and pentobarbitone on plasma 
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suggesting that the latter can interact in more than one way. So that 
even if imipramine is oxidised its metabolites can still compete with pento­
barbitone for the active site.
During the three days of imipramine pretreatment the animals showed 
no gain in weight. Three animals died after the final administration of 
imipramine, probably as a result of the toxicity of the drug. Intraperitoneal 
administration of imipramine has previously been reported to reduce water 
and food intake in animals and to cause paralytic ileus. Hie effect is 
less if the same dose is given by oesophageal tube (Schneider, and Schneider, 
1970).
When animals are pretreated with imipramine for three days the rate 
of plasma disappearance of pentobarbitone is again decreased (Fig. 7.3,
Table 7.1). The half-life of pentobarbitone is approximately doubled, 
reflecting a 501 inhibition of its metabolism. Imipramine has previously 
•been reported to potentiate'the pharmacological actions of pentobarbital, 
meprobamate and carisoprodol without affecting barbital and chloral hydrate 
(Kato, et al, 1963). Desipramine has similar effects (Hammer, et al,1966;
Shah and Lai, 1971). Imipramine re-induces sleep in rats awakening from 
pentobarbital hypnosis and potentiates the inhibitory effect of SKF-525A, 
the microsomal drug-metabolizing enzyme inhibitor. Barbital and chloral 
hydrate are only slightly affected, since barbital is not metabolized in 
the rat to a significant degree (Bums, et al, 1957), and chloral hydrate 
is metabolized’mainly by alcohol dehydrogenase (Friedman and Cooper, 1960). 
■Inhibition caused by imipramine is followed by subsequent induction as in 
the case of SKF-525A (Kato, et al, 1964b). A single imipramine administration 
(80 mg/kg) to rats resulted in inhibition in microsomal metabolism of 
biphenyl, aniline and thiobendazole with no changes in the levels of cytochrome 
P-450 and b  ^ (Wilson, personal communication). '
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Figure 7.3
Effect of imipramine pretreatment on 
pentobarbifone plasma disappearance
■O Control
6
r*
4
3
2
1
•15 1059030 45. 60 75
Time (mins) 
262.
■.The decrease in the rate of plasma disappearance of pentobarbitone 
could also be the result of changes in the pharmacokinetics of the drug. 
Tricyclic antidepressants have been reported to prevent the absorption 
and. uptake of several drugs (Costa, et al, 1966). Desipramine has also 
been-shown to inhibit the intestinal absorption of drugs (Console, 1968;
Consolo and Garattini, 1969).
Extrapolation of plasma pentobarbitone disappearance curves to zero 
time gives initial plasma level after equilibrium. In both experiments 
absorption into the blood stream was completed after 15 minutes. Mien the 
animals were pretreated with imipramine (Fig. 7.3) initial plasma levels were 
not significantly different from control. HoweveT, when imipramine was 
simultaneously administered with pentobarbitone (Fig. 7.2) initial plasma 
levels were significantly lower suggesting competitive impairment of uptake. 
Yet in both cases a markedly decreased rate of pentobarbitone plasma 
clearance was observed; as this is of the same order it indicates that 
metabolism and competition for enzyme site is of paramount importance.
It is now believed that the potentiation of the pharmacological effect 
of drugs by imipramine and desipramine is partly due to inhibition of their 
metabolism and partly due to increased sensitivity of the central nervous 
system (Kato, et al, 1964; Shah and Lai, 1971).
Contrary to the above findings, recent reports (Breyer, 1972) have 
claimed'that in rats pretreated with Imipramine by oesophageal tube daily 
for one week there was stimulation of the microsomal drug metabolizing 
enzymes, the increase exceeding in some cases that of phenobarbitone.
There was also an increase in the hydroxylation of aniline and the 
demethylation of ethylmorphine. Like phenobarbitone, imipramine stimulates 
the demethylation and.decreases' the oxidation of perazine, another
263.
fricyclic drug. Phenobarbital, .however, increases imipramine hydroxylation 
contrary to perazine (Nakazawa, 1970).
In view of the limited existing evidence it is not yet possible to 
define the mechanism of interaction of imipramine with other drugs. It 
is not clear if inhibition of microsomal drug metabolism by imipramine is 
a result of the drug per se or a secondary effect of imipramine toxicity.
The most probable mechanism, however, is the competition of pentobarbitone 
with imipramine or one of its metabolites for the same binding site with 
the consequent inhibition of microsomal metabolism, although changes in 
absorption and changes in the sensitivity of the central nervous system 
must also contribute.
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Chapter Eight 
CHEMICAL INDUCTION OF PORPHYRIA
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CHEMICAL INDUCTION OF PORPHYRIA
PRODUCTION'
The porphyrias are metabolic disorders/mostly of hereditary 
.nature,, associated with increased formation of porphyrins and-their 
precursors, the result of disruption of the regulation of haem 
synthesis. 'hoe porphyrias are divided into two groups (Schmid et al?
1954) namely:- .
• . A.. Erythropoietic porphyria, where porphyrins accumulate in the
bone marrow. The uroporphyrin in man appears to0be the result of 
decreased level of uroporphyrinogen III cosynthetase accounting for 
the great amount of uroporphyrin I excreted (Romeo and Levin, 1969).
B. Hepatic porphyria which involves mainly the liver and is 
subdivided into:-
(a) Hereditary acute porphyrias including .i) acute intermittent, 
porphyria characterised by excessive excretion of 6-amino - 
laevulinic acid (6-ALA) and porphobi lino gen (PBG), ii) hereditary 
coproporphyria characterised by increased excretion of copro­
porphyrin III (Goldberg, et al, 1967) and finally iii) mixed
or variegate porphyria, another genetic disorder'.characterised 
by excessive excretion of'porphobilinogen and of hydrophilic 
porphyrins which are porphyrin peptide conjugates of varying 
molecular size in which a dicarboxylic porphyrin is linked by 
thioetlier linkage to cysteine residues.
(b) Symptomatic or acquired porphyria characterised by the 
increased excretion of porphyrins especially uroporphyrin but 
with normal excretion of porphobilinogen and 5-aminolaevulinic 
acid. These patients usually have impaired liver function and'
i 766 , ' ' " :■
are chronic alcoholics; Recently it was found that hexachloro- 
benzene, a fungicidal agent, brings about porphyria which is an 
acquired condition occurring without genetic disposition to 
porphyria (De Matteis, et al, 1961).
Porphyrin biosynthesis
Porphyrin biosynthesis occurs in three steps (Fig. 8.1), two of 
which take place in the mitochondria- and another in the cytoplasm (Sano 
and Granick, 1961). The formation of 6-aminolaevulinic acid is catalysed 
by 6-ALA synthetase in the mitochondria (Schulman and. Rickert, 1957).
Succinyl CoA is formed through Kreb5 s cycle and some is also produced 
through succinyl-CoA synthetase (Shemin and Ivumin, 1952; .Brown 1958;
Granick and Urata, 1963). Soluble 6-ALA synthetase contains an -SH 
group associated with the initial binding of the cofactor pyridoxal-5- 
phosphate to the enzyme and may be also involved in the activation of 
the enzyme by divalent cations (Scholnick, eh al, 1972). The enzyme and 
pyridoxal-5-phosphate form a thiohemiaceta.1. A Schiff base is formed with 
glycine followed by condesation with succinyl CoA. Finally the glycyl 
carboxyl group undergoes decarboxylation releasing 6-aminolaevulinic acid 
from enzyme.
Two molecules of 6-aminolaevulinic acid condense in the presence 
of 6-ALA dehydratase (EC 4. 2.124) to form-porphobilinogen (Gibson, et al,
1955), four molecules of which- combine to form uroporphyrinogen III 
(Bogorad 1958; Cornford, 1958). Decarboxylation produces copropbrphyrinogen 
III (Mauzerall and Granick, 1958) which undergoes oxidative decarboxylation 
to form protoporphyrin (Sano and Granick 1961; Battle, et al, 1965).
Haem is finally formed by the insertion of ferrous iron into the 
protoporphyrin by ferrochelatase (Porra. and Jones, 1963; Labbe, et al, 1965).
Fig. 8.1
Pathway of porphyrin biosynthesis
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6-ALA synthetase
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Haern is an essential component of many haemoproteins , such as the enzymes 
catalase and tryptophan pyrrolase, and the mitochondrial and microsomal 
cytochromes. Hie rapid turnover of microsomal cytochrome P-450 accounts 
for at least SOI of all haern synthesized in the unstimulated liver of 
rat (Schmid, et al} 1966), and mouse (Wada, et al, 1968).
Biosynthesis of 6-aminolaevulinic acid synthetase
The enzyme 6-aminolaevulinic acid synthetase (6-ALA synthetase) is 
mainly found in liver mitochondria-and to a lesser extent in the soluble 
fraction. Induction of porphyria by allylisopropylacetamide (AXA). 
demonstrated the presence of the enzyme in both Sidney mitochondria and 
soluble fraction (Barnes, et al, 1971) but was not detected in heart or 
brain of normal or porphyric rats. ,
Allylisopropylacetamide induces both mitochondrial and soluble 
6-ALA-synthetase' activities. In the earlier stages of induction the 
activity of 6-ALA-synthetase in the extramitochondrial fraction is higher 
than that of the mitochondrial fraction, while in the latter stages of 
induction activities become nearly the same in both fractions. The half 
life of soluble 6-ALA-synthetase is 20 minutes to the mitochondrial’s 68 
minutes (Hayashi, et al, 1969). Cycloheximide inhibits the activity 
of 6-ALA synthetase in both fractions but chloramphenicol does not affect 
the extramitochondrial fraction (Beattie and Stuchell, 1970). Cyclo- 
heximide is a specific inhibitor of microsomal protein synthesis and 
chloramphenicol is a specific inhibitor of mitodiondrial protein synthesis.
Hie above suggests that after allylisopropylacetamide administration 
extramitochondrial 6-ALA synthetase is first induced, -then the mitodiondrial 
level of the enzyme increases while extramitochondrial is decreased, the 
total activity remaining constant. Thus die enzyme is synthesized in
microsomes , then appears in the soluble fraction and then .is later 
incorporated into mi tochondria (Hayashi et ad, 1969; Beattie and Studiell, 
1970). rihe soluble enzyme was found to have larger molecular size 
(Hayashi et 'al, 1969).
Regulation of haern . syntliesis '
Haern biosynthesis may be controlled by four mechanisms:-
(a) Membrane permeability may control porphyrin biosynthesis since 
6-aiuinoleavulinic acid has to diffuse into the cytoplasm and
. similarly coproporphyrinogen III has to diffuse from the extra- 
' - mitochondrial space back into mitochondria. However, no evidence 
lias been found concerning such a control mechanism. More recent 
work presented evidence that protohaemin acts by preventing transfer 
of 6-ALA synthetase from the site of synthesis into the interior 
of mitochondria (Kurashima, et al, 1970; Hayashi, et al, 1972) thus 
preventing conversion of soluble 6-ALA synthetase into mitodiondrial 
6-ALA synthetase. The above workers showed that haemin suppressed 
the allylisopropylacetamide stimulation of the enzyme in mitochondria 
while extramitochondrial activity was increased.
(b) Formation of6-ALA has been shown to be the rate limiting step in 
porphyrin biosynthesis in both microbial and animal species (Lascelles 
1959; 1960; Granick and Urata, 1963; Wainwright & Wainwright, 1966; Marver
' et al. 1968). In some systems of porphyrin biosynthesis 6-ALA 
dehydratase may also be limiting (Menon and Shemin, 1967).
(c) Availability of succinyl-CoA for 6-ALA synthesis.
270.
pyruvate
^ lcetoglutarate 
2 ICreb's
cycleCO,2V
malate Succinyl CoA—  ^6 -ALA — PBG -— tHAEM 
+ 6-ALA synthetase
fumarate \ glycine
succinate
Mechanisms of haem 
regulation from
Apparatus for 
enzyme synthesis
. Lascelles 1964.
Factors affecting the availability o£' succinyl CoA for glycine 
condensation can also influence the rate of 6-aminolaevulinic acid 
synthesis. If the rate of formation of succinyl CoA synthetase or 
the rate, of removal of succinate by oxidation through Kreb’s cycle is 
disturbed, this will ultimately affect 6-ALA formation (Granick and 
Urata, 1963; Ludwig et al, 1965; Haining and Labbe, 1967).
(d) End product inhibition and end product repression of 6-ALA 
synthetase.
There are two mechanisms by which the amounts of 6-aminolaevulinic acid 
produced can be controlled by 6-ALA synthetase. One involves changes in 
enzyme activity and the other one disturbs the rate of enzyme synthesis. 
Haem the end product, can reversibly inhibit 6-ALA synthetase activity 
(Burnham and Lascelles, 1963). Low concentration of haem can 
also repress formation of 6-aminolaevalinic acid'synthesis in 
cultures of Rhodopseudomonas spheroides during adaptation to photo­
synthesis (Lascelles, 1960; Gibson, et al, 1961). These are two types 
. of enzyme inhibition known as end product (feedback) inhibition and 
end product repression respectively. Inhibition acts quickly to
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release the enzyme to full activity when haem concentration falls,
while repression takes a longer time to become effective as the
existing enzyme will be potentially active for the remainder of its
life span. A similar pattern is observed in animals (London et al,
19]64) but in the isolated liver there is only evidence for end
product repression (Granick 1965; Waxman, et ad, 1966). Recent
/
work has shown that at low protoporphyrin levels hepatic porphyrin 
accumulation after porphyrin induction is directly correlated 
to 6-ALA synthetase. IVhen the protoporphyrin is increased there 
is an inverse correlation between activity and protoporphyrin content 
suggesting that feedback inhibition or feedback repression of
* o '
synthetase occurs (Hutton and Gross, 1970).
Haemin (protohaemin), the oxidised haemp has also been shown 
to strongly suppress induction of mitodiondrial 6-ALA synthetase 
' in chick embryo cell by end product repression (Granick 1966;
Hayashi et al, 1968; Marver, et al, 1968; Wada, et al, 1968; .
Schneck and Marks 1969; Creighton, et al, 1971; Sv/eeney, et al,
1972; Scholnick et al. 1972). Granick (1966) suggested that the 
repressor for 6-ALA synthetase activity consists of a protein 
aporepressor combined with protohaem which functions as corepressor 
Porphyria-inducing drugs are thought to compete with protohaem 
for a site on the corepressor- so that the gene for 6-ALA synthetase 
is derepressed, i.e.'protohaem combines writh an aporepressor 
inhibiting the transcription of a segment of DMA into m-RNA for 
6-ALA synthetase. Subsequent work however (Schneck, et al, 1971) 
showed that protohaemin inhibition is non-competitive and different 
from that of actinomycin D, Other workers (Sassa and Granick, 1970) 
suggested that haemin inhibits 6-ALA'synthetase'at the level of
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translation. Protohaemin however does not have a similar effect 
with cycloheximide so it is unlikely that it inhibits at this 
level (Schneck, et al, 1971).
(e) Introduction of oxygen into anaerobic cultures of Rhodopseudomonas 
spheroides leads to an immediate repression of synthetase formation 
which is'reversed when anaerobic conditions are restored. Similarly, 
high light intensity represses 6-ALA synthetase (Lascelles 1959;
1960). It.has been suggested that light and oxygen effects are 
,f due to oxi do reductive changes of a carrier in the electron transport 
chain (Cohen-Bazire, et. al, 1957). In chicken erythrocyte 
preparations-oxygen decreases the conversion of porphobilinogen 
to uroporphyrinogen indicating that oxygerf is capable of inhibiting 
the enzymes of porphyrin biosynthesis (Falk.and Porra, 1964).
Effect of drugs on porpliyrin biosynthesis
A. Disturbance of human porphyrin metabolism.
A drug can increase porphyrin excretion in a normal person or it 
can precipitate an attack of hepatic porphyria in a patient-who is a carrier 
of the genetic defect where porphyria is latent.
Increased porphyrin excretion is observed in normal persons after 
administration of drugs such as phenobarbitone (Haxthausen, 1927), 
tolbutamide (Rook and Champion, I960)- and oestrogen (Becker, 1965). These 
drugs also cause porphyria in animal, liver cells cultured in vitro.
Administration of certain drugs to patients with hepatic porphyria 
can worsen their condition and also precipitate attacks in persons with latent 
porphyria. Barbiturates have been known for a long time to exacerbate the 
clinical and metabolic state of porphyric patients (Whittaker and Whitehead, 
1956; Goldberg, 1959; Dobrschansky,. 1906). The onset of an
acute attack, however, does not necessarily follow the administration of 
barbiturates (Ward,1965). Chloroquinine causes a marked increase in the 
•urinary excretion of uroporphyrin probably by releasing uroporphyrin from 
•die liver rather than by increasing uroporphyrin synthetase (Sweeney, et' 
al, 1965; Felsher and Redeker, 1966). This is supported by the observation 
that chloroquinine does not induce porphyria in liver cells cultured 
in vitro (De Matteis, 1967).
B. Experimental hepatic porphyria caused by drugs.
For a chemical to induce porphyria it must remain in the liver for 
at .least several hours in order to increase .and maintain porphyrin formation 
(Racz .and Marks, 1972) from which it may be inferred that physicochemical 
properties and metabolic rates of the inducer are related to porphyrin biosynthes 
On the basis of results obtained in chick embryo cultures the porphyrogenic 
compounds can be classified into three chemical groups, (1) sedormid, 
allylisopropylacetamide and barbiturates; (2) DDC (3,5-diethoxycarbonyl-1-4- 
dihydrocollidine) and griseofulvin, and (3) sex steroid hormones and their 
metabolites(Granick and Kappas, 1967). Recently a new class has been 
found which comprises of chlorinated insecticides such as DDT and aldrin.
(1) Sedormid (n-2 (2-isopropyl pent-4-enoyl)urea) was found to induce 
. porphyria and inhibit catalase activity in both rats and rabbits 
(Schmid, et al, 1955). Tire same workers observed that daily pyrrole 
excretion exceeded the amount required for catalase synthesis so that 
under utilization alone could not account for porphyrin over-production. 
Further work showed that liver homogenates from sedormid-treated 
animals converted porphobilinogen to porphyrins at the normal rate 
suggesting that excess porphobilinogen was due to over-production and 
not to the block of further metabolism (Merchante, et al, 1957). This
was subsequently confirmed when sedormid was found to.induce 
6-ALA synthetase in rabbit liver'(Gibson, 1955). The chemically 
related compound 2-allyl-2-isopropylacetamide (AIA) and several 
barbiturates have also been found to increase prophyrin excretion 
.(Goldberg, 1954; Goldberg and Rimington, 1955; Moore et al, 1970). 
Administration of barbiturates to rabbits showed that the members 
of the series which contained the allyl group were the more potent 
while the rest had a slight or no effect (Moore et al, 1970).
However, all barbiturates have been associated wTith. human disease 
(Goldberg, 1959). -These observations suggested that the necessary 
structure required to produce experimental porphyria is a dialkyl 
substituted acetamide or a cyclic ureide where at least one 
substituent is an allyl group. In chick embryo cultures porphyro- 
genic activity was directly related to lipid solubility as seen 
with allylisopropylacetamide derivatives and a series of barbiturates 
(De Matteis, 1971) in which thiopental was found to be the most 
potent barbiturate. Thiopental has also been associated with 
"human porphyrias (Eal.es, 1966) but has no effect on rats or rabbits 
(Goldberg, 1954; Moore et .al, 1970).
(2) Further research discovered compounds chemically unrelated to 
sedormid but capable of inducing porphyria. One of the most studied 
is 3,5-die tho xy c arb ony 1 -1 - 4 - dyhy dr o co H i  dine (DDC) (Solomon and 
Figge, 1959; Ackner et al, 1961; Satyanarayana Rao et al, 1971).
This compound like allylisopropylacetamide also causes a reduction 
in liver catalase (Ginsburg and’ Dowdle, 1963).
After the outbreak of cutaneous porphyria in Turkey another 
compound, hexachlorobenzene, was found to be porphyrogenic (Ockner
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and Schmid,' 1961). Griseofulvin, a drug used for treatment of. 
fungal, infections was also found, to induce porphyria and also to 
interfere with porphyrin metabolism in the 'erythropoietic system 
(De Matteis and Rimington, 1963).
(3) Almost all progestational components of contraceptive mixtures 
increase porphyrin excretion whereas oestrogenic compounds have 
no effect. Women talcing contraceptive steroids were found to excrete 
• 'larger amounts of 6-aminolaevulinic acid than normal (Granick, 1966; 
Rifkind.et al, 1970).
Mechanisms of chemical induction of porphyrin biosynthesis
Hie increased level of porphyrin excretion was found to be the
result of increased activity of 6-ALA synthetase and not due to an
increased generation of succinyl CoA (Granick and Urata, 1963; De Matteis,
1964; Narisawa and Kikuchi, 1965; Marver et a.1, 1966). Hie activity
of 6-ALA dehydratase is also increased by DDC or allylisopropylacetamide
administration (Hutton and Gross, 1970: Satyanarayana Rao ei^  a l 1971).
*
The much greater concentration of protoporphyrin accumulating in the 
liver in porphyria induced by DDC and griseofulvin, compared to that of 
allylisopropylacetamide is explained by the finding that DDC (Qnisawa- 
and Labbe, 1963; Tephly et al, 1971) and griseofulvin (Lockhead et al,
1967) but not allylisopropylacetamide (Barnes' et al, 19^1) decreased
ferrochelatase activity. Another possible mechanism is the action of
drugs at reaction sites other than the haem pathway, the induction of
6-ALA synthetase-activity being a secondary effect. Animals treated
with allylisopropylacetamide or DDC have increased succinyl-CoA synthetase
activities (Labbe et al, 1965) due to an increased generation of succinate
from carboxylation of pyruvate to malate via fumarate (Haining and Labbe, 1967).
The glucose effect
Glucose completely abolishes the effect of allylisopropylacetamide 
and a balanced diet can prevent induction of porphyria (Rose et al, 1961; 
De Matteis, 1964). Glucose has been reported to inhibit synthesis of 
many bacterial enzymes and in rat liver prevents induction of threonine 
dehydrase and ornithine-6-transaminase (Pitot and Peraino, 1963).
Similarly glucose repressed the increase of 6-ALA synthetase activity 
caused by porphyrogenic drugs (Tschudy et al, 1964) and a similar diet 
effect was reported in acute intermittent porphyria.
Destruction of haem by porphyrogenic compounds
A rapid transient decline in cytochrome P-450 coinciding with the 
rise in activity of 6-ALA synthetase has been shown to occur after a 
single dose of DDC (Marver et al, 1968; De Matteis and Gibbs, 1972), 
allylisopropylacetamide (De Matteis, 1970; Waterfield et al, 1970; Meyer 
and Maiver, 1971; Levin et al, 1972) , griseofulvin (Wada et al, 1968) and 
barbiturates containing an allyl grouping (Levin et al, 1972). Hie 
latter workers observed that there were no comparable changes in cyto­
chrome b^. Isopropyl valeramide, the structural analogue of allyliso­
propylacetamide, and barbiturates with no allyl group have no effect,
3
Using H-6-ALA. it was shown that the reduction in cytochrome P-450 . 
is due to destruction of pre-existing cytochrome and not due to inhibition 
of enzyme synthesis (Levin et al, 1972) . The breakdown is biphasic 
having a rapid phase with a half-life of 7-8 hrs and a slow one with a 
half-life of 11-12 hrs (Levin and Kuntzman, 1969; Meyer and Marver, 1971). 
Hie lost, haem undergoes chemical changes to certain unidentified green
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pigments (De Matteis, 1971). Since haem is known to exercise a 
negative feedback control at the level of o-ALA synthetase, it is 
possible that by destruction of haem the allyl group contained in 
certain drugs may reduce this feedback control by haem and thus 
stimulate enzyme activity (Abritti and De Matteis, 1971/72)... The rapid 
loss of cytochrome P-450 is followed by a gradual increase to above 
the-normal concentrations (De Matteis, 1971).
Present work investigates the porphyrogenic effect of some 
allyl compounds and attempts to correlate porphyrogenic activity with 
induction of hepatic microsomal drug metabolizing enzymes.
MATERIALS AND METHODS
Allylisopropylacetamide was a gift from Hoffman-La-Roche; safrole 
and isosafrole were obtained from Koch and Light and triallyl cyanurate 
•from B.D.H., alclophenac was donated, by Berk Pharmaceuticals.
Allylisopropylacetamide was dissolved in saline (20 mg/ml), isosafrole 
safrole and triallyl cyanurate in propylene glycol (20 or 50 mg/ml) and 
barbiturates and alclophenac (20 mg/ml) in alkaline solution as previously 
described (Chapter 4). When 6-ALA -synthetase was estimated the animals 
used were 40 day-old male Wistar albino rats.. Animals were starved for 
24 hrs prior to sacrifice and received 100 mg/kg^of test compound sub­
cutaneous ly 16 hours before sacrifice. Control animals received a 
corresponding volume of either saline or propylene glycol.
■For microsomal enzyme induction studies animals were 37 day-old male 
Wistar-albino rats. These received daily intraperitoneal administration of 
75 mg/kg of the drug for three days and were killed 24 hrs after the last 
injection. Controls received a corresponding volume of saline or propylene 
glycol.
The determination of activities of 6-ALA synthetase, biphenyl and 
aniline hydroxylase, NADPH-cytochrome c reductase and concentration of 
cytochrome P-450, cytochrome b^ and microsomal protein were carried out as 
previously described (Chapter 2). Hie structures of the compounds used . 
is shown in Figure 8.2.
Fig. 8.2
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RESULTS
All the compounds investigated increased the activity of 6-ALA 
synthetase but to different extents (Tables 8.1 and 8.2). Both barbiturates 
increased the enzyme activity but allobarbitone is by far the most potent 
resulting in more than a two-fold increase. The compound ally lis op ropy 1- 
acetamide was found to be a potent inducer of this enzyme as expected.
The analgesic alclophenac also increased the enzyme activity and the 
industrial chemical triallyl cyanurate increased the enzyme activity by 
771. ■ The methylene dioxyphenyl compounds safrole and isosafrole caused 
only a slight increase in the activity of 6-ALA synthetase.
The analgesic alclophenac (Drug Therap. Bull. 1972) was found 
not to induce hepatic microsomal drug metabolism (Table 8.3) . Hydroxylation 
of biphenyl is unaffected while there is a slight increase in reduction 
of cytochrome c by NADPH. The microsomal content of protein, cytochrome 
P-450 and cytochrome b^ are unaltered. However there is a decrease in 
the liver/100 g body wt ratio which probably reflects a toxic effect of 
alclophenac.
The industrial chemical triallylcyanurate also does not act as an* 
inducer of hepatic microsomal drug metabolism (Table 8.4). There is an 
increase in aniline metabolism but microsomal contents of cytochrome 
P-450 and cytochrome b^ are unchanged. Reduction of cytochrome c and 
microsomal protein are also unaffected.
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Table 8.1
Effect of safrole and isosafrole on 6-amiholaevulinic acid 
. synthetase activity
Compound studied 6-ALA synthetase activity 
(nmoles/g liver/min)
% Change
Control 3.0 ± 0.5 -
Safrole 3.8 ± 0.2 + 40
Isosafrole 3.6 ± 0.3 + 30
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DISCUSSION
Preliminary findings suggested that the necessary structure required 
to produce experimental porphyria is either a dialkyl substituted acetamd.de 
or a cyclic urei.de (in barbiturates) where at least one of the alkyl 
substituents is an allyl group, e.g. allylisopropylacetamide and seco- 
barbitone. •
All the compounds used in the present study contained at least one 
allyl group but do not necessarily fall into the above categories. However, 
all of them were found to induce 6-ALA synthetase activity to different 
degrees. Safrole and its isomer, isosafrole, have only a slight effect 
while allobarbitone, allylisopropylacetamide, triallyl cyanurate and 
alclophenac are more potent. Secobarbital also had only a slight effect.
Correlation between rate of metabolism and porphyrogenicity of drugs
Previous work has suggested that compounds with low metabolic rates 
are good inducers of 6-ALA synthetase (Goldberg and Rimington, 1962;
Hirsch et al, 1967; Schneck et al, 1968; Racz and Marks, 1972; Schneck 
and Marks,.1972). . Pretreatment of rats with phenobarbitone abolishes the 
ability of progesterone and allylisopropylacetamide to stimulate 6-ALA 
synthetase, possibly by increasing their metabolism (Kaufman et al, 1970). 
These observations suggest that porphyrogenicity is the property of the 
parent drug and not of a metabolic product. This was further confirmed 
by the finding that allylisopropylacetic acid is inactive (Schneck et al,
1968). Hexachlorobenzene, which is not readily metabolized (Parke and 
'Williams, 1960), highly stimulates 6-ALA synthetase activity.
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Administration of porphyrogenic compounds to animals results in a 
stimulation of 6-ALA synthetase which, after reaching a maximum, declines, 
even if drug administration is continued. This has been shown during 
administration of phenobarbital (Moore et al, 1970), allylisopropylacetamide 
•DDC (Satyanarayana Rao et al, 1971) and m-dichlorobenzene (Poland et al 
1971). Thus this tolerance effect is very similar to the one seen with 
the barbiturates. Further evidence is given by the finding that hexachloro- 
benzene, which is not metabolized (Parke and Williams, 1960) produces a 
sustained induction of 6-ALA synthetase (Ockner and'Schmid, 1961). Present 
work shows that allobarbitone "having a slower rate of metabolism in the 
rat when compared to secobarbitone (Chapter 4) is the better stimulator 
of 6-ALA synthetase. Since the rate of metabolism is dependent on lipid 
solubility and protein binding these factors will also affect porphyrogenic 
activity. Using a series of acetanilides and a series of barbiturates it 
was found that lipid solubility of the drug was directly related to 
porphyrogenic activity in chick embryo cells (De Matteis, 1971).
Porphyrogenic activity and induction of microsomal drug metabolism
Both secobarbitone and allobarbitone are substrates of the mixed 
function oxidase and interact with cytochrome P-450 to produce spectral 
changes (Chapter 5). The hepatic metabolism of secobarbital has been 
studied in many species (Waddell, 1965; Ide et al, 1967) but no report 
exists on the metabolism of allobarbitone. However, both barbiturates 
act as inducers of microsomal drug metabolism allobarbitone being the 
more potent (Chapter 5).
Lie effect of allylisopropylacetamide on mixed function oxidase 
has been investigated by many workers and the compound lias been found to
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increase body weight and also liver weight by increasing total protein and 
RNA with no changes in DNA indicating that cell size rather than number 
is responsible for increased liver size (Cowger et al, 1963; Taddeini 
et al, 1964; Kaufman et al, 1966; De Matteis, 1971), and increases the 
activity of NADPH-cytochrome c reductase (Narisawa & Kikuchi,1966), nitro­
reductase and hexobarbital oxidase (De Matteis, 1966; Kaufman et al, 1966) 
but has little effect on cytochrome P-450 (Wada et al, 1968; Meyer and Marver, 
1971). Other workers, however, reported increases of cytochrome P-450 
after an initial rapid fall (De Matteis, 1970). Administration of allyl­
isopropylacetamide also results in an increased urinary excretion of 
ascorbic acid (De Matteis, 1964). It also affects the activity of many 
soluble enzymes such as glucose-6-phosphate dehydrogenase, uridine- 
glucose diphosphate dehydrogenase (Ginsburg and Dowdle, 1963; Narisawa 
and Kikuchi, 1965;. De Matteis, 1966), tryptophan pyrrolase (Feigelson 
and. Greengard, 1961). The levels of cholesterol and fatty acids are 
also increased (Labbe et al, 1961; De Matteis, 1966a; Taddeini 
et al, 1968).
Safrole, a weak hepatic carcinogen (Long et al, 1961) and its 
isomer isosafrole are potent inducers of microsomal drug metabolism 
(Rahman, 1970; Parke and Rahman, 1970). In the rat they Induced hydroxyl- 
ation of biphenyl, especially at the 2-position, reduction of p-nitro- 
benzoic acid and glucuronide formation. Cytochrome P-450 is increased 
by more than 1001 and level of' microsomal protein is also elevated.
Both compounds give rise to formation of a new haemoprotein in the 
rat microsomes (Parke and Rahman, 1971).
Alclophenac, an analgesic, is readily absorbed and excreted and 
is metabolized into three major metabolites (Roncucci et al, 1970, 1971).
Alclophenac is not an inducer of' microsomal drug metabolism (Table 8.3).
There are no changes in rate of metabolism of biphenyl microsomal cyto­
chrome content after alclophenac pretreatment.
Triallyl cyanurate known to-inhibit, sarcoma and carcinoma in mice 
(Endo et al, 1964) does not also act as an inducer of drug metabolism in 
the rat (Table 8.4). Hie rate of aniline metabolism is not significantly.' 
altered and microsomal cytochrome'content and microsomal protein are also 
unchanged. There appears to be no report on the metabolism of this compound.
Classification of porphyrogenic compounds
The above findings indicate that inducers of drug metabolism 
do not necessarily stimulate haem biosynthesis. Similar results by 
other workers indicated the extreme of two classes of compounds (De 
Matteis and Gibbs, 1972), (a) compounds like DDC stimulating <5-ALA
synthetase without affecting cytochrome P-450 concentration. In this 
category, allylisopropylacetamide, alclophenac and triallyl cyanurate 
can be added, (b) compounds like phenylbutazone which increase cyto­
chrome P-450 without affecting 6-ALA synthetase activity significantly.
In this.group safrole and isosafrole can be. classified. Finally another 
group can be formed including drugs like allobarbitone and secobarbitone 
which induce both microsomal drug metabolism and porphyrin biosynthesis.
Drugs of the.first group may lower the level of haem in the liver, 
reducing feedback control on 6-ALA synthetase and thus stimulate the 
enzyme activity. Both DDC and allylisopropylacetamide cause a transient 
decline in cytochrome P-450-and haem coincidental with the rise in 
6-ALA synthetase activity (De Matteis, 1970; Meyer and Marver, 1971).
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The same compounds also lower the activity of liver catalase (De Matteis, 
1967; Abritti and De Matteis, 1971 /l972). A drug may reduce haem 
concentration in two ways: (1) by destroying haem like allylisopropyl­
acetamide (De Matteis, 1971; Meyer and Marver, 1971) or by (2) inhibiting 
'haem synthesis (Onisawa and Labbe, 1963;. Tephyl et al, 1971).
Induction of 6-ALA synthetase b>r alclophenac and triallyl cyanurate 
is not as pronounced'as with allylisopropylacetamide probably as the result 
of a fast rate of biotransformation resulting in metabolism or removal of 
the allyloxy grouping. Alclophenac is rapidly and readily absorbed and 
excreted. More than 80% of the absorbed drug' is excreted within 24 hours 
of its administration in'humans (Roncucci et al,°1971). Hie main metabolites 
ar e ■3 - chlo ropheny 1. ace tic acid resulting from the removal of the allyl group 
and 3-chloro-4-dihydroxypropyloxyphenylacetic acid resulting from metabolism 
of the allyl group to the diol(Lambelin et al, 1970; Roncucci et al, 1971). 
Hie' metabolism of triallyl cyanurate has not yet been investigated.
Hie second group contains compounds increasing cytochrome P-450 level 
without affecting the activity of 6-ALA synthetase suggesting that no extra 
haem production is required for the formation of cytochrome P-450. Safrole 
and isosafrole do not increase the level of 6-ALA synthetase although 
they are both known to give rise to the formation'.of a new haemoprotein 
(Parke and Rahman, 1971) 5 suggesting that enhancement of drug metabolism 
and increase in 6-ALA synthetase probably result from different action 
of these drugs.
The last group contains compounds like barbiturates, griseofulvin, 
chlorinated insecticides and steroids which are enzyme inducers and also 
induce 6-ALA synthetase activity presumably to provide the haem required 
for the formation of new P-450 (Wada et al, 1968). Induction of 6-ALA
synthetase activity and increases in cytochrome P-450 concentration and 
microsomal protein levels are all abolished by simultaneous administration 
of haem confirming the fact that drug metabolism may be controlled by 
the pathway of haem biosynthesis (Marver et al, 1968; Baron and Tephly,
1969). Further. supporting evidence is provided by the observation that 
3,amino-1,2,4-triazole,-an'inhibitor of 6-ALA dehydratase (Tschudy and 
Collins, 1957), inhibits increase in hepatic haem synthesis and drug 
oxidations but has no effect of 6-ALA synthetase activity (Tephly et al, 
1971). Similar results have been obtained when inducing agent was 
3,4-benzpyrene (Baron and Tephly, 1969). The inducers in this group 
probably act by stimulating haem utilization in order to form new cyto­
chrome P-450 and thus decrease the concentration of ’’regulation haem” 
still further (Kaufman and Marver, 1970). Phenobarbital has also been 
shown to induce hepatic mitochondrial ferrochelatase (Hasegawa et al,
1970). Allobarbitone, the more potent inducer of drug metabolism when 
compared to secobarbitone is also the better stimulator of 6-ALA 
synthetase activity.
Correlation between destruction.of cytochrome P-450 and rate of 
drug metabolism
Recent work suggested a more direct relation between drug metabolism 
and porphyrogenic compounds. Pretreatment of rats with phenobarbitone 
stimulates destruction of cytochrome P-450 by allylisopropylacetamide while 
SI(F 525A administration results in decreased loss suggesting that allyl­
isopropylacetamide must be metabolized by liver microsomes in order to 
produce its effect on cytochrome P-450. This has been confirmed in an 
in vitro microsomal system requiring NADPIi confirming that allyl containing 
porphyrogenic compounds are converted to an active metabolite (De Matteis,
1970: De Matteis, 1971; Abritti and De Matteis, 1971 /l972). Pheno- 
barbitone has been shown, to induce in vivo metabolism of allylisopropyl­
acetamide (Kaufman et al, 1970), and secobarbital (Levin et al, 1972).
In conclusion, there are similarities between stimulation of drug 
metabolism and drug induced, porphyria. In both cases several unrelated 
drugs are equally effective and these drugs act directly on the liver 
and not through hormones. Lipid solubility is an important property of 
effecfive drugs and in both cases metabolic change can be prevented 
by inhibitors of protein synthesis and by carbohydrates. The initial 
breakdown of haem and cytochrome P-450 by barbiturates and followed 
stimulation of 6-ALA synthetase probably reflects the initial inhibition 
and subsequent induction of microsomal drug metabolism. It is possible 
that the biochemical aberration in human genetic porphyria may be 
influenced by the metabolism of circulating inducers of porphyrin 
biosynthesis (Kaufman and Marver, 1969; Kappas et. al, 1969).
Therefore the rate of metabolism of these endogenous 
substances can regulate porphyrin metabolism, through 6-ALA synthetase 
during human disease.
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